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Regenerative medicine is a rapidly developing field, merging engineering and biological life 
sciences to create biological replacements for damaged tissue and organ function. 
Development of cellular based therapies has the potential of curing present untreatable 
diseases and conditions, such as diabetes. The identification of protein expression patterns, 
that guide undifferentiated cells to different lineages, can provide important information 
about the progression of cellular differentiation at various stages.  
 
This research project utilizes proteomics and in vitro live-cell microscopy to investigate two 
distinct cellular systems: (1) the signaling pathways of calmodulin (CaM) in the 
differentiation of a human glioblastoma cell line; and (2) the effect of islet neogenesis 
associated protein (INGAP) on human islet-derived progenitor cells (hIPCs). Using a 
proteomic readout with a long term live-cell imagining approach, it was hypothesized that 
highly specific binding proteins of a CaM-mutant, and proteins in hIPCs perturbed by 
INGAP, could be identified and studied in vitro, characterizing specific signaling 
pathways which control the function of CaM in brain tumour cells and the 
mechanism(s) of INGAP in islet-derived progenitor cells. 
 
This thesis presents the utility of a proteomics and an in vitro cell microscopy approach to 
investigate therapeutic proteins, such as INGAP, on cell culture systems. The results have 
established the limitations and the utility of DIGE, differential binding of a CaM-mutant 
versus calcium-CaM, and the cell specific uptake feasibility of using the TAT-binding 
domain. In the hIPC system, proteomic, phenotypic, motility, proliferation and nuclear 
effects of INGAP were determined. Specifically, hIPCs exposed to INGAP had 50% 
decrease in average nuclear speed, the translocation of two identified proteins caldesmon and 
tropomyosin and INGAP was found to bind specifically to hIPCs. However, hIPCs had no 
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Chapter 1 Introduction 
Since the publication of the complete human genome in 2001, analyzing the expression of 
many genes has become a focus of drug screening and development. The publication was 
molecularly historic and it has provided scientists with vast amounts of data at the genomic 
level. However, genes are simply blueprints for the construction of proteins, whereas protein 
interactions determine cellular functions. Therefore, understanding the ‘gene products’ and 
their associated proteomes is essential to reveal critical signaling pathways involved in 
cellular responses. 
 
Currently, the evaluation of protein expression levels and the identification of the proteins are 
most commonly determined using two-dimensional gel electrophoresis coupled with mass 
spectroscopy (MS). With this approach, proteins are separated in the first dimension by their 
isoelectric point, followed in the second dimension by their mass. Each protein localizes 
specifically, creating a spot pattern for each protein separated. Proteins of interest can then be 
selected for MS analysis, with proteins identified based on their peptide fragments and cross-
referencing with the proteome database. However, the nature of these techniques requires 
collecting destructive results at various time points, followed by extrapolation to translate 
and infer the non-observed cellular activities. Often such interpretations assume a linear 
order of events between the experimented time points, however certainly more complex 
interrelations are occurring. As a result, the benefits to be obtained from real-time dynamic 
studies of cells in culture are becoming increasingly more evident. 
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Live-cell imaging and cell tracking techniques enable the direct observation of cells in real-
time on the single cell level. The technology provides opportunity for detailed analysis of the 
fundamentals of cell biology, such as: division, apoptosis, migration, and phenotype 
classification.  Adaptability, sensitivity, resolution and non-invasiveness are but a few of the 
advantages of in vitro live-cell imaging and tracking. Proteomics is vital to understanding the 
molecular basis of cell signaling, and live-cell imaging enables real-time observation on the 
single cell level. Therefore, proteomics coupled with live-cell imaging was employed to 
study two cellular systems: 
1) Calmodulin (CaM) in the differentiation of a human glioblastoma cell line 
2) Human islet-derived progenitor cells (hIPCs) treated with islet neogenesis associated 
protein (INGAP) 
1.1 Calmodulin (CaM) in the differentiation of a human glioblastoma cell line 
The first cellular system is focused around the protein calmodulin (CaM) and its associated 
bindome; the bindome includes all binding proteins of CaM. CaM is the primary receptor of 
calcium, playing an essential role in calcium signaling. CaM is the fifth most highly 
conserved protein in eukaryotes and is responsible for regulating numerous intracellular 
processes, such as: cell motility, growth, proliferation, and apoptosis (Yokouchi, Numaguchi 
et al. 2006; Bennett, Mauer et al. 2007; Colomer and Means 2007). As it is a primary 
receptor for calcium and an allosteric activator of several protein kinases, the Ca2+/CaM 
dependent signaling cascades are essential to many intracellular processes, including but not 
limited to: the immune system, the inflammatory response, the activation of T lymphocytes 
and hematopoietic stem cell maintenance (Braun and Schulman 1995). Although CaM 
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dependent signaling cascades are still not yet fully understood, it is clear that the mis-
regulation of CaM signaling can lead to many diseases (Colomer and Means 2007), 
emphasizing the importance of developing methods to mediate and study CaM signaling in 
the cell. 
 
Studying CaM-dependent signaling cascades using proteomics coupled with long term live-
cell imaging is a means to dissect CaMs cellular functions. CaM regulates protein binding 
activity based on intracellular levels of calcium, in its calcium bound and calcium free states. 
Protein interactions were characterized using calcium-CaM and a CaM-mutant which had 
mutated calcium binding sites rendering the protein unable to bind calcium. Identifying the 
binding proteins of CaM was first achieved by probing the bindome of calcium-CaM in 
comparison to that of the CaM-mutant using affinity chromatography and 2D differential in 
gel electrophoresis (2D DIGE). By comparing the binding proteins of the calcium free form 
to the calcium bound form of CaM, it was hypothesized that a subset of proteins would be 
identified which bind specifically to the mutant. Once the specific binding proteins of the 
CaMs were identified, in vitro characterization of the protein interactions using fluorescent 
microscopy during brain tumour cell differentiation was proposed. Using these methods, it 
was hypothesized that the CaM-mutant would selectively control (up regulate or down 
regulate) critical signaling pathways involved in cell differentiation. To test this 






1.1.1 Objective 1: Proteomic analysis of calcium-CaM vs. CaM-mutant binding 
proteins 
Milestone 1.  Affinity Chromatography 
Optimal affinity chromatography conditions were first determined. Once determined, 
several affinity runs were completed by passing porcine brain extract through 
calcium-CaM and CaM-mutant columns. The columns were first eluted with EDTA 
(calcium chelator), followed by NaOH (strong base). The isolation of a sufficient 
quantity of the binding proteins specifically bound to either calcium-CaM or the 
CaM-mutant in a calcium independent manner (NaOH elution fraction) was the 
central aim of this milestone.   
 
Milestone 2. Proteomic Analysis 
Once isolated, a proteomic analysis was completed using DIGE to compare the two 
bound protein populations. Prior to performing DIGE, optimal separation conditions 
were determined using two-dimensional polyacryladmide gel electrophoresis (2D 
PAGE) and silver staining. Subsequent to the protein populations being optimally 
separated, a design of experiments for DIGE was completed considering biological 
and technical replication to achieve acceptable statistical significance between 





1.1.2 Objective 2: In vitro characterization of CaM delivery into cells 
Milestone 3. TAT-CaM Uptake into a Human Glioblastoma Cell Line 
Once the specific CaM-mutant binding proteins had been identified in vitro, the 
second aim of the project was the delivery of CaM into brain tumour cells. The CaM-
mutant and calcium-CaM proteins were fluorescently labeled using different 
fluorophores and introduced into cells using a cell penetrating peptide: HIV-derived 
TAT. Achieving TAT uptake into various cell types was required prior to performing 
TAT-CaM uptake experiments. It was anticipated that the method of TAT uptake 
would not be straightforward. Therefore, this milestone was understood to require 
optimization of culture conditions and trials using several primary cell types. The 
final aim of this milestone was the successful delivery of TAT-CaM and the effective 
release of CaM into the cytoplasm. 
 
Milestone 4. Live-Cell Imaging and the Characterization of CaM Uptake 
Once TAT-CaM uptake had been confirmed, the aim of this milestone was to perform 
live-cell imaging and cell tracking of cells treated with the fluorescently labeled 
CaMs. Fluorescently labeled TAT-CaM was delivered to the cytoplasm of human 
glioblastoma cells. Time course imaging would allow observation of cell phenotype 
(differentiation state) and the relative distributions of the two labeled forms of CaM.   
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1.2 Effects of islet neogenesis associated protein (INGAP) on human islet-
derived progenitor cells (hIPCs) 
It is well known that long term in vitro culture of islets of Langerhans results in a population 
of proliferative fibroblast-like islet hormone-negative cells (Schmied, Ulrich et al. 2001), 
which have been termed islet-derived progenitor cells (IPCs). The second cellular system is 
focused around the protein INGAP and studying its proteomic and phenotypic effects on 
human islet-derived progenitor cells (hIPCs). INGAP is a protein believed to initiate duct cell 
proliferation and islet neogenesis (Rafaeloff, Pittenger et al. 1997). The mechanism of 
INGAP action, including cellular specificity and receptor, and the therapeutic potential of 
hIPCs are unknown. It was hypothesized that a clinically relevant understanding of 
INGAPs mechanistic and phenotypic effects will be determined by studying hIPCs 
treated with INGAP using 2D DIGE and long term live-cell imaging. 
 
To test this overall hypothesis, the following objectives and milestones for the experimental 
plan were identified: 
1.2.1 Objective 1: Proteomic analysis of hIPCs treated with rINGAP 
Milestone 1.  Long Term Live-Cell Imaging and rINGAP Treatment of hIPCs 
Obtaining islets, followed by culturing them into hIPCs while imaging the 
proliferation and rINGAP treatment, were the primary aims of this milestone. 
Established live-cell imaging techniques were used to study isolated human islets 
proliferating from islets into hIPCs, followed by rINGAP treatment. The imaging 
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allowed for the comparison of rINGAP-treated cells to untreated cells, the 
classification of the observed phenotype(s), analysis of the cell cycle times, and 
analysis of hIPC migration rates. 
 
Milestone 2. Proteomic Analysis-DIGE 
Separating and identifying proteins influenced by rINGAP at the various treatment 
times was the aim of this milestone. Following the rINGAP treatments (or non-
treatment controls) cells were lysed and both protein populations were separated and 
compared using 2D DIGE. Once the protein populations were separated using 2D 
PAGE and silver staining, a design of experiments for DIGE was completed 
considering biological and technical replication to achieve acceptable statistical 
significance. With the correct design of experiments, proteomic effects of rINGAP on 
the hIPCs were determined. 
1.2.2 Objective 2: Endpoint in vitro characterization of INGAP’s effect on hIPCs 
Milestone 3. Protein Validation and Aggregate Formation using rINGAP 
The primary aims of this milestone were to identify and validate the proteins 
determined through DIGE and mass spectrometry (MS). Based on the MS results, two 
proteins of most interest (proteins identified at multiple treatment times) were 
validated using immunofluorescence staining. The DIGE results represented the 
average protein expression of all the cells. Endpoint immunofluorescent staining for 
the specific proteins of interest was used to validate protein expression and the 
protein distributions on an individual cell basis. These methods were semi-
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quantitative, therefore, quantitative real-time PCR, were employed to further validate 
the rINGAP effect. Lastly, it was determined that aggregation of the hIPCs treated 
with rINGAP had additional cellular organization effects.  
Milestone 4. INGAP-PP effects on hIPCs 
The primary aim of this milestone was to evaluate the effects of the peptide form of 
INGAP on hIPCs. To understand the specificity of binding of INGAP on hIPCs, the 
cells were treated with fluorescently labeled islet neogenesis associated protein 
pentadecapeptide (INGAP-PP) and fluorescent scrambled-INGAP-PP. hIPCs were 
analyzed for phenotypic effects and significant nuclear effects were observed. 
Therefore, flow cytometry was utilized to analyze INGAP-PPs effect on cell cycle.  
 
1.3 Justification and Overall Hypothesis 
The overall goal of this research was to utilize proteomics and long term live-cell imaging to 
develop clinically relevant understandings of CaMs bindome and its effects on signaling in 
differentiation and INGAPs mechanistic and phenotypic effects on hIPCs. CaM dependent 
signaling cascades are still not fully understood and it is clear that their mis-regulation can 
lead to many diseases. Furthermore, although there are many issues surrounding the 
implementation of standard medical practices for the transplantation of organs and tissues, 
one of the primary challenges related to islet transplantation is islet supply. An available 
source of insulin-secreting cells is required to improve the quality of life of diabetes patients. 
hIPCs may offer a scalable supply of human derived cells which given the correct stimuli can 
be differentiated into insulin producing cells for diabetes transplantation. Therefore, 
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investigating the effects of INGAP on hIPCs ultimately would determine potential 
mechanisms of INGAP as a drug in the treatment of type 1 and type II diabetes. 
 
The underlying overall hypothesis of this thesis is: 
 
Live-cell imaging and proteomics can be collectively employed to systematically 
image and identify regulatory cellular changes, such as phenotypic variations and 
protein expression differences, which guide undifferentiated cells to different 
lineages; providing important information about the progression of cellular 
signaling at various stages of its development, having an impact in the fields of 











Chapter 2 Literature Review 
2.1 Calmodulin (CaM) 
CaM is a small 17kDa calcium binding protein found in all eukaryotic cells. It is a ubiquitous 
protein composed of two lobes: an N- and a C-terminal domain connected by a flexible 
central linker region. Each domain consists of two EF-hand calcium binding motifs. In its 
unbound state, the protein structure is a small dumbbell shape, consisting of 148 amino acids.  
CaM regulates cellular activity based on intracellular levels of calcium. Calcium is an 
essential intracellular secondary messenger that is able to regulate numerous physiological 
processes. Calcium concentrations can rise intracellularly from influxes from outside the cell 
or from internal calcium stores found in the endoplasmic and sarcoplasmic reticulum within 
the cell (Clapham 1995). For example, calcium can influx through channels which span the 
plasma cell membrane, such as through voltage-gated calcium channels found in excitable 
cells (Dolphin 2009).  
 
Upon calcium signaling, the calcium ions bind to CaMs EF-hand motifs causing a 
conformational change in the protein to a calcium bound form of CaM, termed calcium-CaM. 
The conformational change upon calcium binding, results in the exposure of hydrophobic 
patches which bind and control the activity of hundreds of proteins (Weljie, Yamniuk et al. 
2003). Calcium-free calmodulin (apo-CaM) also plays an important intracellular role in the 
regulation of target proteins and numerous signaling pathways (Jurado, Chockalingam et al. 
1999), however it is much less understood. Apo-CaM differs from calcium-CaM in its 
tertiary structure (Yamniuk and Vogel 2004). It has an overall more compact structure, in 
 
 11 
comparison to calcium-CaM which has an open “relaxed” structure. In addition, the 
hydrophilic nature of apo-CaM allows it to bind its target proteins differently, utilizing IQ 
binding motifs and noncontiguous binding sites (Jurado, Chockalingam et al. 1999; Vogel, 
Brokx et al. 2002; Houdusse, Gaucher et al. 2006).  
 
Differentiation, effector function and gene transcription are but a few cellular functions 
dependent on calcium and therefore also upon calcium-CaM (Oh-hora and Rao 2008). As a 
result, there are several drugs which target calmodulin-binding proteins to interfere with 
protein signaling required for cell function. For example, cyclosporine A (CsA) is a potent 
immunosuppressive drug which deregulates part of a calcium-CaM signaling cascade. 
Initially CsA was used to extend kidney allograft survival, however CsA was also shown to 
be partially effective in preventing graft-versus-host disease (GVHD) in bone marrow 
transplantation (Pai, Fruman et al. 1994). CsA binds to intracellular cyclophilin receptors, 
which combine to form a complex to target and inhibit calcineurin, a CaM dependent binding 
phosphatase whose activity is required for the induction of T-cell lymphokine production and 
proliferation (Hayden-Martinez, Kane et al. 2000). Although CsA has proven to be somewhat 
effective in the treatment of GVHD, chronic administration can lead to resistant acute 
GVHD, which is not yet fully understood (Pai, Fruman et al. 1994). As an alternative, CaM 
with mutated calcium binding sites can potentially be used as inhibitors of proliferation that 
do not act by direct inhibition, such as CsA, but as a drug to simultaneously selectively 





CaM binds specifically to a large number of proteins, termed CaM binding proteins 
(CaMBPs) and binding is precisely controlled within the cell. Elucidating CaMs binding to 
its numerous target proteins is essential to understanding the many CaM-signaling cascades 
in which several physiological processes are dependent. The binding of calcium-CaM to its 
target proteins has been studied extensively over the past several decades, rising from a 
reported 30 target proteins in 1995 to a reported potential 300 target proteins which have 
been reported using protein software packages and databases which recognize calcium-CaM 
binding motifs (Crivici and Ikura 1995; Ikura and Ames 2006). Tremendous progress has 
been made, however a large number of these target proteins remain to be functionally 
characterized.   
 
One of the most interesting characteristics of CaM is its diversity in binding proteins between 
the calcium-dependent and calcium-free forms. It is known that certain CaMBPs bind only to 
calcium-CaM, while other proteins bind preferentially to apo-CaM and less commonly to 
other forms of CaM (Jurado, Chockalingam et al. 1999). Apo-CaM has roles in the cell that 
have been suggested essential for life (Yamniuk and Vogel 2004). In 1999, 15 apo-CaM 
binding proteins were classified and discussed. The report consisted of a diverse group of 
proteins, including: enzymes, actin-binding proteins, as well as cytoskeletal and other 
membrane proteins, including receptors and ion channels (Jurado, Chockalingam et al. 1999). 
In comparison, it has already been systematically shown that calcium-CaM binds to over 120 
proteins (Jang, Guo et al. 2007) and mediates vital processes including memory, immune 
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response and the cell cycle (Li, Heim et al. 1999; Limback-Stokin, Korzus et al. 2004; 
Colomer and Means 2007). Furthermore, calcium-CaM has been implicated in many 
diseases, including, Alzheimer’s and some cancers (Murray, Gall et al. 1994; Bartolome, de 
Las Cuevas et al. 2007; Shigeri, Ishida et al. 2008). Although much less understood, apo-
CaM and its binding proteins are equally vital to our understanding of cell signaling and 
disease, however it is believed that many remain to be identified. 
2.2 TAT-Mediated Protein Delivery  
TAT is a peptide of the human immunodeficiency virus 1 (HIV-1) cell targeting capsid used 
to deliver functional cargo proteins intracellularly in an efficient and controlled manner when 
added exogenously to cultured cells (Schwarze, Ho et al. 1999). Twenty years ago, Frankel 
and Pabo discovered a short basic segment at amino acids 48-60 of the human 
immunodeficiency virus (HIV) transactivator of transcription (TAT) protein which was 
capable of penetrating cell membranes to activate HIV-specific genes (Frankel, Bredt et al. 
1988; Frankel and Pabo 1988). Ten years later, in 1999, it was reported that the TAT protein 
was used to deliver the active enzyme β-galactosidase to all tissues in the mouse, including 
the brain, following intraperitoneal injection (Schwarze, Ho et al. 1999). Subsequent to this 
study, several other groups reported using TAT to transduce many other cell types, including 
human T cells, primary astrocytes, rat cortical neurons, PC12 cells and human aortic 
endothelial cells (HAECs) (Nagahara, Vocero-Akbani et al. 1998; Matsushita, Tomizawa et 
al. 2001; Asoh, Ohsawa et al. 2002; Cao, Pei et al. 2002). Besides the fact that these early 
reports revealed that TAT could penetrate a large variety of cell types, it was reported that 
uptake was at nearly 100% efficiency (Nagahara, Vocero-Akbani et al. 1998; Matsushita, 
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Tomizawa et al. 2001; Asoh, Ohsawa et al. 2002; Cao, Pei et al. 2002). However, since these 
publications, several groups have reported conflicting results surrounding the penetration to 
every cell type, as well as its efficiency.   
 
Wunderli-Allenspach 2003 and Violini et al. 2002 reported TAT was not capable to permeate 
intact plasma membranes of MDCK cells (Violini, Sharma et al. 2002; Kramer and 
Wunderli-Allenspach 2003). Similarly, TAT-mediated cargo delivery was unsuccessful in 
colonic carcinoma cells (Violini, Sharma et al. 2002) and muscle cells in vivo (Caron, 
Torrente et al. 2001). Richard et al. 2003 demonstrated that both fixation prior to fluorescent 
microscopic analysis and lack of trypsinization before flow cytometric analysis, which the 
previous ‘successful’ TAT-mediated studies employed, produce erroneous results of TAT-
mediated uptake (Richard, Melikov et al. 2003; Vives, Richard et al. 2003). Following these 
results, Cai et al. 2006 using the same constructs as the original reports by Schwarze et al. 
1999 and Cao et al. 2002 could not successfully repeat the in vivo results from these 
respective groups; ultimately, questioning the ability of TAT to penetrate plasma membranes 
of different cell types under diverse conditions (Cai, Xu et al. 2006). 
 
As with many scientific advancements, the first two years of TAT-mediated protein delivery 
proved to be successful, demonstrating uptake into various cell types and at high efficiencies. 
The next generation of reports, however, demonstrated inconsistencies in achievability of 
using TAT to transduce many of the reported cell types. Since, determining the mechanism 
of TAT-mediated uptake has been central to its application. As a result, the mechanism of 
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TAT-mediated transduction has been investigated in many cell lines, as well as in primary 
cells. The controversy of transduction extends from results of required receptors, 
transporters, endocytosis and/or required electrostatic interactions. In the literature, all 
possible mechanisms have each been proven, disproven and proven over, with the current 
consensus being a combination of mechanisms.  
 
In 2001, Tyagi et al. 2001 reported internalization of the TAT protein through electrostatic 
interactions with cell surface heparin sulphate proteoglycans. Using 20 different recombinant 
TAT mutants, it was discovered that the arginines in the basic domain of the TAT protein 
interact with heparan sulphate, a member of the cell surface glycosaminoglycans (GAGs) 
family of carbohydrates (Tyagi, Rusnati et al. 2001). Since then, using various cell lines, 
several groups confirmed these results (Tyagi, Rusnati et al. 2001; Vives 2003; Wadia, Stan 
et al. 2004; Wadia and Dowdy 2005; Bugatti, Urbinati et al. 2007; Duchardt, Fotin-Mleczek 
et al. 2007; Kumarasuriyar, Dombrowski et al. 2007; Nakase, Tadokoro et al. 2007; Poon, 
Chang et al. 2007).  A more recent study extended the previous results on the cell lines to 
TAT-mediated protein delivery in primary brain cells, also revealing a dependence on GAG 
expression. In this study, it was hypothesized through observation of variability in reported 
TAT-mediated transduction efficiencies that the amount of cell surface proteoglycan may 
contribute to some of the observed variability. Proteoglycan expression was increased 
through treatment of astrocytes with ascorbic acid and TAT-uptake efficiencies were 
evaluated. The increase in proteoglycan content resulted in a significant increase in TAT-
mediated transduction, whereas trypsinizing the cells resulted in a 30% decrease in GAG 
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expression and a significant decrease in TAT-mediated transduction. It was therefore 
concluded that TAT protein delivery is strongly dependent on the cell type, as well as the 
growth environment.  
 
The mechanism of endocyotosis was proposed in one of the first studies of TAT uptake. 
Frankal et al. 1991 demonstrated TAT-mediated uptake through endocytosis by performing 
fluorescence pulse-chase experiments, in which rhodamine conjugated with TAT was found 
on the cell surface, followed by localization to the cytoplasm and nucleus (Mann and Frankel 
1991). However, following these results, it was demonstrated that internalization was not 
significantly inhibited by incubation at low temperatures, by depletion of the cellular ATP 
pool or by inhibitors of endocytosis (Suzuki, Futaki et al. 2002), concluding endocytosis was 
not the mechanism of TAT-mediated uptake. In 2005, Chernomordik et al. demonstrated that 
cellular uptake of unconjugated TAT peptide involved clathrin-dependent endocytosis and 
heparan sulfate receptors (Richard, Melikov et al. 2005). Using different primary cells and 
inhibitors of clathrin-dependent endocytosis, they demonstrated that TAT uptake was ATP 
and temperature dependent, as well as partially dependent on the clathrin endocytosis 
pathway and heparan sulfate receptors (Richard, Melikov et al. 2005). However, uptake was 
only partially inhibited by clathrin and heparan sulfate inhibitors, therefore it was concluded 
that internalization of the TAT peptide may be through a combination of several unidentified 




In 2009, Yezid et al., summarized nicely a proposed ‘endosomal translocating mechanism’ of 
TAT-mediated protein delivery: “Tat first binds to several cellular receptors such as CD26, 
CXCR4, heparan sulfate proteoglycans, and the low-density lipoprotein receptor-related 
protein. Tat is then endocytosed, essentially by the clathrin-coated pit pathway. Once in the 
endosome, Tat crosses the membrane to enter the cytosol. This translocation step is triggered 
by endosome low pH (pH 5.3-5.5) and is facilitated by the cytosolic chaperone Hsp90. 
Hence, Tat enters cells using a “conventional” endosomal translocating toxin strategy, just 
like diphtheria toxin, which is the best characterized example of this type of toxin.” (Yezid, 
Konate et al. 2009). It remains to be proven whether this is the precise and complete step by 
step mechanism of TAT translocation across the plasma membrane or if additional receptors 
and mechanisms will be proposed and identified.  
 
Although the exact mechanism of TAT-mediated protein delivery remains somewhat 
ambiguous, over the past five years there has been significant demonstration of the diversity 
of cellular uptake made using a TAT-based delivery system. The TAT-mediated delivery 
system has been extended from proteins to a large variety of cargoes such as 
oligonucleotides, imaging agents, low molecular mass drugs, nanoparticles, micelles and 
liposomes (Gump and Dowdy 2007). Its delivering potential has been described as almost 
unlimited. However, for a given drug or protein to be considered successfully delivered, it 
must be transported across the plasma membrane and efficiently released into the cytoplasm. 
The plasma membrane of mammalian cells has been a barrier to effective delivery of 
potential drug candidates into the cell for decades. Several other methods have been 
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employed to facilitate delivery across the plasma membrane, such as electroporation, 
microinjection or macromolecular systems. However, these strategies often do not yield 
sufficient delivery, while comprising the cells and frequently resulting in cell death. 
Although perhaps not perfectly understood on a mechanistic level, TAT-mediated delivery 
has overcome many of the obstacles surrounding other therapeutic delivery systems. As a 
result, future investigations which attempt to utilize TAT as a delivery mechanism are 
warranted. 
2.3 Islets of Langerhans and Diabetes 
The pancreas is a multi-function gland organ. It acts as both an endocrine gland, secreting 
vital hormones directly into the blood and as an exocrine gland by secreting and transporting 
22 digestive enzymes such as lipases, proteases and amylases through the branched ductal 
network to the small intestine (Slack 1995). The majority of the pancreas mass is comprised 
of exocrine cells, with less than 2% of its mass consisting of endocrine cells. The endocrine 
cells are located throughout the organ primarily in clusters, termed islets of Langerhans or 
islets. A healthy adult human pancreas has approximately one million islets, with a combined 
mass of only 1 gram. Islets are composed of four cells types: alpha, beta, delta and pancreatic 
polypeptide secreting cells. Each cell type is responsible for producing the hormones 
glucagon, insulin, somatostatin and pancreatic polypeptide, respectively, which work 
together as complex micro-organs to regulate blood glucose levels. Beta cells are the most 
prevalent cell type, comprising 65-85% of an islet and are solely responsible for the secretion 




Type I and type II diabetes are both characterized by the impairment of islet secretary 
function of insulin. Specially, type I diabetes is associated with the autoimmune destruction 
of insulin producing beta cells and type II diabetes by an insulin resistance. One of the most 
widely used current treatment strategies requires administration of exogenous insulin, which 
ultimately can lead to unstable blood glucose control, resulting in the risk of hypo- or 
hyperglycemic episodes. As well, there are many associated long-term effects of insulin use, 
including: cardiovascular disease, nephropathy, retinopathy, and neuropathy (Shamoon, 
Duffy et al. 1993; Steffes, Chavers et al. 2003). In attempts to achieve independence from 
insulin therapy, clinical trials have demonstrated promise of islet transplantation (Ryan, 
Lakey et al. 2001; Shapiro, Ryan et al. 2001); however, up to three islet transplants are 
needed to achieve insulin independence. Furthermore, often five years post-transplantation 
patients require insulin injections due to the decline in graft function related to the immune 
response to the transplanted islets (de Kort, de Koning et al. 2011). Besides the poor long-
term results of islet transplantation, there remains a short supply of donor pancreata in which 
the islet cells are isolated (Noguchi 2009). 
 
The regenerative potential of islets of Langerhans has been demonstrated in animal models of 
decreased beta cell mass (Montana, Bonner-Weir et al. 1993). In these in vivo studies 
however, it has proven difficult to implicate specific cell phenotypes, while clearly 
identifying the mechanisms involved in the regeneration process. Although some studies 
have implicated the pancreatic ductal region as the site of islet regeneration (Bouwens and 
Pipeleers 1998), others have implicated stem or progenitor cells which reside within the islet 
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as the source of regeneration (Guz, Nasir et al. 2001; Zulewski, Abraham et al. 2001). 
Additionally, one group has suggested that insulin-producing β-cells self-duplicate to expand 
islet cell mass (Dor, Brown et al. 2004). Not only does the mechanism of islet regeneration 
remain unknown, it is also unclear how similar human islets are to other species. Therefore, it 
remains to be identified the degree to which animal models can be applied to interpret the 
human system. This emphasizes the importance of studying human patient derived cells. 
2.4 Human Islet-Derived Progenitor Cells (hIPCs) 
Isolated islets cultured in vitro are a promising source of progenitor cells for islet 
replacement because they expand exponentially into a large mixed population of proliferative 
islet hormone-negative cells (Russ and Tobin 1998; Schmied, Ulrich et al. 2000). These 
proliferative cells have been termed islet-derived progenitor cells (IPCs). The 
characterization of origin of IPCs however, has not yet been determined. Several groups have 
attempted to characterize the origins of IPCs, debating β-cell origin versus non-β-cell origin. 
Dedifferentiated human β-cells have been implicated as a source of IPCs (Gershengorn, 
Hardikar et al. 2004; Bar, Russ et al. 2008), but appear to require soluble factors from other 
non-β cells. Conversely, using a mouse model, several groups (Chase 2007, Atouf 2007 and 
Morton 2007) have demonstrated that the proliferative IPC populations from dedifferentiated 
islets were not of β-cell origin (Atouf, Park et al. 2007; Chase, Ulloa-Montoya et al. 2007; 
Morton, Geras-Raaka et al. 2007). Mesenchymal stromal cells present within islets or the 
pancreas have also been suggested as a source of IPCs (Davani, Ikonomou et al. 2007; Gallo, 
Gambelli et al. 2007). Despite the lack of scientific consensus on IPC origin, IPCs hold 
promise in cell replacement therapies for the treatment of diabetes, by potentially providing a 
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large cell source which ideally can be coaxed to differentiate into functional insulin-
producing cells.  
 
Epithelial-mesenchymal transition (EMT) has been shown to be critical in embryogenesis, in 
which epithelial cells lose their mature characteristics (i.e. gap junctions) and acquire 
characteristics of mesenchymal cells (i.e. vimentin expression) (Vicovac and Aplin 1996). 
Studies have suggested that pancreatic beta-cells undergo EMT and dedifferentiate into IPCs. 
However, it is argued that these results may be flawed, since the harvested islet fractions 
studied are never pure endocrine cell populations (Atouf, Park et al. 2007). Therefore, those 
studies cannot definitively prove that the IPCs are not derived from, for example exocrine 
cells, and as a result are not definitively of beta-cell origin (Atouf, Park et al. 2007). Chase 
2007, demonstrated using genetic-based lineage-tracing models that IPCs were not derived 
from beta-cells undergoing EMT, but that the IPCs are a population of MSCs from within the 
pancreas (Chase, Ulloa-Montoya et al. 2007). However, it was unclear if the observed 
differences of EMT hypothesis versus MSC origin were due to undetermined animal model 
and/or cell culture differences (Chase, Ulloa-Montoya et al. 2007). 
 
To date, efforts to dedifferentiate IPCs into insulin-producing cells have demonstrated 
promising, however, inconsistent results. Gershengorn 2007 reported characterization of 
human IPCs (hIPCs) as a population of MSCs capable of dedifferentiation into islet-like 
structures following proliferative expansion. In this study, the hIPCs expressed the MSC 
surface markers CD73/90/105-positive and CD14/19/34-negative (Davani, Ikonomou et al. 
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2007). Contrary to Chase 2007, the origin of the hIPCs was described as migrating out in 
vitro from the islets spreading into mono-layers not simply from pancreatic tissue.  Following 
proliferative expansion, cell clusters were generated which were transplanted into a small 
pocket created under the renal capsule of SCID mice. It was reported that 22 of 35 
transplanted clusters differentiated and matured into functional cells which secreted human 
C-peptide (marker of endogenous insulin production) in response to glucose. However, 
secretion was only at levels of 1% compared to adult islets (Chase, Ulloa-Montoya et al. 
2007). 
 
Melton 2004 demonstrated that beta-cells were formed by self-duplication of pre-existing 
beta-cells (Dor, Brown et al. 2004), which are results inconsistent with beta-cells arising 
from stem or progenitor cells. These results were in the context of normal growth of beta-
cells; therefore, it remains possible that stem or progenitor cells do participate in beta-cell 
regenerative repair. It was concluded that beta-cells are the major source of new beta-cells in 
normal adult life, challenging the view that a stem cell population is responsible for beta-cell 
homeostasis (Dor, Brown et al. 2004). Later in 2007, Melton et al. published further evidence 
confirming the capability of beta-cell duplication and maintenance, demonstrating that the 
beta-cell population is homogeneous with respect to replication capacity. Therefore, 
suggesting that all beta cells are candidates for in vitro expansion (Brennand, Huangfu et al. 




In 2008, Melton took a different approach to generating beta-cells for transplantation.  Rather 
than focusing on the previous findings of beta-cell duplication, the focus was shifted to 
converting adult cells into beta-cells. Examples of adult cell reprogramming are known, such 
as the discovery of induced-pluriopotent stem cells (Takahashi, Tanabe et al. 2007). 
However, unknown are controlled methods of intentionally directing one cell type into a 
specific desired differentiated cell type. Recently, Melton et al. using key developmental 
regulators in vitro (Ngn3, Pdx1 and Mafa), reprogrammed exocrine cells in adult mice into 
beta-like cells which could ameliorate hyperglycemia. This suggested that beta-cells may 
regenerate from non-beta-cell origin, such as a stem cell population (Zhou, Brown et al. 
2008). 
 
In summary, the identification and confirmation of a pancreatic stem cell population remains 
elusive. There is strong evidence that isolated human islets contain a distinct population of 
mesenchymal stem cells (MSCs) (Carlotti, Zaldumbide et al. 2010). Although these 
transplanted MSCs are reported to express insulin mRNA at low levels, they are indeed 
capable of differentiating into hormone-expressing cells at levels 1% of adult islets (Davani, 
Ikonomou et al. 2007). However, it is unclear how and if these cells contribute to islet 
neogenesis in vivo. It is known that during the life of a healthy adult, beta cells are 
regenerated perhaps from self-duplication or activation of a dormant stem cell population 
contained in the pancreatic ducts, from within the islets or the bone marrow. It is possible 
that a combination of several of the proposed cell types may contribute to islet neogenesis. 
For example, during embryonic induction, islets may arise from cells found within the ductal 
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network, whereas during adulthood beta cells may self-duplicate or dormant ‘MSC like’ stem 
cell populations may differentiate into islets. Lastly, it is important to note that the 
identification of extrinsic factors and the culture conditions required to promote islet 
neogenesis is another key required to produce cells for transplantation. Ultimately, 
continuous and rigorous characterization of the discussed cell types in parallel with the study 
of important regulatory factors involved in islet neogenesis will result in insulin secreting 
cells which are adequate for islet transplantation.   
2.5 Islet Neogenesis Associated Protein (INGAP) 
INGAP is a 17 KDa member of the Reg family of proteins that was first discovered in 1997 
by Dr. Aaron Vinik and Dr. Lawrence Rosenberg who identified a gene, islet neogenesis 
associated protein (INGAP), whose product stimulated the growth of insulin-producing cells 
in the pancreas of a hamster model (Rafaeloff, Pittenger et al. 1997). Although not 
conclusive, they postulated that the gene expressed a protein that appeared to initiate cell 
proliferation in pancreatic ducts but not directly in islets. In this model, animals developed 
increased beta cell mass that  was able to reverse induced diabetes. Initially, a crude protein 
extract was prepared from the pancreas of the model hamsters, termed ilotropin (Pittenger, 
Vinik et al. 1992). The protein INGAP was later identified as the active component of the 
crude hamster extract (Rosenberg, Vinik et al. 1996). Sequencing of the full-length protein 
identified a region (amino acids 104-118) that was specific in comparison to other Reg 
proteins. This region, termed INGAP peptide (INGAP-PP), was synthetically produced and 
proposed to be the region of INGAP which induced islet neogenesis in hamsters (Rafaeloff, 




To date, studies of INGAP have focused on evaluating the islet neogenesis effects of 
INGAP-PP. Jamal et al. were the first to demonstrate the phenotypic plasticity of pancreatic 
islets using an INGAP-PP treatment. In this study, isolated islets were induced to duct-like 
structures which displayed the loss of islet-specific hormones and then treated with INGAP-
PP. It was reported the reversion of the islet-derived duct/cystic structures back to islet-like 
structures displaying the expression of islet hormones and glucose responsiveness following 
INGAP-PP treatment (Jamal, Lipsett et al. 2005). These results suggested that human islets 
may possess a remarkable degree of morphogenetic plasticity when exposed to INGAP-PP. 
As a result, since this publication several groups have focused on evaluating the effects of 
INGAP-PP on various animal islets. 
 
INGAP-PP has been studied extensively in rat islets. In 2006, Barbosa et al. cultured 
neonatal rat islets for 4 days with INGAP-PP. These islets released significantly more insulin 
in response to glucose in comparison to islets which were cultured without the peptide. 
Furthermore, several genes related to islet metabolism, insulin secretion and beta cell mass 
were modified by INGAP-PP. It was concluded that INGAP-PP enhances the secretion of 
insulin and the transcription of genes involved with islet neogenesis (Barbosa, Bordin et al. 
2006). Following this study, Barbosa et al. attempted to elucidate the mechanistic pathways 
involved in INGAP-PP signaling in rat islets. Studying both neonatal and adult rat islets, it 
was observed that INGAP-PP stimulated the up-regulation of cholinergic receptors which 
suggested the participation of the cholinergic pathway in INGAP-PP mediated effects in rat 
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islets (Silva, Barbosa et al. 2008). Subsequent to this publication, the group wanted to further 
understand the mechanisms involved in INGAP-PP effects upon their findings of increased 
beta cell mass and function. They shifted their focus to working with a complete animal 
model, the hamster, whereas their previous work had focused on studying isolated rat islets in 
vitro. This study concluded that INGAP-PP promoted a controlled and functionally active 
increase in beta cell mass in vivo and suggested the existence of a negative feedback loop 
which involved Ngn-3, a transcription factor involved with the specification of endocrine 
lineage (Madrid, Del Zotto et al. 2009).  
 
In 2009, this group took a different approach to evaluating the effects of INGAP-PP by 
focusing on islet beta cell differentiation of mouse embryonic stem (mES) cells. Using 
established mES differentiation protocols with or without the addition of INGAP-PP, gene 
expression was quantified using qPCR. It was determined that INGAP-PP increased 
significantly insulin gene expression, while reducing glucagon and somatostatin gene 
expression. Additionally, PdX-1 gene expression increased by 115% in INGAP-PP treated 
cells. It was concluded that INGAP-PP promoted stem cell differentiation into beta cell-like 
phenotype, while simultaneously decreasing mES differentiation towards non-beta cell 
precursors (Francini, Del Zotto et al. 2009). This significant finding indicated for the first 





In addition to rats, hamsters and mice, INGAP-PP has been investigated in dogs by Vinik’s 
group in 2007. Non-diabetic beagle dogs received either a placebo or three different doses of 
INGAP-PP injections (0.5, 1.5 or 10 mg/kg). It was determined that dogs which were treated 
with INGAP had a significant (P < 0.001) increase in the percentage of insulin-positive cells 
and insulin gene expression. Additionally, there was a dose dependent trend of increased 
insulin-positive cells and gene expression (Pittenger, Taylor-Fishwick et al. 2007). It was 
concluded that INGAP-PP stimulates islet neogenesis in dogs. However, like in other animal 
models it was not possible to determine with certainty specifically which cells contributed to 
the neogenesis effect. It was suggested that islet progenitor cells found in the pancreatic duct 
epithelium of the healthy dogs stimulated islet neogenesis. However, this was based on 
previous findings from this group in which the duct cells of INGAP-PP treated diabetic mice 
whose diabetes was reversed had increased PDX-1 expression specifically in the duct cells 
(Rosenberg, Lipsett et al. 2004). 
 
The mechanism of INGAP is still under debate. However, the evidence presented from a 
range of groups using several different animal models (rats, hamsters, mice and dogs) 
demonstrates its potential role in the cure of diabetes. As a result, in 2003 the FDA approved 
human trials using INGAP-PP as a drug to treat diabetic patients. The first phase 2 clinical 
trials evaluated INGAP-PP in 200 patients with both type I and type II diabetes. Patients 
received INGAP-PP treatment for 90 days and overall INGAP-PP was found to increase C-
peptide secretion in Type 1 diabetic patients and improve glycemic control in Type 2 diabetic 
patients (Dungan, Buse et al. 2009). Clear trends of efficacy were demonstrated, however, 
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evaluating the effects of a refined formulation, delivery regimen, appropriate dosage, site of 
administration, as well as the duration of therapy were concluded as necessary considerations 
in future clinical trials. 
 
Although the original work of cloning and sequencing  INGAP concluded that both the 
peptide and the protein demonstrated effects of islet neogenesis, it was noted that INGAP 
protein appeared to have a more potent effect in comparison to the peptide (Rafaeloff, 
Pittenger et al. 1997). Recently, the production and characterization of full-length 
recombinant INGAP (rINGAP) has been reported to facilitate studies of the mechanism(s) of 
INGAP action (Assouline-Thomas, Pilotte et al. 2009). Importantly, rINGAP exhibited 100 
times the bioactivity in comparison to INGAP-PP using an in vitro assay (Assouline-Thomas, 
Pilotte et al. 2009). To date, there have been no subsequent publications which study the 
effects of rINGAP on islet neogenesis. 
 
In summary, since INGAP’s discovery, several groups have attempted to determine its 
mechanism and role in islet neogenesis, as well as its been investigated as a drug in phase 
two human clinical trials for the treatment of type I and type II diabetes. It is believed that in 
the animal pancreas, INGAP differentiates islet progenitor cells or stem cells into insulin 
secreting islet-like cells; and/or that INGAP induces a reversion of proliferative duct-like 
epithelial cells of non-β cell origin to insulin secreting cells; and/or that INGAP acts on 
existing islets by increasing insulin secretion (Yuan, Rosenberg et al. 1996; Jamal, Lipsett et 
al. 2003; Lu, Gu et al. 2005). Evidence suggests that hIPCs may represent an important adult 
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precursor or stem cell population. If so, it is conceivable that when expanded and cultured in 
vitro, hIPCs could offer a useful supply of cells which, given the right factor(s), could be 
coaxed into islet-like cells and used for transplantation. To date, studies using only INGAP to 
dedifferentiate hIPCs into insulin-producing islet-like cells have yet to be published. As a 
result, investigating INGAP’s effect on hIPCs at the proteomic, behavioral and phenotypic 
levels, will further characterize both INGAP and hIPCs therapeutic potential in the treatment 
of diabetes.  
2.6 Proteomics 
Like the human genome work, there is valuable information to be obtained from studying 
protein-protein interactions. Proteomics focuses on the identification and function of proteins 
in the cell. The proteins in a cell change with the conditions of the cell including: the stage of 
cell cycle, the age of the cell, and with external or internal signaling. As a result, the amount 
and complexity of the data obtained from the sequencing and mapping of every organism’s 
proteome is several times greater than that of the same organism’s genome. Unfortunately, 
because of the quantity and complexity of the data required to elucidate a proteome, 
proteomic technology has not advanced at the same rate as that of the genome. The current 
and most commonly used laboratory technique for expression proteomics is separation using 
two-dimensional polyacrylamide gel electrophoresis (2D PAGE), in which an electric current 
is applied to a gel matrix to separate an entire protein population. There are several variations 
to the technique, such as the dimensions of separation, the composition of the polyacrylamide 
gel, as well as the pH range utilized. To achieve quantitative analysis, two-dimensional 
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differential in gel electrophoresis (2D DIGE) uses fluorescent dye labeling in combination 
with 2D PAGE, allowing statistical analysis of the protein abundances. Once the lysate 
mixture of cell-derived proteins has been separated, they are identified primarily by mass 
spectrometry (MS). Finally, after the proteins have been identified, bioinformatic analysis is 
used to elucidate the protein interaction networks. 
2.6.1 Two-Dimensional Gel Electrophoresis (2D PAGE) 
In 2D PAGE, proteins are separated in the first dimension  based on their isoelectric point, 
followed in a second dimension by mass. Each protein localizes differently throughout the 
gel, creating individual spots based on their unique size and charge. After the proteins have 
been separated and stained, spots can then be cut out from the gel, digested into short 
peptides and analyzed using MS. For over three decades 2D PAGE has been used as a 
powerful tool for the analysis of large protein sample populations. However, there are several 
limitations which render this technique more of a qualitative tool. 2D PAGE requires 
significant preparation and consideration of the protein sample being analyzed. A significant 
amount of hydrophobic proteins, such as transmembrane receptors and alkalines, are 
underrepresented on the gel as they cannot be integrated into the aqueous buffer system (Cho 
2007). Additionally, 2D PAGE is a time-consuming, labour-intensive process, requiring 
skilled and trained operators. Depending on the optimal voltage for separation, the process 
can take up to 60 hours before the gels can be stained and visualized. Proteins present at low 
concentrations in the protein sample are generally not detected on the stained gels, even 
when using highly sensitive stains such as Deep PurpleTM (Xie, Goldys et al. 2007). 
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Furthermore, a resolved protein spot on a 2D gel can represent more than one protein, as 
often some proteins cannot be completely resolved within a single gel.  
Conceivably the biggest limitations of 2D PAGE are reproducibility and variability. 
Experimental or technical variability can be introduced by: heterogeneities in the gel 
polymerization, incomplete protein uptake into the isoelectric focusing strips, deficient 
migration of the proteins during isoelectric focusing and incomplete protein transfer from the 
first to second dimension (Smith 2006). The unavoidable introduction of these experimental 
errors results in gel-to-gel technical variation that can potentially mask the biological 
variation between protein samples, therefore resulting in erroneous results (Smith 2006). 
Lastly, in order to compare protein samples and protein populations, different samples have 
to be separated using individual gels. The individual gels are then visually aligned to 
compare spot patterns or differences in intensities from one gel to another. As there are many 
explicit experimental steps in 2D PAGE, there is tremendous potential for the introduction of 
gel-to-gel variability and the mis-match of proteins across gels.  
2.6.2 Two-Dimensional Differential In Gel Electrophoresis (2D DIGE) 
Over the past three decades, 2D PAGE coupled with MS has been one of the only methods of 
high resolution protein separation and identification (Issaq and Veenstra 2008). However, as 
the study of proteomics advances, the limitations of 2D PAGE have driven the development 
of a quantitative technique. 2D DIGE builds on the principles of separation in 2D PAGE by 
adding an accurate quantitative dimension that allows simultaneous separation and 
comparison of two protein samples on a single gel (Marouga, David et al. 2005). This is 
 
 32 
achieved by first labeling each protein sample with specifically engineered fluorescent Cy 
dyes: Cy2, Cy3 and Cy 5. The Cy dyes are charge matched with the residues they bind and 
have the same molecular weights (0.5kDa). The size and charge matching of the three dyes 
results in the labeling having an equal impact on protein migration in the gel, allowing for 
accurate comparison of the fluorescent intensities (Karp, Kreil et al. 2004). Digital protein 
spot images of each labeled sample within a gel is created through sequential excitation of 
the three fluorophores. Following a similar three day separation process as 2D PAGE (with 
the addition of fluorescent labeling), the proteins are visualized using a fluorescence scanner 
(GE Healthcare) and a computer software package, such as DeCyder (GE Healthcare), which 
provides analysis of the protein abundances between populations. 
An additional advantage of the DIGE technology is the use of an internal standard. The 
internal standard is a pooled sample loaded on all gels in the experiment, containing equal 
amounts of the protein samples. The internal standard assists with inter-gel alignment, which 
allows for a relative measurement between the same protein spot in different gels. While 
viewed as advancement, the dependence of DIGE on fluorescent labeling for quantification is 
costly, as well as it introduces new technical concerns. 2D DIGE was designed to reduce the 
main limitations of 2D PAGE, which are gel-to-gel variation and quantification. Although 
2D DIGE does reduce gel-to-gel variation, through the use of an internal standard to align the 
gels, gel-to-gel variation is not eliminated and therefore several issues remain which limit the 
use of the technology. Besides the introduction of fluorescent dye labeling, the technology is 
based on 2D PAGE, therefore limitations, such as: heterogeneities in the gel polymerization, 
incomplete protein uptake into the isoelectric focusing strips, deficient migration of the 
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proteins during isoelectric focusing and incomplete protein transfer from the first to second 
dimension, all remain significant in 2D DIGE. 
2.6.2.1 2D DIGE Quantification and Statistical Analysis 
Although there remain issues surrounding the 2D DIGE technology, its development has 
permitted the multiplexing of samples and the quantification of protein spots across a gel 
series. This is achieved by the internal standard and by protein labeling with the fluorescent 
Cy Dyes. Since these dyes have different system gains based on differences in fluorescence, 
to account for these differences the measured spot volumes from the gels are first 
normalized. The software co-detects the spots from the digital images, performs 
normalization and compares the spot volumes (fluorescent intensities).  Normalization in 
DeCyder is based on the assumption that the majority of proteins are not differently 
expressed (Karp, Kreil et al. 2004). Normalization adjusts the primary spot volumes ( 1) by 
a scaling factor ( ) so that the frequency histogram of the log volume ratios centres on zero, 
resulting in a calculated normalized spot volume ( 1):  
                                                                              1 1    (1)   
To determine the scaling factor ( ), a normal distribution is fitted to the main peak of the 
frequency histogram and the mean of the fitted normal distribution is shifted to zero by the 
factor ( ). Shifting the mean of the fitted normal distribution to zero is done because of the 
assumption that most proteins are not differently expressed. However, depending on the 
biological system being analyzed this assumption is not always accurate. Therefore, 




Once the spot volumes have been normalized by a factor ( ), DeCyder calculates a log 
volume ratio ( ) of the primary spot volume in the secondary image ( 2) over the 
normalized spot volume ( 1): 
                                                                                log    (2) 
Using the log volume ratio ( ), an expression ratio ( ), is calculated based on if  is less 
than or greater than zero:   
                                                                            0, 1   (3) 
                                                                           0, 1   (4) 
The expression ratio ( ) is reported to the user as the measurement of fold change and is 
greater than one or less than minus one (Karp, Kreil et al. 2004).  
     
In addition to the reported fold change of a protein spot between the two samples ( ), a p-
value is also reported to the user.  The p-value is a measure of significance of the fold change 
in terms of the false positive rate (Karp, McCormick et al. 2007). A Student’s t-test is used to 
calculate the statistical significance of an abundance change between the two groups, 
considering both the within group variance and the between group variance. For example, a 
large p-value indicates that the within group variance is large compared to the between group 
variance, hence the reason why gel-to-gel variation has such an immediate effect on the 
statistical analysis. The null hypothesis being tested in the Student t-test is that there is no 
significant change in the protein abundance between the two experimental groups (Storey 
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and Tibshirani 2003). The Student’s t-test assumes a normal distribution of protein 
abundances and a frequency distribution of the p-values is used to estimate the proportion of 
features that are unchanging (Karp, McCormick et al. 2007).  P-values reflect the probability 
that the observed change has occurred from random chance alone, supporting the null 
hypothesis.  In other statistical analyses, probability values less than 0.05 from a Student t-
test are generally used to determine a statistically significant difference from the null 
hypothesis. However, when evaluating 1000 proteins, for example, a p-value cut off of 0.05 
would represent potentially 50 false-positives. As a result, it is argued that stringent 
confidence intervals in the 99th percentile (p<0.001), are more valid for DIGE applications 
(Storey and Tibshirani 2003).  
Although a prescribed significance threshold of, for example 0.001, is more stringent than 
0.05, a substantial number of false positives may still accumulate. For example, often protein 
systems studied have greater than 2000 proteins detected, resulting in potentially 20 false-
positives out of a list of 50. This accumulation of false-positives at even low p-value cut-offs 
is due to the lack of consideration of multiple testing in the Student t-test. Thousands of 
statistical Student t-tests are being conducted, however on an individual spot basis, without 
taking into account that the spots being simultaneously tested have between-feature 
dependence (Storey and Tibshirani 2003). For example, often in 2D-gel proteomics, proteins 
can be represented multiple times in a charge train (Karp, McCormick et al. 2007). As a 
result, Benjamini and Hochberg recognized this multiple testing phenomenon and defined the 
false discovery rate (FDR) as the proportion of changes identified as significant that are 
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actually false (Hochberg and Benjamini 1990). As an extension to the FDR, Storey et al. 
developed a q-value, which is a measure of FDR in comparison to the p-value.   
In summary, Student t-tests control the rate in which unchanging features are indicated as 
significant, whereas the FDR test controls the rate of those significant features being actually 
false (Storey and Tibshirani 2003). As a result, the q-values are calculated directly from the 
p-values using the FDR feature within the DeCyder software. The exact algorithm is 
confidential, however a frequency distribution of the p-values is used to determine the 
number of features which are unchanging. If there were no changes in protein expression, a 
uniform distribution of the p-values is expected because it is assumed through testing 
thousands of features that p-values of all ranges to one will be obtained by chance. However, 
proteins which change in expression will have low p-values (<0.05) and stand out above the 
unchanging proteins which contribute to a uniform frequency distribution. A q-value is then 
calculated for each protein using the corresponding p-value and through estimating the 
proportion of false positives within the total number of proteins considered initially 
significant (Karp, McCormick et al. 2007). 
2.6.2.2 DIGE Experimental Design 
The development of the spectrally resolvable Cy Dye’s permits quantification across many 
gels, which ultimately allows for statistical analysis, such as the Student’s t-test and the FDR 
analysis. However, both the Student’s t-test and the FDR approach rely on the use of a 
correct experimental design. The design of any experiment is critical to a hypothesis being 
successfully answered and to the validity of the results obtained. To maximize the 
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information gained from a DIGE experiment one must consider replication type, replication 
number and overall design. The replication type affects what can be concluded from the 
experiment. There are two types of replicates: biological and technical. Biological replicates 
are different biological samples from the same treatment group (Karp, Spencer et al. 2005). 
Technical replicates are repeated measures on the same biological sample (Karp, Spencer et 
al. 2005). For example, biological replication of a brain would consist of each replicate being 
from a different brain, whereas technical replication would be replicate samples from the 
same brain. Biological variability is inherent between all organisms, arising from genetic 
and/or environmental factors (Karp, Spencer et al. 2005). Without the consideration of 
biological replicates, false conclusions which assume there is no biological variability will be 
drawn. Including biological replication into an experimental design considers the natural 
variation within a sample population. In summary, false deductions may be made in the 
absence of biological replication. On the other hand, in experiments with only biological 
replication in which technical replication is not included, the uncertainty about the true 
reading for a given sample is reduced (Karp, Spencer et al. 2005). Technical replicates are 
essentially repeat measurements on the sample and therefore reduce experimental noise 
and/or measurement error. 
 
Replication allows experimentally collected data to be analyzed statistically. Therefore, 
considering both biological and technical replication in the experimental design is critical to 
allowing more vigorous data analysis and interpretation.  The power of a DIGE experiment is 
the probability that a true positive will be detected (Horgan 2007). Ideally both replicate 
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types should be employed to achieve sufficient power of analysis in an experiment, however 
depending on the experimental circumstances incorporation of both replicate types into the 
experimental design may not be feasible.  Particularly, in experiments with low sample yields 
and/or experiments with cost restrictions, using both types of replication is not always 
possible or practical.  For example, when performing proteomic analysis on human samples, 
which are often a highly-limited resource and availability cannot be guaranteed, biological 
replication is directly dependent on availability of independent biological samples. In 
comparison, in studies with cost and equipment restrictions, a large number of technical 
replicates may not be reasonable. Overall, it is important to be aware of the fact that the 
number of replicates (gels) is directly related to the power of the experiment for the size of 
expression changes detected (Horgan 2007). Therefore, maximizing the replication within an 
experimental design increases the power of the experiment.  
 
Sample pooling is an alternative to using several individual organisms through reducing the 
number of independent biological samples (Karp and Lilley 2009). Individually prepared 
biological samples are combined using equal contributions from each to form a pooled 
sample. If the material is available, a sub-pooling design can be employed, in which 
additional biological pools can be formed, each representing a biological replicate. Technical 
replicates of the pooled samples can then be measured through repeat measurements on the 
pools. Changes in protein expression will not be identified if the biological variability of the 
population is greater than the protein expression changes, therefore sample pooling is 
especially favorable when biological variability is high (Karp and Lilley 2009). When sample 
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pooling is utilized, identified protein expression changes are changes in the average 
biological pooled sample detected above the technical noise. It is important to consider that 
sample pooling should not be incorporated into the design of experiments if the intention of 
the experiment is to show a relationship between the detected protein expression changes and 
the biological subjects which were pooled (Karp and Lilley 2009). As information about 
variables at the biological subject level is lost in the pooling process. 
 
In summary, sample pooling reduces biological variability by minimizing individual 
biological variation. Sample pooling, however, assumes biological averaging; that the 
measurements taken on the pooled sample are equal to the average of the individual samples 
which contributed to the pool (Karp and Lilley 2009). In other words, pooling assumes that 
the biological mean equals the mathematical mean. However, in biological samples with a 
large degree of variation, Jensen’s inequality effect, in which the mean of the individuals is 
less than the mean of the pool, may apply and therefore this assumption may not hold (Karp 
and Lilley 2009). The average of the pool must be greater than or equal to the average of the 
individuals when outliers in the individual samples are attenuated through the log 
transformation and then averaged (Karp and Lilley 2009). Karp et al 2009 demonstrated that 
the Jensen’s inequality effect may be significant for some biological systems, but not for all.  
For example, the biological variation between human brains is much greater than mouse and 
therefore there is balance between biological variation, technical variation and sample 
pooling. Thus, sample pooling is beneficial when there is large biological variation, however 
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to avoid systematic biasing, the correct design of experiments needs to be employed (Karp 
and Lilley 2009).  
 
Depending on the biological variability of the samples, the technical variability of the 
process, the availability of financial and equipment resources, as well as the overall aim of 
the experiment, an indefinite number of experimental designs can be considered. Figure 2-1  
represents four different possible experimental designs for comparing a treatment group 
versus a controlled group. The first option is an experiment with only technical replication 
(figure 2-1i). All that can be concluded from this experiment is that one biological sample is 
different from the other, however no broader application to the entire biological populations 
can be made. The second option is an experiment with only biological replication (figure 2-
1ii). Biological changes will be detected above the technical variability and no conclusions 
within each of the biological populations can be drawn. A third design of experiments 
represents an ideal, largely funded and supported experiment, incorporating both technical 
and biological replication (figure 2-1iii). Lastly, the fourth experimental design is a sub-
pooling design, in which two biological replicates are pooled and three independent pools are 
compared (figure 2-1iv). In conclusion, there are many factors to consider when designing a 
2D DIGE experiment. With the proper consideration of the ultimate goal of the experiment 
and the correct experimental design, the obtained results can serve to answer the original 






Figure 2-1: Representation of possible experimental DIGE designs when comparing control (C) 
versus treated (T). (i) Represents an experiment with only technical replication. (ii) Represents 
an experiment with only biological replication. (iii) Represents an ideal, largely funded and 
supported experiment, incorporating both technical and biological replication. (iv) Depicts an 
ideal sub-pooling design of experiments, in which two biological replicates are pooled and three 
independent pools are compared. B is biological replicate. T is technical replicate. P is pooled 
replicate. Image adapted from Karp and Lilley 2009. 
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2.6.3 Mass Spectrometry (MS) 
Mass spectrometry (MS) is an analytical technology that generates a mass spectrum of the 
peptides in the sample. The mass spectrometer scans the population of eluting ions, measures 
the mass to charge ratio, fragments the peptides through collision and then obtains a mass 
spectrum from the fragment patterns. The generated mass spectrum is compared to model 
spectrums in databases to identify the protein originally separated using 2D PAGE (Webb-
Robertson and Cannon 2007). Over the past three decades, 2D PAGE and 2D DIGE coupled 
with MS has been the preferred approach of global protein profiling. MS has provided an 
essential analytical component to the process of understanding biology from a systems level. 
The process of computational peptide identification, although fundamental to MS, provides 
limitations to the technology (Webb-Robertson and Cannon 2007). Computational peptide 
identification compares generated mass spectrums to model spectrums, created from 
predicted peptides of a sequenced genome. However, these computational database searches 
can return false-positives. Additionally, to allow for the expected experimental variation 
between the generated mass spectrums and the model spectrums, a normal mass error 
distribution is used in the computational process which can ultimately also result in proteins 
being falsely identified (Webb-Robertson and Cannon 2007). 
 
2D PAGE is the main technique used to separate proteins of interest prior to MS analysis. 
However, although widely used it poses problems for high-throughput MS sample 
preparation.  Specifically, it is time-consuming to pick protein spots and it is often difficult to 
detect low abundant proteins on the 2D gels. Therefore, rendering the identification of low 
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abundant proteins unreliable and/or infeasible. As a result, over the past five years companies 
have been focusing on technology developments which automate many of the steps involved 
in 2D-PAGE. One method has been transferring the protein samples from 2D gels onto 
matrix assisted laser desorption/ionization (MALDI) targets. This novel technology supports 
micro-scale digestion of proteins using pico to nanoliter volumes of reagents and delivers the 
proteins directly to the mass spectrometer from the 2D gels (Sommerer, Centeno et al. 2007). 
2.7 Long Term Live Cell Imaging and Cell Tracking 
Over the past two decades, cell biology has developed into an integrative discipline which 
combines areas such as genetics, proteomics and molecular biology to understand the many 
complex mechanisms of living cells. However, these disciplines employ techniques, such as 
2D PAGE and immunohistochemistry, which require destroying cells to obtain results. 
Furthermore, time-course analysis is frequently applied to these techniques which require 
collecting destructive results at various time points, followed by the interpolation of the data 
to infer non-measured cellular activities. Regularly, such interpretations assume a linear 
order of events between the experiment time points, however further complex interrelations 
are occurring in real-time which ultimately are not detected with these destructive 
techniques. In general, this means that events which occur at interim time points can go 
undetected, ultimately potentially leading to the publication of incomplete cellular 
information. Although these will remain critical to understanding the molecular basis of the 
cell, it is becoming increasingly more evident that there are numerous benefits to be obtained 
from real-time dynamic studies of cells in culture.   
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Time course imaging and cell tracking techniques enable the direct observation in real-time 
on the single cell level. This provides opportunity for detailed analysis of the fundamentals of 
cell biology, such as: differentiation, apoptosis, migration rates, morphological and 
phenotype classifications. Adaptability, sensitivity, resolution and non-invasiveness are but a 
few of the advantages of the technique. Adapting long term live-cell imaging and cell 
tracking techniques to study the fundamentals of disease is essential to advancing our ability 
to investigate and monitor disease mechanisms in experimental degeneration models 
(Weissmann and Brandt 2008).  Non-invasive cell tracking in combination with fluorescent 
markers has permitted, for example, tracking the long-term dynamics of transgene expression 
to investigate the timing and expression patterns leading to transgene variegation (Ramunas, 
Montgomery et al. 2007). 
Time course imaging and cell tracking are not recently invented techniques; however some 
of their recent applications are innovative, with further advancement allowing for studies 
with an increasingly higher level of complexity. Time course cell imaging techniques were 
originally developed in the 1960s and were initially employed to study the generation times 
of monolayer cell cultures (Hsu and Kellogg 1960; Earle 1962; Froese 1964). Over the past 
decade, the improvements to the microscope in combination with a computer technology 
revolution and new engineering innovations, have facilitated tracking single cell movements 
through three-dimensional substrates (Demou and McIntire 2002; Rabut and Ellenberg 
2004). In our lab, Moogk et al. 2007 described a novel imaging chamber engineered to 
facilitate long-term three-dimensional imaging of human islets in culture. The imaging 
chamber enables the high resolution imaging of three-dimensional islets while maintaining 
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the structure of the islet cells and intercellular matrix components (Moogk, Hanley et al. 
2007).  
Ultimately, it is essential to be proficient at analyzing in real-time cell behavior and growth 
on a single cell level. This data can be correlated and connected with genetics, proteomics 
and other molecular biology techniques. Genome sequencing projects were intended to 
answer global biological questions, however with the reality of post-transcriptional 
modifications, such projects have resulted in endless amounts of convoluted experimental 
data which often cannot be directly understood and applied to cellular function. Combining 
more conventional cell biology techniques, such as proteomics, with long term live-cell 
imaging and cell tracking, allows for the identification of cellular changes in real-time that 




Chapter 3 Proteomic analysis of calcium-CaM versus CaM-mutant 
binding proteins (BPs) and the in vitro characterization of CaM 
3.1 Preamble 
This chapter presents the findings from the study of the first proposed cellular system: 
calmodulin (CaM) in the differentiation of a human glioblastoma cell line. Specifically, this 
chapter outlines CaM affinity chromatography optimization, 2D DIGE design of experiments 
considerations and results, as well as the feasibility of delivering CaM into a brain tumour 
cell line. 
3.2 Overview 
Transient rises in intracellular calcium levels initiate most signaling cascades essential for 
processes such as cell motility, proliferation, differentiation and apoptosis. Calmodulin 
(CaM) is the major intracellular receptor of calcium and in all organisms in which the CaM 
gene was deleted, it was found to be essential. CaM regulates signaling through its binding to 
a diverse population of protein targets, called calmodulin-binding proteins (CaMBPs). 
Although known to be essential, it is believed that there are many CaMBPs which remain to 
be identified and understood at the cellular level. Here, CaM protein interactions are 
characterized by probing the binding proteome of calcium-CaM in comparison to the binding 
proteome of a CaM-mutant that mimics apo-CaM, a calcium-free-CaM. Affinity 
chromatography and 2D DIGE was used to compare the respective bindomes. Furthermore, 
using live-cell imaging and a cell penetrating peptide, trans-activating transcriptional 
activator (TAT), protein trafficking experiments were performed on calcium CaM to evaluate 
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the feasibility of CaM cellular delivery; which if accomplished, would extend the current 
knowledge of CaMs role in mammalian cells.  
3.3 Introduction 
CaM is a small ubiquitous calcium binding protein found in all eukaryotic cells. The protein 
features two lobes, an N- and a C-terminal domain connected by a flexible central linker 
region and each domain consists of two EF-hand calcium binding motifs. CaM is an essential 
regulator of cellular activity mediated by intracellular levels of calcium. Upon calcium 
signaling, the calcium ions bind to CaM causing a conformational change in the protein to a 
calcium bound form, termed calcium-CaM. The conformational change upon calcium 
binding results in the exposure of hydrophobic patches that bind hundreds of proteins, termed 
CaM binding proteins (CaMBPs), which control the activity of numerous cellular processes 
(Weljie, Yamniuk et al. 2003). 
 
Apo-CaM is the calcium unbound form of CaM, therefore its protein binding is not 
dependent on calcium. The protein plays an important intracellular role in numerous 
signaling pathways and has several unknown target proteins (Jurado, Chockalingam et al. 
1999). It was discovered much later than calcium-CaM, as a result its binding proteins (BPs) 
and its cellular role is much less well understood.  Apo-CaM differs from calcium-CaM in its 
tertiary structure (Yamniuk and Vogel 2004). It has a more compact structure overall, in 
comparison to calcium-CaM that has an open, “relaxed” structure. Due to its hydrophilic 
nature, apo-CaM binds its BPs differently than calcium-CaM, utilizing IQ binding motifs and 
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noncontiguous binding sites (Jurado, Chockalingam et al. 1999; Vogel, Brokx et al. 2002; 
Houdusse, Gaucher et al. 2006). 
 
For a complete literature review on CaM and its BPs see section 2.1 Calmodulin (CaM). 
 
Studying CaM-dependent signaling cascades using proteomics coupled with live-cell 
imaging was proposed as a means to dissect CaMs cellular functions. Protein interactions 
were characterized using a purified calcium-CaM and a CaM-mutant, which had the four 
calcium binding sites mutated rendering it incapable of binding calcium to mimic apo-CaM. 
The identification of the relevant CaMBPs was performed by comparing the BPs of calcium-
CaM to the BPs of the CaM-mutant using affinity chromatography and 2D DIGE. It was 
proposed that once the differentially bound CaMBPs were determined by 2D DIGE and 
identified using MS, an in vitro characterization of the two forms of CaM and their protein 
interactions would be completed using live-cell imaging and fluorescent microscopy. 
 
Here, HPLC elution protocols were created and optimized, followed by affinity 
chromatography runs which confirmed protocol, technique and elution profiles. Preliminary 
2D DIGE experiments were performed to understand a suitable design of experiments in 
which statistically valid results could be achieved through the use of this technology.  
Furthermore, preliminary in vitro cell microscopy experiments were performed to evaluate 
the feasibility of cellular uptake of the CaM-TAT constructs. In these studies, calcium-CaM 
(labeled red) was introduced into various cells using the HIV-derived TAT-binding domain. 
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It was proposed that following uptake of the labeled CaM, the cells would be tracked over 
time using live-cell fluorescent video microscopy to record and study cell phenotype. 
Specifically, analysis of the relative distributions of the labeled forms of CaM was proposed, 
as well as CaMs cellular effect. The hypothesis behind this experimental plan was that 
mutations to the calcium binding sites of CaM would identify a new sub-population of 
CaMBPs which bind to the CaM-mutant at high affinities and upon cellular delivery, the 
CaM-mutant would perturb critical signaling pathways involved in cellular function. 
3.4 Experimental Materials and Methods 
3.4.1 Affinity Chromatography 
3.4.1.1 CaM expression, purification and mutation 
Calcium-CaM and the CaM-mutant were provided by Dr. Guy Guillemette in the Department 
of Chemistry at the University of Waterloo. Calcium-CaM was purified following a 
previously published protocol with a few minor modifications (Gopalakrishna and Anderson 
1982). The CaM-mutant, which was defective in calcium binding at all four of the calcium 
binding EF hands in both the C-terminal and N-terminal lobes was also purified following a 
previously published protocol (Sienaert, Nadif Kasri et al. 2002). 
3.4.1.2 Porcine brain extraction 
The fetal porcine brains were isolated by Dr. Douglas Wey at the University of Guelph.  The 
brains, each weighing approximately 30g, were flash frozen and kept at -80C until the extract 
was prepared. Porcine brains were homogenized on ice in 200 mL of a solution containing 
 
 50 
50mM Tris-HCl pH 7.5, 0.15M NaCl, 1mM DTT and protease inhibitor. Once the brains 
were homogenized until approximately 90% liquid, the homogenate was centrifuged at        
20 000 rpm for 20 minutes.  The supernatant was collected and sonicated on ice for 20 
seconds three times. The sonicated solution was then clarified by centrifugation at 20 000 
rpm for 30 minutes. After centrifugation, the supernatant was filtered through a 0.45 um 
filter, and protein concentrations were quantified using the standard Lowry method and 
aliquoted at approximately 10 mg/mL. 
3.4.1.3 Packing 
Following purification of the CaM proteins, the protein was coupled to N-
hydroxysuccinimide (NHS) activated Sepharose 4 Fast Flow resin following the 
recommended standard procedures from GE Healthcare. Briefly, the proteins to be coupled 
(approximately 15 mg/mL resin) must be Tris free, therefore the CaM proteins were dialysed 
overnight against three changes of 0.1M NaHCO3, 0.5M NaCl and 1mM CaCl2. After 
dialysis and immediately before use, the NHS-activated resin was washed with 10-15 column 
volumes (60 mL) of cold 1mM HCl. The purified and dialysed CaMs were then mixed 
individually with the resin and rotated overnight at 4oC. Following coupling overnight and 
prior to blocking non-reacted groups on the resin, the resin was left to settle and the 
supernatant removed.  The supernatant protein concentration was promptly quantified using 
the Lowry method to confirm coupling efficiency. The coupling efficiency was determined 
as the ratio between the concentration of CaM in the supernatant before and after coupling 
with the resin overnight. Once the coupling was completed and confirmed, any non-reacted 
groups were blocked by adding 0.1M Tris-HCl pH 8.5, 0.5M NaCl for three hours. This resin 
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slurry was then washed four times with three column volumes (20 mL) of alternating 
between high and low pH buffers: 0.1M Tris-HCl buffer, 0.5M NaCl pH 8.5 and 0.1M 
acetate buffer, 0.5M NaCl pH 4.5.  Prior to packing the columns, two additional washes of 
0.1M Tris-HCl buffer, 0.5M NaCl pH 8.5 were performed and the pH was verified to be 
approximately 8.5. Once the resin was coupled to the protein, Bio Rad Bio-Scale MT5 
Columns were packed using the manufacturers’ slurry packing method. Briefly, the column 
was assembled without the upper end cap or upper bed support. Placing the column 
vertically, the slurry was slowly poured into the column and allowed to settle.  The high pH 
buffer (0.1M Tris-HCl buffer, 0.5NaCl, pH 8.5) was first de-gassed and continuously used to 
keep the column wet while packing. When the columns were filled to the top with resin 
(approximately 5.7 mL total volume each) the upper assembly of the column was attached. 




Prior to use, the columns were equilibrated with 5 column volumes of 50mM Tris-HCl pH 
7.5, 0.15M NaCl, 1mM CaCl2. Affinity chromatography was performed by diluting 
approximately 150mg of porcine brain extract to 50 mL using 50mM Tris-HCl pH 7.5, 
0.15M NaCl, 1mM CaCl2, 1mM DTT and protease inhibitor. The extract was loaded using an 
external sample loop at 0.05 mL/min, allowing overnight incubation at 4oC. Prior to the 
elution of the interacting proteins, the column was washed at 0.3 mL/min for ten column 
volumes with 50mM Tris-HCl pH 7.5, 0.15M NaCl, 1mM CaCl2. Once washed, there were 
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two elution steps, a subsequent wash, a final elution step and a stripping step, each three 
column volumes at 0.5 mL/min. The first step was a calcium dependent elution using EDTA 
(50mM Tris-HCl pH 7.5, 0.15M NaCl, 5mM EDTA). EDTA is a calcium chelator therefore 
in the case of calcium-CaM, EDTA will chelate the calcium ions bound to CaM resulting in a 
reversal of the conformational change of CaM and elution of the bound interacting proteins. 
The next elution step was with 1M KCl. Any charge-charge interactions will be broken and 
proteins bound through electrostatic interactions are eluted. To avoid compromising the 
column following the KCl elution, the column was washed with 50mM Tris-HCl pH 7.5, 
0.15M NaCl, 1mM CaCl2. Once washed, the final elution step was performed using 0.1M 
NaOH. NaOH is such a strong base such that any proteins which were hydrophobically 
bound to CaM and therefore were not eluted by the EDTA or KCl elution steps, would be 
eluted. Lastly, to ensure there were no remaining bound proteins, the columns were stripped 
with 1M NaOH, washed with 50mM Tris-HCl pH 7.5, 0.15M NaCl, 1mM CaCl2 and then 
water, followed by storage in 20% ethanol at 4oC. 
3.4.2 Differential In Gel Electrophoresis (DIGE) 
3.4.2.1 Sample preparation 
Protein samples of interest which were eluted from the CaM columns were quantified using 
the 2-D Quant Kit (GE Healthcare) and aliquoted into 50µg or 25µg. To remove urea and 
salt, the samples were cleaned-up using PlusOne 2-D Clean-Up Kit (GE Healthcare) and re-
suspended in 10µl of DIGE lysis buffer. 
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3.4.2.2 Cy dye labeling 
Protein samples were labeled using fluorescent Cyanine dyes 2, 3 and 5 developed by GE 
Healthcare for DIGE. Fifty micrograms of the two protein populations to be compared were 
each labeled with 200 pmol of amine reactive cyanine dye 3 or 5 freshly dissolved in 
anhydrous DMF. As a standard, twenty-five micrograms of the two protein populations to be 
compared, were combined and labeled with 200 pmol of amine reactive cyanine dye 2 
freshly dissolved in anhydrous DMF. The three labeling reactions were incubated at room 
temperature in the dark for 30 min. The reactions were then terminated by the addition of 10 
nmol lysine to each sample for 10 min in the dark. Rehydration buffer (8M Urea, 2M 
Thiourea, 2% CHAPS, 0.5% IPG Buffer 3-10, 13 mM DTT and bromophenol blue) was then 
used to mix the three labeled samples to a final volume of 450 µl prior to rehydration and 
iso-electric focusing. 
3.4.2.3 Protein separation 
In-gel sample rehydration was performed at room temperature for 20 hours using 
immobilized 24-cm linear pH 3-10 gradient (IPG) strips. The rehydrated strips were focused 
using an Ettan IPGphor II (Amersham Biosciences) for approximately 67 000 VhrT with a 
gradual voltage ramp to a maximum of 8000V for 18 hours. Focused strips were immediately 
equilibrated in two steps, reduction followed by alkylation, each for 15 min on a shaker in 
15mL of 50mM Tris-HCl pH 8.8, 6M Urea, 30% (v/v) glycerol, 2% (w/v) SDS and 1% DTT 
(reduction) or 2.5% iodoacetamide (alkylation). Equilibrated strips were then loaded between 
1mm thick 18x20cm 12.5% polyacrylamide poured gels with low fluorescence glass plates. 
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The strips were then overlaid with 0.5% (w/v) agarose in 1X running buffer (25 mM Tris, 
0.2M glycine, 0.1% (w/v) SDS, pH 8.3) with 0.002 mg of bromophenol blue on a shaker. 
The gels were run in an Ettan Dalt 6 apparatus (GE Healthcare) at 5 W/gel for 30 min and 
then 20 W/gel at 15oC until the dye front had reached the bottom of the gels. 
3.4.2.4 Gel imaging and analysis 
Gels were visualized using a Typhoon 9410 imager (Amersham Biosciences). For optimal 
resolution the gels were scanned at 100 µm pixel size. The photomultiplier tube was set to 
ensure maximum pixel intensity, 40 000-60 000 units. Once the gels were scanned, the 
scanned images were then cropped using ImageQuant 5.2 (GE Healthcare) to remove the 
boarder of the gels. The cropped images were analyzed using DeCyder 6.5 software (GE 
Healthcare).  The estimated number of spots for detection was set to 2000.  No area, volume 
or peak height exclusion filters were applied. 
3.4.3 CaM-TAT coupling and cell culture treatment 
The TAT-FITC peptide was purchased from ANASPEC (Fremont, California, USA). The 
CaM proteins (calcium-CaM and CaM-mutant) were coupled with the TAT-FITC peptide by 
Odi Israel, a master’s student in Professor Guillemette’s lab in the Chemistry Department, 
University of Waterloo. To achieve a reported 100% coupling efficiency the CaM proteins 
were devoid of Dithiothriotol (DTT) and Tris buffer were removed by gel filtration using a 
Sephadex G-25 PD-10 column (Amersham Biosciences) with a coupling buffer of 100 mM 
Phosphate buffer and a pH of 6.3. The CaMs (calcium-CaM and CaM-mutant) were then 
reacted with 4 fold excess TAT-FITC to CaM protein to ensure maximum coupling. The 
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reaction was carried out at room temperature on a shaker flask for 12 hours. The samples 
were then washed three times with deionized water using a 10 kDa cut-off spin column (Pall 
Scientific, USA) to remove excess unbound FITC-TAT. MS was performed on the samples 
to confirm FITC-TAT labeling of the CaM proteins. Human glioblastoma cells were obtained 
from the Peter Dirks laboratory University of Toronto, Ontario. The cells were adhered to the 
surface of poly-ornathane treated glass chambers which contained 500 μL of DMEM/F12 
media. Each chamber was then incubated with one of the following constructs: TRITC, TAT-
FITC, CaM-TRITC or FITC-TAT-CaM-TRITC, each with a concentration of 20 μM for 2 
hours at 37°C. Following incubation, the cells were washed three times with 500 μL of media 
and imaged using 40X or 63X objective lens on a fluorescence microscope (Zeiss Axiovert 
200M). 
3.5 Results 
In attempts to identify the CaMBPs of calcium-CaM and the CaM-mutant, CaM was coupled 
to resin and packed into columns at various densities. HPLC elution protocols were created 
and optimized, followed by numerous affinity chromatography experiments which confirmed 
protocol, technique and the expected elution profiles. Following the affinity chromatography 
optimization described next, several 1D gels were then completed, as well as 2D PAGE 
separation methods and conditions were established. Preliminary 2D DIGE experiments were 
completed to determine DIGE capabilities and limitations. Lastly, TAT-CaM mediated 
uptake into human glioblastoma cells was performed with inconclusive results. 
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3.5.1 CaM Affinity Chromatography Column Optimization 
To understand the diversity of the porcine brain protein population to be loaded to the 
columns, a 400 µg preparative 2D gel was performed. Figure 3-1 confirmed a large and 
diverse protein population to pass through the columns.  
 
Figure 3-1: 2D gel of 400 µg of porcine brain extract pH range 3-10 
 
Three column packings were studied, each with different experimental conditions which 
included increasing the amount of porcine brain loaded to the columns and increased 










Establishing the techniques and protocols of the affinity chromatography was the focus of the 
first packing experiment. As outlined in table 3-1, a CaM coupling density of 2.5 mg/mL 
was evaluated with a loading 38 mg of porcine brain extract to each column. Following the 
elution protocol described in section 3.3.1.4, two fractionation peaks were obtained (a 
calcium-dependent and independent). Figures 3-2 and 3-3 are the HPLC run profiles of the 
loading and elution of the calcium-CaM and CaM-mutant columns, respectively. Depicted is 
the porcine brain being continuously loaded into the column (0-50 mL on the x-axis), 
followed by a buffer wash (50-100 mL), an elution with EDTA at 105 mL, an elution with 
0.1M NaOH at 130 mL and lastly a stripping elution with 1M NaOH at 155 mL.  Each run 





Figure 3-2: calcium-CaM first loading and elution profile using the elution sequence: EDTA, Buffer, 
NaOH. The blue line is A280nm and the pink line is A215nm. The first peak is calcium-dependent 
binding proteins. The second peak represents non-specific calcium-CaM binding proteins. 
 
Figure 3-3: CaM-mutant first loading and elution profile using the elution sequence: EDTA, Buffer, 
NaOH. The blue line is A280nm and the pink line is A215nm. Two small peaks are evident, representing 
proteins bound to the CaM-mutant non-specifically and CaM-mutant binding proteins, respectively. 
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Comparison of the two HPLC profiles (figures 3-2 and 3-3) indicated that overall less 
protein had bound to the CaM-mutant column. To clearly show the peak heights, the 
absorbance scale on the y-axis in figure 3-3 is much smaller than in figure 3-2. In 
specifically evaluating the two fractionation peaks at 105 mL and 130 mL in both figures, the 
magnitude of the calcium-CaM column peaks were both at approximately 750 mAU. 
However, both of the elution peaks from the CaM-mutant column were much less in 
magnitude in comparison to the calcium-CaM column. The EDTA peak of the CaM-mutant 
column was 150 mAU and the 0.1M NaOH elution peak was 375 mAU, 2.5 less than the 
EDTA peak of calcium-CaM. Although every attempt was made to couple and load 
equivalent amounts of CaM and porcine extract to both columns, these findings suggested 
that the CaM-mutant was coupled at a lower efficiency than the calcium-CaM column or that 
less porcine brain had been loaded to the CaM-mutant column or that the CaM-mutant has 
few CaMBPs in comparison to calcium-CaM. 
 
Protein quantification of the 0.1M NaOH elution peaks of interest, further confirmed the 
difference between column runs. Approximately 350 µg and 75 µg of protein were eluted 
from each of the calcium-CaM and CaM-mutant 0.1M NaOH elution peaks, respectively. In 
evaluating the loading of the 50 mL of porcine brain in figures 3-2 and 3-3, the absorbance 
reading during loading of calcium-CaM column was near 1500 mAU. However, the 
absorbance reading during loading of CaM-mutant column was less than 1000 mAU. 
Although both runs were performed using the same protocol, this indicated that an 
inaccuracy had occurred in which less porcine brain was loaded onto the CaM-mutant 
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column. To determine if there were qualitative proteomic differences between the calcium-
CaM and CaM-mutant binding protein populations, the EDTA and 0.1M NaOH elution peaks 
were separated using 1D gel electrophoresis, figures 3-4 and 3-5 below. In order to optimize 
the number of lanes to be compared, no molecular standard was run. Comparison of the gels 
at both elution peaks (calcium-dependent and calcium-independent), revealed protein bands 
which were unique between columns (indicated by the small black arrows in figures 3-4 and 
3-5). To determine if the 0.1M NaOH elution removed the majority of bound proteins after 
the EDTA elution, the final stripping elution of 1M NaOH was also evaluated using 1D-gels, 
figure 3-6. Both of the column gels showed a minimal amount of protein bands, indicating 





CaM-mutant EDTA Calcium-CaM EDTA 
A B 
Figure 3-4: 1-D 12% SDS-PAGE analysis of EDTA peaks with arrows indicating differences in
protein populations (A) Calcium-CaM column (B) CaM-mutant column. Each lane represents 10















Figure 3-5: 1-D 12% SDS-PAGE analysis of 0.1M NaOH peaks with arrows indicating differences
in protein populations (A) Calcium-CaM column (B) CaM-mutant column. Each lane represents
10 µL from a 1mL collection sample during the elution peak. 
Figure 3-6: 1-D 12% SDS-PAGE analysis of 1M NaOH wash peaks. Comparable clear gels
indicated the columns were effectively eluted using the previous EDTA and 0.1M NaOH steps.
(A) Calcium-CaM column (B) CaM-mutant column. Each lane represents  10 µL from a 1mL







The elution sequence of EDTA, 0.1M NaOH and 1M NaOH was confirmed to be an 
effective protocol for separating CaMBPs. However, the coupling conditions were not 
optimized to achieve sufficient yields of eluted protein to complete a comprehensive 
proteomic analysis which would include trials of 2D gel separation, followed by a 2D DIGE 
analysis. A combined 425 µg of total protein was eluted during the two 0.1M NaOH elution 
peaks, and the majority of this eluted protein was used in the 1D-gel analysis presented 
above. Based on this 1D-gel analysis it was concluded that there appeared to be proteomic 
differences in BPs to calcium-CaM in comparison to the CaM-mutant.  However, to improve 
protein yields, re-coupling the columns at a higher CaM density in combination with 
ensuring that accurate and excess porcine brain extract was passed through the column, was 
necessary to complete a proteomic analysis. 
Packing 2 
In the second packing experiment, calcium-CaM and the CaM-mutant were coupled to the 
resin at two times the concentration (5 mg/mL) of the first packing experiments. 
Additionally, to ensure greater protein yields, the amount of porcine brain passed through the 
columns was increased by two times to 76 mg. Figures 3-7 and 3-8 below are the overnight 
loadings of the porcine brain at 0.05 mL/min. Unlike during the first packing experiment, the 
loading profiles between both columns were consistent, with the absorbance remaining 





Figure 3-7: Second packing, calcium-CaM column loading. The blue line is A280nm, the red line is 
A260nm and the pink line is A215nm. 
 
 
Figure 3-8: Second packing, CaM-mutant column loading. The blue line is A280nm, the red line is 




It was anticipated that increasing the CaM coupling density in combination with increasing 
the amount of porcine brain to be loaded to the columns, would ultimately result in greater 
protein elution for a proteomic analysis.  Figures 3-9 and 3-10 are the elution profiles for 
calcium-CaM and the CaM-mutant with the second packing conditions outlined above in 
table 3-1. Comparison of these two elution profiles with first two (figures 3-2 and 3-3), 
illustrated smaller elution peaks, qualitatively suggesting that increasing the amount of 
porcine brain to be loaded to the columns, in combination with an increased CaM coupling 
density, did not achieve greater protein yields. Quantification of the calcium-CaM and the 
CaM-mutant 0.1M NaOH elution peaks, revealed only 230 µg and 65 µg of protein was 
eluted from each column, respectively. This eluted protein (295 µg) was combined and used 
to determine optimal 2D-gel separation conditions. A 2D-gel with a pH range of 4-7 was first 





Figure 3-9: calcium-CaM second packing elution profile using the elution sequence: EDTA, 
Buffer, NaOH. The blue line is A280nm and the pink line is A215nm. The first peak is calcium-
dependent binding proteins. The second peak represents non-specific calcium-CaM binding 
proteins. 
 
Figure 3-10: CaM-mutant second packing elution profile using the elution sequence: EDTA, 
Buffer, NaOH. The blue line is A280nm and the pink line is A215nm. Two small peaks are 
evident, representing proteins bound to the CaM-mutant non-specifically and CaM-mutant 








The overall objective of the third packing was to increase the quantity of CaMBPs. This was 
achieved by increasing the coupling density of CaM and through loading excess porcine 
brain extract. Calcium-CaM and the CaM-mutant were coupled to the resin at approximately 
three times the concentration (14 mg/mL) of the second packing experiment. In addition, the 
amount of porcine brain passed through the columns was increased by five times, to 200 mg. 
Figure 3-12 and figure 3-13 show the overnight loadings of the third packing (200 mg of 
porcine brain at 0.05 mL/min). In comparing these absorbance readings during loading to the 
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second packing experiments, it was evident that twice the amount of porcine brain was 
loaded. In the second experiments (CaM packing 5 mg/mL, porcine brain loading 76 mg) the 
absorbance during loading was 2700 mAU. In comparison, in the third (packing 14mg/mL, 




Figure 3-12: Third packing, calcium-CaM column loading. The blue line is A280nm, the 





Figure 3-13: Third packing, CaM-mutant column loading. The blue line is A280nm, the 
pink line is A260nm and the red line is A215nm. 
 
Following loading of the columns, the columns were eluted to fractionate and collect the 
CaMBPs. Although the EDTA followed by 0.1M NaOH elution sequence was found to be 
effective in the preliminary packing trials, an additional KCl elution step followed by a 
buffer wash was introduced in between the EDTA and 0.1M NaOH elution’s to break any 
charge-charge interactions. To avoid compromising the column following the KCl elution, 
the column was first washed in Tris buffer and the final elution step was performed using 
0.1M NaOH. Figure 3-14 and figure 3-15 are the elution profiles for calcium-CaM and the 




Figure 3-14: Calcium-CaM third packing elution profile using the elution sequence: 
EDTA, KCl, Buffer, NaOH. The blue line is A280nm and the red line is A215nm. The 
first peak is calcium-dependent binding proteins. At the introduction of the KCl, as well 
as at the introduction of the wash step which follows, two small peaks are evident, 
representing proteins bound to CaM by charge-charge interactions. The last peak 




Figure 3-15: CaM-mutant third packing elution profile using the elution sequence: 
EDTA, KCl, Buffer, NaOH. The blue line is A280nm and the red line is A215nm. Three 
small peaks are evident, representing proteins bound to CaM-mutant non-specifically 
or by charge-charge interactions. The last larger peak represents specific CaM-mutant 
binding proteins.  
 
It was anticipated that the introduction of the KCl elution step would further fractionate the 
interacting proteins based on the nature of binding. In evaluating the elution profiles at the 
introduction of KCl, as well as at the introduction of the wash step which follows, two small 
peaks were evident, representing proteins which were bound to CaM by charge-charge 
interactions. Furthermore, comparison of these two elution profiles with the previous 
(figures 3-2, 3-3, 3-9, 3-10) indicated similar elution profiles. However, illustrated are much 
larger elution peaks. Quantification of the calcium-CaM and CaM-mutant 0.1M NaOH 
elution peaks of interest, determined that 1550 µg and 350 µg of protein was eluted from 
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each column, respectively. Approximately six times more protein than the two previous run 
series was eluted, however the CaM-mutant column achieved much lower yields in 
comparison to the calcium-CaM column. This suggested that calcium-CaM binds a larger 
protein population than the CaM-mutant. Analysis of the affinity chromatography elution 
profiles and protein quantification of the elution peaks from all three packing experiments, 
concluded that the addition of the KCl elution step followed by buffer wash in between the 
EDTA and 0.1M NaOH elutions, was an effective protocol for further fractionating the CaM 
BPs. In addition, the CaM coupling density of 14 mg/mL, in combination with loading 
200mg of porcine brain, resulted in the necessary yields to perform a 2D DIGE analysis.  A 
summary of the three column packing results is found in Table 3-2 and 3-3. 
 
3.5.2 Analysis of Re-Using the CaM Affinity Chromatography Columns 
Once the CaM coupling density, quantity of porcine brain extract and elution method were 
optimized to yield quantities of protein which would be adequate to complete a 2D DIGE 
analysis, the columns were re-loaded and re-used for two additional runs.  It was theorized 
that these optimally packed columns could be re-used to establish three replicates, the 
minimum replicate requirement for a 2D DIGE analysis. Once the two columns were re-used 
three times each with the same elution sequence, a comparison of the calcium-CaM run 
elution profiles, figure 3-16 below, revealed the column performed repeatability, however 




Table 3-2: Summary of the elution’s (mAU) for each packing experiment. The 280 
absorbance of the peaks (relationship to quantity of protein) increased as the porcine 
brain extract and CaM coupling densities were optimized. 
      
Loading Abs 
(mAU) 
EDTA Peak 280 Abs 
(mAU) 
0.1M NaOH Peak 




















1 38 2.5 1500 1000 750 750 140 350 
2 76 5 2700 2700 725 300 100 100 
3 200 14 4700 4700 1500 500 100 750 
 
 
Table 3-3: Summary of eluted protein (µg) for each packing experiment and the end use 
of the protein. A CaM coupling density of 14 mg/mL, in combination with loading 200 












(mg/mL) Calcium-CaM Apo-CaM   
1 38 2.5 350 75 1-D Gels 
2 76 5 230 65 2-D Gels 
3 200 14 1550 350 DIGE 
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elution profiles from re-using the CaM-mutant column, figure 3-17, indicated the same 
trend.  In both figures, the 0.1M NaOH elution peak increased with use, perhaps due to 
degradation from the harsh 1M NaOH wash stripping step used at the end of each run. The 
EDTA elution peaks on the CaM-mutant column were ten times smaller than the calcium-




























Figure 3-16: Analysis of re-using the calcium-CaM column once optimized. The elution
profiles of three successive runs are overlaid for comparison. The column performed
repeatability however the non-specific binding increased (0.1M NaOH peak) as the






























3.5.3 DIGE Analysis of Eluted CaM binding proteins 
To achieve statistical inference from 2D DIGE, a minimum of three gels are required. 
Therefore, if obtaining replicates is limited, either three technical replicates could be 
incorporated into the design of experiments, or three biological replicates. When initially 
designing the experiment, it was thought that through re-using the columns to achieve 
replication, technical replicates would be obtained. However, comparative analysis of the 



















Figure 3-17: Analysis of re-using the CaM-mutant column once optimized. The elution
profiles of three successive runs are overlaid for comparison. The column performed
repeatability however the non-specific binding increased (0.1M NaOH peak) as the




increased substantially with each run (figures 3-16 and 3-17). As discussed in the previous 
section, it is believed that this was due to an increase in the non-specific binding of the 
porcine brain proteins to the columns. Since technical replicates are considered to be repeat 
measurements on the same biological sample, the repeat column runs did not represent 
technical replicates as the elution’s (measurements) were not repeatable. Technical replicates 
ideally have small variation between samples, however based on the elution comparative 
analysis, the non-specifically bound BP expression levels and perhaps overall protein 
populations would have large variation between column runs.  
 
Biological replicates are different biological samples from the same treatment group. 
Although each elution peak was obtained from loading the columns with the same pooled 
sample of porcine brain, the column replicates represented more similar to biological 
replicates than technical replicates. Biological replicates have greater variability within the 
same treatment group, similar to the columns having variation between runs on the same 
column. Using a replicate design of experiments discussed in Section 2.6.2.2 DIGE 
Experimental Design, three 2D DIGE gels were processed in which each column run 
represented a replicate. The replicates however did not represent a true technical or a true 
biological replicate. Figure 3-18 shows a schematic of the design of experiments. One of the 
main limitations of this experimental design was the limited number of replicates. As there 
are many technical challenges (discussed previously) related to 2D gel separation and protein 
transfer, there is potential to not obtain statistically valid results. For example, in this 2D 
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DIGE experiment, one gel ran unsuccessfully, therefore only two gels were analyzed and no 
statistical inference was possible.  
 
The two gels analyzed (runs 1 and 2) identified a proteomic difference between the BPs of 
the CaM-mutant and calcium-CaM with a large fold change range of 2-10. However, these 
results have no statistical confidence associated with the findings since they are based on 
only two column runs. Therefore, no proteins were chosen for MS identification. Figure 3-19 
shows a 2D DIGE ImageQuant gel with separation of the CaM binding proteins. As an 
example, figure 3-20 is a protein spot comparative representation from the DeCyder analysis 
of a protein detected with an approximate 2 fold change. Thirteen proteins were detected 
(highlighted in pink) with a proteomic difference between the BPs of the CaM-mutant and 
calcium-CaM columns, however of the 13 spots detected, only 6 would be feasible to pick 






Figure 3-18: CaM Affinity Chromatography DIGE Design of Experiments. 3 DIGE gels 





Figure 3-19: 2D DIGE ImageQuant gel with the separation of CaM binding proteins. 
Thirteen proteins outlined in pink had a fold range of 2-10 between the two columns. 
 
 
Figure 3-20: Protein spot comparative representation from DeCyder of a CaM binding 




3.5.4 CaM-TAT Mediated Uptake 
Following the affinity chromatography and DIGE experiments, TAT-CaM mediated uptake 
into human glioblastoma cells was studied using fluorescent microscopy. These preliminary 
in vitro cell microscopy experiments were performed to evaluate the feasibility of cellular 
uptake of the CaM-TAT construct. In these studies, the calcium-CaM was labeled with 
TRITC (red) and disulfide bond linked to the HIV-derived TAT cell penetrating peptide 
which was labeled with FITC (green). It was proposed that following up-take of the labeled 
CaMs, the cells would be tracked over time using live-cell fluorescent video microscopy to 
record and study cell phenotype, specifically the state of differentiation of the human 
glioblastoma cells, and the cellular distribution of CaM. 
 
Prior to evaluating the full TAT-CaM construct, TAT-FITC, FITC and TRITC were imaged 
in separate chambers after two hours of incubation with 20 µm of each sample (figures 3-21 
and 3-22). The TAT-FITC signal was punctate and observed on every cell. This initially 
suggested that TAT had penetrated the cell membrane and was internalized. As discussed in 
the literature review, although TAT has been established as a cell penetrating peptide capable 
of penetrating various cell types, there has been an emergence of evidence suggesting that the 
peptide is not capable of penetrating many cell types. It is proposed that differing membrane 
compositions interfere with TAT uptake (Fonseca, Pereira et al. 2009). It is important we 
acknowledge that it was not confirmed with certainty if the TAT-FITC construct was 
internalized or if the observed signal was an artifact of nonspecific interactions between 
TAT-FITC and cell membrane constituents as confocal microscopy was not employed. It was 
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however confirmed that the detected green punctate signal was not due to excess non-specific 
FITC interaction or excess free FITC (figure 3-21). As an additional control, TRITC, the 
fluorophore used to label CaM was also evaluated for non-specific binding. Despite the 
notion that TRITC is impermeable to the cell membrane, non-specific emission was detected 
even after three wash steps in PBS (figure 3-21). 
 
Although TRITC was found to bind non-specifically to the human glioblastoma cells, the full 
CaM-TRITC-TAT-FITC construct was incubated with the cells for 2 hours at 37oC to 
evaluate the distribution and co-localization of TAT and CaM. Both fluorophores were 
colocalized with punctate emission signals (figure 3-22). This suggested that the disulfide 
bond used to link the TAT-FITC and CaM-TRITC constructs was not broken and that the full 
construct was bound to the cell membrane, as the disulfide bond would have been reduced 
once inside the cell. It has been reported that thiol/disulfide exchange reactions can occur 
between cell penetrating peptide residues and thiols on the cell-surface (Aubry, Burlina et al. 
2009).  Therefore, it is possible that the TAT-FITC peptide used in this study may be 
interacting with cell membrane thiol groups via a cysteine residue, leading to its binding to 
the cell membrane. 
 
Overall, the results of cellular uptake of the full CaM-TAT construct into the human 
glioblastoma cells was inconclusive. Although punctate cellular signal was detected, it was 
not confirmed if the construct was intracellular or membrane bound. Additionally, the 
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detected non-specific TRITC signal in the TRITC only control rendered all obtained results 
disputable since CaM localization could not be confirmed. 
 








Figure 3-22: 40X fluorescent images two hours after 20µm CaM-TRITC, TAT-FITC 
and CaM-TRITC-TAT-FITC incubation. 
 
3.6 Discussion and Conclusions 
 
CaM cycles between its calcium-bound and calcium-free states binding different proteins 
based on its conformation. The BPs of the two primary forms of CaM, calcium- bound and 
apo-CaM, were studied using purified calcium-CaM and a purified CaM which was mutated 
to mimic apo-CaM. CaM protein interactions were isolated and characterized by comparing 
calcium-CaM BPs to the CaM-mutants using affinity chromatography and 2D DIGE. Eluting 
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sufficient protein from the columns to perform proteomic techniques, including 1D and 2D 
gel electrophoresis followed by 2D DIGE, was an initial constraint in completing a 
successful proteomic analysis. Three affinity chromatography packing trials were performed 
with increasing CaM coupling densities and amount of porcine brain extract passed through 
the columns.  
 
In the first set of affinity chromatography experiments, the NHS-resin and CaMs were 
coupled and packed effectively, however at a low packing density of 2.5 mg/mL. Although 
two fraction peaks were obtained (figures 3-2 and 3-3), a limited quantity of protein was 
eluted. A 1D-gel analysis (figures 3-4, 3-5, 3-6) consumed all of the eluted protein and 
qualitatively confirmed proteomic differences between calcium-CaM and the CaM-mutant 
BPs. In contacting the supplier, it was recommended that the ligand density for CaM to the 
NHS-resin be 5 mg/mL. Therefore, in the second series of runs a packing density of 5 mg/mL 
was employed and double the amount of porcine brain was loaded to the columns. The 
results remained promising, as the elution peaks were greater than the first run series (figures 
3-9 and 3-10), as well as the coupling, packing, elution and collection methods were 
determined to be repeatable. However, the eluted protein was consumed performing a 2D gel 
optimization which was necessary to achieve clear separation to perform a 2D DIGE 
analysis.  
 
It is believed that the insufficient amounts of CaMBPs eluted from the columns was due to 
either not all the CaM being coupled efficiently to the resin, or since theoretically only the 
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proteins which interact with CaM will bind and be eluted, this may have been a small 
quantity of protein in the mg’s of porcine brain extract being loaded to the columns. 
Consequently, for the third run three times the CaM coupling density was utilized and five 
times the amount of porcine brain extract was loaded. These packing conditions eluted the 
necessary CaMBP yields to perform one 2D DIGE gel. Each column was loaded and eluted 
three times to obtain three replicates; the minimum number of replicates required to perform 
a 2D DIGE analysis. Unfortunately, one gel ran unsuccessfully therefore no statistical 
analysis could be performed. Analysis of the two successful gels confirmed the proof of 
concept that the CaM affinity chromatography method of isolating and fractionating CaM 
binding proteins could be analyzed using 2D DIGE. There were 13 proteins detected with 
expressions differences between the CaM-mutant and calcium-CaM populations. However, 
in order to make quantitative proteomic conclusions, statistical analysis is necessary before 
proteins can be identified and reported as significantly changed. As a result, no proteins were 
chosen for mass spec identification. 
 
The DIGE technique simultaneously separates two fluorescently labeled protein populations 
and achieves statistical inference through replication. Although DIGE is a very powerful 
proteomics technique, it has several associated technical limitations, including achieving the 
separation of sufficient replicates to determine statistically valid protein differences. Analysis 
of re-using the columns determined that the non-specific binding to CaM increased as the 
columns were re-used, therefore re-using the affinity columns to obtain replicates for the 2D 
DIGE analysis was concluded to be a poor design of experiments. Alternatively, using the 
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determined affinity chromatography elution conditions and perhaps a column sub-pooling 2D 
DIGE design of experiments which incorporates at least six gels (either through technical 
replication or biological like replication or a combination of both) would be necessary to 
achieve quantitative DIGE results. This experiment would require a minimum of twelve 
accurate and successful column packings in which the resin is coupled in batch in attempts to 
achieve negligible column to column variation. However, this large scale experiment was not 
undertaken due to time and resource limitations.   
 
The second objective of the proposed experimental plan, the cellular uptake of the TAT-
TRITC-CaM-FITC construct, overall, gave inconclusive results. The TAT-FITC construct 
which was used as a control to confirm TAT cellular uptake independent of CaM, emitted a 
punctate cellular signal however it was not confirmed if TAT was indeed internalized or if 
TAT was actually bound to the cellular membrane. It was confirmed that there was no non-
specific interactions between FITC and the human glioblastoma cells, as no signal was 
detected in the FITC only control. It is therefore concluded that FITC is a suitable 
fluorophore to be utilized to label TAT for fluorescent cellular analysis. On the other hand, 
the TRITC fluorophore used to label CaM is concluded to be unsuitable for cellular analysis. 
Although the CaM-TRITC construct was punctate and appeared to be specific, the TRITC 
only control revealed a similar punctate signal, providing evidence that TRITC is not a 
suitable fluorophore to be used in cellular specificity experimentation. It is suggested that a 
different fluorophore be utilized to label CaM and recommended that the chosen fluorophore 
be evaluated for non-specific cellular interaction prior to being labeled with CaM and di-
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sulfide bond linked to the TAT-FITC construct.  The observed fluorescent results suggested 
that the disulfide bond link between TAT and CaM was not broken as both of the respective 
fluorescent signals were co-localized. However, due to the negative results of the CaM-
TRITC control, it is inconclusive if the observed co-localized punctate signal was indeed the 
TAT-CaM construct interacting with the cell membrane or an artifact of TRITC non-specific 
interactions with the cells.  
 
In conclusion, although the outlined experimental design did not give conclusive results, 
there is valuable cell signaling information to be obtained from studying CaM protein 
interactions. Besides the apo-CaM ‘mutant’ which was studied, various other CaM-mutants 
which have different combinations of the 1,2,3,4-mutated calcium binding sites had already 
been generated in collaboration with Professor Guy Guillemette in the Chemistry Department 
at the University of Waterloo. Therefore, there was great promise in elucidating a wide 
spectrum of CaM binding interactions and cell signaling using the proposed methods and 
purified CaM proteins. With the correct design of affinity chromatography and DIGE 
experiments, potentially new CaMBPs would have been identified and then studied at the 
cellular level using the TAT cell penetrating peptide. Unfortunately, time did not allow for 




Chapter 4 Proteomic Analysis of Human Islet-Derived Progenitor 
Cells Treated with rINGAP 
4.1 Preamble 
This chapter shifts focus from the study of calmodulin to the second proposed cellular 
system: human islet-derived progenitor cells (hIPCs) treated with islet neogenesis associated 
protein (INGAP). Specifically, this chapter investigates recombinant INGAPs (rINGAP) 
affect on hIPCs at the proteomic and mRNA levels. 
4.1.1 Objective and Justification 
The main objective of this chapter was to identify the differential expression of proteins as a 
result of recombinant INGAP (rINGAP) induction of human islet-derived progenitor cells 
(hIPCs). Additionally, the effects of rINGAP on mRNA expression by real time quantitative 
reverse transcriptase polymerase chain reaction (real time qRT-PCR) was performed. This 
research is of importance because revealing mechanistic clues of INGAPs cellular affects on 
hIPCs may prove to be critical for the clinical development of INGAP and the treatment of 
diabetes. 
4.2 Publication Title and Authors 
The results presented in this chapter have been prepared for publication for the Journal of 
Proteomics Clinical Applications. The results have not yet been submitted for publication 
because additional real time qRT-PCR is currently being completed on genes of the proteins 
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4.3 Statement of clinical relevance 
Islet neogenesis associated protein (INGAP) is a protein first discovered for its pancreatic 
regeneration effects in hamsters. In diabetic animal model studies INGAP has demonstrated 
beta-cell regenerating effects with an evident increase in beta-cell mass in animals treated 
with INGAP peptide.  Additionally, recent phase-two human clinical trials concluded INGAP 
peptide increased C-peptide secretion in type 1 diabetics and improved glycemic control in 
type 2 diabetics. Although studies have demonstrated an increase in beta-cell mass in animal 
models, the precise mechanism of INGAP action remains unknown, including active 
transcription pathways and the identification of a potential cellular receptor. Long-term 
expansion of isolated human islets in culture results in a population of islet-derived 
progenitor cells (IPCs), which have been characterized as pancreatic mesenchymal stem cells 
(pMSCs) by several groups. When transplanted with minimal pancreatic islet cell mass, 
pMSCs have demonstrated restoration of normoglycemia in mice. To our knowledge, to date, 
no proteomic analysis of INGAP on any cell type has been performed. The present work 
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investigates the differential expression of proteins and pancreatic genes as result of 
recombinant INGAP (rINGAP) stimulation of human islet-derived progenitor cells (hIPCs). 
These proteomic findings in combination with the PCR results provide insight into INGAPs 
mechanistic affects on hIPCs. 
4.4 Overview 
We applied 2-D difference gel electrophoresis (2-D DIGE) to compare recombinant INGAP 
(rINGAP) treated hIPCs with non-treated cells to determine at the proteomic level hIPCs 
responses to rINGAP. Analysis was performed using hIPCs derived from three donors at 
three different time points (24 hrs, 48 hrs and 96 hrs) of rINGAP exposure. The differential 
proteome analysis revealed 35 statistically significant affected proteins (between -1.2 – 1.95 
fold change), in which rINGAP altered protein levels. Of the 10 proteins identified by mass 
spectrometry, 5 are cytoskeletal proteins involved in process formation, migration and 
differentiation. Specifically, the identification of the proteins caldesmon, transgelin, 
tropomyosin, STRN and cofilin-1, revealed major regulation of the hIPC cytoskeleton at 48 
hours of rINGAP induction. Our results provide, for the first time, mechanistic clues for an 
understanding of proteins that may be clinically relevant to INGAP’s action on hIPCs and the 
treatment of diabetes.   
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Diabetes is a disease manifested by the destruction of beta-cell mass in the pancreas. Type 1 
diabetes mellitus is the result of a progressive autoimmune-mediated destruction of beta-cells 
(Halban 2004). Similarly, beta-cell mass is decreased in Type 2 diabetes mellitus cases and 
the mechanism is increased beta-cell apoptosis (Butler, Janson et al. 2003). This decrease in 
β-cell mass, results in a decline of insulin production and loss of glucose homeostasis; 
requiring often as a treatment option regular insulin injections which can result in long term 
complications. Currently, diabetes researchers focus on islet cell regeneration both in vivo 
and in vitro. In vivo, therapeutic molecules, such as INGAP, are being administered into 
animal models as well as humans, and studied for inducing islet cell neogenesis, C-peptide 
secretion and glycemic control. 
 
INGAP is a 17 kDa protein that was first discovered to be a constituent of ilotropin 
(Pittenger, Vinik et al. 1992), an islet-specific growth factor, which is expressed during islet 
neogenesis. Further sequencing determined a region of the protein consisting of 15 amino 
acids (104-118) to induce similar islet neogenesis effects (Rafaeloff, Pittenger et al. 1997).  
This active region of INGAP was synthetically produced and named INGAP-PP or 
INGAP104-118. Since its discovery, the synthetically produced INGAP peptide has been 
extensively investigated for its islet neogenesis affects in diabetic animal models, as well as 
in human clinical trials. In type 1 diabetic mice INGAP-PP reversed hyperglycemia and 
further dissection of the mice pancreata demonstrated that INGAP-PP increased beta-cell 
mass (Rosenberg, Lipsett et al. 2004). In vivo, studies of normoglycemic rodents and dogs 
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who received intramuscular injections of INGAP-PP showed a dose-dependent expansion of 
beta-cell mass (Pittenger, Taylor-Fishwick et al. 2007). At the genomic level, INGAP-PP 
enhances the transcription of genes implicated in islet metabolism, β-cell mass, islet 
neogenesis and specifically, the release of insulin in rats (Barbosa, Bordin et al. 2006). Of the 
greatest clinical significance, are the results of phase 2 clinical trials in which INGAP-PP 
was concluded to increase C-peptide secretion in type 1 diabetics and improved glycemic 
control in type 2 diabetics (Dungan, Buse et al. 2009).  
 
Although there is sufficient evidence to conclude INGAP-PP holds therapeutic potential in 
the cure of diabetes, there remains limited information about a potential INGAP cellular 
receptor or its signal transduction pathways. In the original publication of the cloning and 
sequencing of INGAP it was concluded that both the peptide and the protein were capable of 
initiating cell proliferation, a prerequisite for islet neogenesis, though it was noted that the 
full length recombinant protein appeared to have an even more potent proliferative effect 
(Rafaeloff, Pittenger et al. 1997). To date, however, studies of INGAP have focused on 
evaluating the islet neogenesis effects of the synthetic peptide, not the full length 
recombinant protein (rINGAP). The production and characterization of rINGAP has recently 
been reported in hopes to facilitate the delineation of the INGAP mechanism(s) (Assouline-
Thomas, Pilotte et al. 2009). Of importance, it was concluded using an in vitro assay of 
human islet regeneration, that rINGAP exhibits 100-times the bioactivity of the INGAP-PP 




During fetal development, new endocrine cells appear to arise from progenitor cells in the 
pancreatic ducts. Many researchers have maintained these progenitor cells are islet stem cells 
residing within the ductal cell population which give rise to endocrine cells as the fetus 
develops.  If this is accurate, it is hypothesized that the pancreata stem cell population would 
require stimulation from extrinsic factor(s), such as INGAP, which initiate and terminate 
their differentiation into functional insulin producing cells. The long term culture of islets on 
tissue culture-treated surfaces results in a population of proliferative fibroblast-like islet-
derived precursor cells (Gallo, Gambelli et al. 2007), which were shown to be mesenchymal 
stromal cells that were capable of differentiating into hormone-expressing cells (Davani, 
Ikonomou et al. 2007). Recently, it was demonstrated that the cells outgrowing from isolated 
islets are pancreatic mesenchymal stem cells (pMSCs) which had the capacity to improve 
transplanted islet function, through facilitating the restoration of normoglycemia and 
neovascularization of the graft in mice (Sordi, Melzi et al. 2010).  
 
Although it remains unknown if the pMSCs expanded from human islets in culture are 
representative of an in vivo pancreata stem cell population, characterization of potential 
extrinsic factors, such as INGAP, which may induce pMSC differentiation and the 
identification of activated transcription pathways are necessary. In this study, we isolated and 
expanded human islet cells from three different donors into a population of islet-derived 
progenitor cells (hIPCs). After positively evaluating the hIPCs for established mesenchymal 
pMSC markers using immunocytochemistry, the hIPCs were cultured in media supplemented 
with rINGAP for 24, 48 and 96 hours. A two-dimensional differential in-gel electrophoresis 
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(2D DIGE) analysis was then performed in order to identify differentially expressed proteins 
that characterize rINGAPs mechanistic effects on hIPCs. Furthermore, the effect of rINGAP 
on mRNA expression by real time quantitative reverse transcriptase polymerase chain 
reaction (real time qRT-PCR) was performed. 
4.6 Materials and Methods 
4.6.1  Cell Culture and rINGAP treatment 
Human islet isolation protocols were first approved by the Institutional Review Board of 
McGill University, Montreal, QC. Human islets were isolated according to established 
protocols (Shapiro, Lakey et al. 2000) from three healthy cadaveric donor pancreases through 
an organ procurement organization at the Montreal General Hospital, as previously described 
(Jamali, Emmerson et al. 2005). Upon isolation, the islets were washed and re-suspended in 
CMRL-1066 medium with penicillin, streptomycin, and amphotericin B (Antibiotic-
Antimycotic (100X) liquid; Gibco, Burlington, ON, Canada) and 10% fetal bovine serum 
(MBI, Amherst, NY, USA). The islet cells were then shipped on ice overnight in a 
polypropylene container without airspace from Montreal, QC to Waterloo, ON. 
 
The hIPCs were derived from the isolated human islets as previously described 
(Gershengorn, Hardikar et al. 2004; Gallo, Gambelli et al. 2007; Sordi, Melzi et al. 2010), 
with minor modifications. Briefly, the islets were plated in 75cm2 tissue culture-treated flasks 
at a density of approximately 1 islet/mm2 in modified RPMI-1640 medium (11.1 mM 
glucose) (Invitrogen, Burlington, ON), supplemented with 10% FBS (Invitrogen, Burlington, 
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ON). The flasks were incubated at 37°C, 5% CO2 and 95% humidified air, and after 24 hours 
non-adherent cells were removed and 12.5 mL of fresh media was replenished. The media 
was then replaced every 3 days for the remainder of the culture. At day 15 of culture the 
islets which were spread into a monolayer were detached from the surface with 2.5 g/L 
trypsin with 0.38 g/L EDTA (Invitrogen, Burlington, ON) and reseeded as single cells at a 
density of 1.2x104 cells/cm2, followed by subsequent passaging at 4x103 cells/cm2 once 90% 
confluence had been obtained, approximately every 10 days. After 6 passages, half of the 
flasks were treated with rINGAP which was supplemented in the media. The rINGAP was 
provided by Dr. Rosenberg’s lab from the Montreal Diabetes Research Center, QC, which 
was produced and purified as previously described (Assouline-Thomas, Pilotte et al. 2009). 
The hIPCs were treated with 10 nM of rINGAP at various treatment times (24, 48 and 96 
hours). After culturing hIPCs in media supplemented with and without rINGAP for the 
respective treatment times, the cells were detached from the flask surfaces with 0.25% 
Trypsin EDTA, transferred to 1.5 mL eppendorf tubes and washed three times in PBS. The 
hIPCs were then frozen in liquid nitrogen as a pellet in PBS until protein extraction. 
4.6.2 Protein extraction and preparation 
hIPC cell pellets were lysed in 1mL of DIGE lysis buffer containing 30mM Tris-HCl pH 8.5, 
8M Urea, 2M Thiourea, 4% CHAPS and 13 mM DTT. Lysing the pellets efficiently was 
critical. The DIGE lysis buffer was added to the pellet, vortexed and left to sit on ice for 10 
min. The samples were then sonicated in a small bath sonicator for 30 seconds, three times 
and then homogenized by passing through a 25-gauge needle five times. The minimal 
insoluble material was removed by centrifugation at 13 000 rpm for 15 min at 40C. The 
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proteins of interest were then quantified using 2-D Quant Kit (GE Healthcare) and aliquoted 
into 50 ug or 25 ug samples. To remove urea and salt, the samples were cleaned-up using 
PlusOne 2-D Clean-Up Kit (GE Healthcare) and re-suspended in 10ul of DIGE lysis buffer. 
4.6.3 CyDye labeling 
Protein samples were labeled using fluorescent Cyanine dyes 2, 3 and 5 developed by GE 
Healthcare for 2-D DIGE. Fifty micrograms of the two protein populations to be compared, 
were each labeled with 200 pmol of amine reactive cyanine dye 3 or 5 freshly dissolved in 
anhydrous DMF. As a standard, twenty-five micrograms of the two protein populations to be 
compared, were combined and labeled with 200 pmol of amine reactive cyanine dye 2 
freshly dissolved in anhydrous DMF. The three labeling reactions were then incubated at 
room temperature in the dark for 30 min. The reactions were terminated by the addition of 10 
nmol lysine to each sample for 10 min in the dark. Rehydration buffer (7M Urea, 2M 
Thiourea, 2% CHAPS, 0.5% Triton X-100, Pharmalyte 3-10 for IEF, 0.1% NP-7, 13 mM 
DTT and bromophenol blue) was then used to mix the three labeled samples to a final 
volume of 450 µl prior to rehydration and iso-electric focusing.  
4.6.4 Isoelectric focusing and two-dimensional SDS-PAGE electrophoresis (2D-gels) 
In-gel sample rehydration was performed at room temperature for 20 hours using 
immobilized 24-cm non-linear pH 3-10 gradient (IPG) strips (GE Healthcare). The 
rehydrated strips were focused using an Ettan IPGphor II (Amersham Biosciences) for 
approximately 56 000 VhrT with a gradual voltage ramp to a maximum of 8000V for 12.5 
hours. Focused strips were then immediately equilibrated in two steps, reduction followed by 
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alkylation, each for 15min on a shaker in 15mL of 50mM Tris-HCl pH 8.8, 6M Urea, 30% 
(v/v) glycerol, 2% (w/v) SDS and 1% DTT (reduction) or 2.5% iodoacetamide (alkylation). 
Equilibrated strips were then loaded between 1mm thick 18x20cm pre-cast gradient 8-16% 
polyacrylamide poured gels with low fluorescence glass plates (Jule Inc.). The strips were 
then overlaid with 0.5% (w/v) agarose in 1X running buffer (25 mM Tris, 0.2M glycine, 
0.1% (w/v) SDS, pH 8.3) with 0.002 mg of bromophenol blue on a shaker. The gels were run 
in an Ettan Dalt 6 apparatus (GE Healthcare) at 5 W/gel for 30 min and then 20 W/gel at 
150C until the dye ran off the bottom of the gels. 
4.6.5  Scanning, image processing and statistical analysis 
Gels were visualized using a Typhoon 9410 imager (Amersham Biosciences), scanned at  
100 µm pixel size. The photomultiplier tube was set to ensure maximum pixel intensity at 
40000-60000 pixel units. Scanned images were cropped using ImageQuant 5.2 (GE 
Healthcare) to remove the border of the gels. The cropped images were analyzed using 
DeCyder 6.5 software (GE Healthcare). The estimated number of spots for detection was set 
to 2000. No area, volume or peak height exclusion filters were applied. 
4.6.6  In-gel tryptic digestion and protein identification by mass spectrometry 
Preparative gels were made using 450 µg of protein separated using the same rehydration, 
iso-electric focusing and SDS-PAGE procedures described above. Total protein was detected 
by post-staining with 500 mL of 1% Coomassie Blue G-250 (GE Healthcare) overnight at 
room temperature on a shaker. Excess dye was removed by washing the gels three times in 
excess water, followed de-staining over night in water. Protein spots of interest were cut from 
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the stained preparative gel and the proteins were excised from the gel using in-gel trypsin 
digestion. The digested proteins were sent for mass spectrometry analysis and protein 
identification performed by the Mass Spectrometry Facilities at McMaster University, 
Hamilton, Ontario and Queen’s University, Kingston, Ontario. 
4.6.7 RNA isolation and quantitative real time RT-PCR 
Total RNA was isolated using the Trizol reagent, according to the instructions of the 
company (Invitrogen). Briefly, cells were centrifuged, resuspended in Trizol, vortexed, and 
frozen. After thawing and standing at room temperature for 5 min, 17% (v/v) chloroform was 
added, and tubes were shaken by hand. After centrifugation at 12000g for 15 min at 4°C, the 
upper aqueous phase was transferred to isopropanol, incubated for 10 min at room 
temperature and centrifuged at 12000g for 10 min at 4°C. The RNA precipitate was then 
washed with 70% EtOH, and centrifuged at 7500g for 5 min at 4°C. The pellet was air-dried 
briefly, resuspended in ddH2O, and frozen at -80°C. The RNA was reverse-transcribed (RT) 
using SuperScript III RT (Invitrogen). Up to 2 μg of RNA (equal among samples) was mixed 
with 2.5 μM Oligo(dT)20 primer, without prior DNAase digestion, heated at 70°C for 5 min 
and quick-chilled on ice. This was added to a master mix, giving final concentrations of 1x 
first strand buffer, 20 mM DTT, and 200 units of RT enzyme. The reaction was then carried 
out at 50°C for 60 min, followed by inactivation of enzyme at 70°C for 15 min. Real time 
PCR reactions were performed by Julia Makhlin (Department of Surgery, Research Institute 
of the McGill University Health Center) using SYBR Green method and exon-boundary-
spanning forward and reverse primers. The conditions of reaction were 95°C for 3 min, and 
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40 cycles of 95°C for 10 sec, 58°C for 30 sec, and 72°C for 30 sec. Islet cDNA was used as 
control and a melting curve analysis confirmed the nature of the products. 
4.7 Results and Discussion 
4.7.1 rINGAP Treatment Alters Protein Expression of hIPCs 
To identify specific protein expression changes following rINGAP treatment of hIPCs in 
culture, we analyzed protein lysates from hIPCs cultured in media supplemented with 
rINGAP in comparison to control hIPCs which were cultured in standard media. It was of 
interest to evaluate rINGAPs temporal effects on hIPCs in attempts to gain mechanistic clues 
vital for the clinical development of INGAP and the treatment of diabetes.  The hIPCs were 
derived from three healthy donors and each population received a different rINGAP 
treatment time. Three independent proteomic analyses were performed at 24, 48 and 96 hrs 
of rINGAP exposure in comparison to the control hIPCs. Lastly, it was determined that a 
sub-pooling design of experiments was necessary to complete the DIGE analysis of treated 
hIPCs in culture. 
 
To determine if there were preliminary apparent proteomic differences between the rINGAP 
treated cells and the non-treated controls, proteins were first analyzed using 1D gels, 
comparing INGAP treated and non-treated flasks of the same and different donors. The 1D 
gel analysis using various molecular weight ranges revealed no proteomic differences 
between rINGAP treated hIPCs (results not shown). Therefore, separation into the second 
dimension was necessary. To date, there is no published data of 2D gel analysis on hIPCs. As 
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a result, determining optimal 2D gel separating conditions was required before performing a 
DIGE analysis. Three pH ranges (4-7, 3-10 and 3-10NL) were evaluated in combination with 
five rehydration buffers, which had different combinations of detergents to improve protein 
solubilization. Several iso-electric focusing programs, incorporating different voltages and 
rates of separation, in combination with using a reducing agent (DTT) in the wicks during 
separation, were studied to determine ideal iso-electric focusing conditions. Lastly, various 
concentrations of acrylamide gels (8%, 12% and 8-16% gradient) were also tested to 
determine optimal molecular weight range. The final 2D separation conditions were listed in 
section 4.6 Material and Methods.  
Proteomic analysis at 24 hours of rINGAP treatment with no pooling 
Following the 2D gel optimization, the optimized separating conditions were used in an un-
pooled 2D DIGE analysis with a 24 hour rINGAP treatment. The experiment was designed 
with each protein flask representing a replicate (4 treated and 4 non-treated flasks) (figure 4-
1). Subsequent to the 2D DIGE experiment and analysis performed in DeCyder, the 
distribution of the obtained p-values was compiled. As discussed in section 2.6.2.1, DIGE 
Quantification and Statistical Analysis, the p-values reflect the probability that the observed 
change has occurred from random chance alone. Therefore, a frequency histogram of the 
distribution of obtained p-values is expected to be uniform when comparing two identical 
protein populations, towards 1 when there is a biased or large inter-treatment variability, and 
towards 0 when there are significantly changed proteins between the two compared protein 
populations (Karp, McCormick et al. 2007). The un-pooled DIGE experimental design at 24 
hours resulted in a bias in the p-values towards 1 (figure 4-2). This indicated that an 
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underlying assumption of the Student’s t-test was not being met, leading to a distortion in the 
obtained p-value distribution (Karp, McCormick et al. 2007). This effect was postulated to 
arise from large flask to flask variability between the same treatment group. In other words, it 
was believed that the protein expression levels of the non-treated flasks (and/or the rINGAP-




Figure 4-1: Representation of DIGE hIPC Non Pooling Design of Experiments. 4 DIGE 
gels were processed to compare the overall proteomic effect of rINGAP on individual 






Figure 4-2: Frequency distribution of the p-values obtained from the 24 hour rINGAP 
treatment using a non-pooled experimental design. A distribution towards 1 was 
obtained and therefore no valid statistical inference was made from this experiment. 
 
Proteomic analysis at 24 hours of rINGAP treatment: with pooling 
To reduce the flask to flask variability, the DIGE analysis at 24 hours of rINGAP treatment 
was repeated using a sub-pooling design of experiment. Specifically, it was of interest to 
determine if a suitable p-value distribution towards p<0.05 could be obtained. A sub-pooling 
DIGE design of experiments described in Section 2.6.2.2 DIGE Experimental Design was 
performed. In short, resolved proteins of hIPCs treated with rINGAP for 24 hours were 
compared to proteins of hIPCs that received no treatment using four sub-pooled replicates in 

















which two flasks from each treatment group were combined to create a replicate. Figure 4-3 
shows a representation of the sub-pooled design of experiments, which considered the 
objective of studying the overall proteomic effect on all flasks, and the fact that the hIPCs 
were derived from one biological replicate. Subsequent to the DIGE experiment and 
statistical analysis, the distribution of the obtained p-values was compiled. The frequency 
histogram revealed a distribution of p-values towards 0 (figure 4-4), indicating that there 
were significantly changed proteins between the rINGAP-treated and non-treated hIPC 
protein populations (Karp, McCormick et al. 2007). 
 
A total of 910 proteins were detected and 527 proteins were matched. Statistically significant 
differences were found between 16 protein spots using a stringent Student t-test and false 
discovery rate cut-offs of p<0.05 and q<0.15, respectively. A significant but small fold-
change range was determined for the 16 proteins between -1.10 to 1.25.  Furthermore, 
rINGAP both up-regulated and down-regulated proteins compared to the untreated control.  
Figure 4-5 shows a 2D gel with proteins which were found down-regulated by rINGAP in 
blue and up-regulated by INGAP in red. As further representation of the analysis performed 
in DeCyder, figure 4-6 shows a workspace page with a protein identified as significantly 
changed being evaluated. Since the average fold change range was found to be small at 24 
hours of rINGAP treatment, no proteins were chosen immediately for MS identification. An 
extended treatment time of 48 hours was proposed to determine if the overall detected protein 






Figure 4-3: Representation of DIGE hIPC Sub-Pooling Design of Experiments. 4 DIGE 
gels were processed to compare the overall proteomic effect of rINGAP on two pooled 








Figure 4-4: Frequency distribution of the p-values obtained from the 24 hour rINGAP 
treatment using a sub-pooled experimental design. A distribution towards 0.1 was 























Figure 4-5: 2D pH 3-10NL DIGE gel of 24 hour rINGAP treatment. Proteins outlined in 
red represent up-regulated proteins identified as significantly changed (p<0.05, q<0.15).  
Proteins outlined in blue represent down-regulated proteins identified as significantly 







Figure 4-6: DeCyder analysis workspace page. A protein identified as significantly 
changed is presented. (a) Overall depiction of gel area of the protein. The protein spot 
circled in red is being analyzed and the other significant proteins are circled in green. 
(b) Graphic representation of standardized log abundance detected differences in 4 gels. 
(c) Abundance representation of the spot in 2 gels. (d) Protein table with list of matched 








Proteomic analysis at 48 hours of rINGAP treatment: with pooling 
Using the same sub-pooling design as the above 24 hour treatment analysis (figure 4-3), 
hIPCs treated with rINGAP for 48 hours were lysed and their protein expression levels were 
compared to hIPCs which received no treatment. Following the DIGE experiment of 
separation and data analysis (which included p-value calculations for every detected spot 
matched across the gels), a frequency histogram of p-values towards 0 was obtained (figure 
4-7). This distribution was comparable to the p-value distribution obtained in the 24 hour 
sub-pooling experiment and confirmed that there were significantly changed proteins 
between rINGAP-treated and non-treated hIPC protein populations at 48 hours (Karp, 
McCormick et al. 2007). Of noted interest, in comparison to the 24 hour p-value distribution, 
the p-value distribution at the 48 hours had a greater number of proteins distributed at low p-
values and an overall smaller background distribution. 
 
A total of 802 proteins were detected and 369 proteins were matched. Statistically significant 
differences were found between 27 protein spots using stringent Student t-test and false 
discovery rate cut-offs of p<0.05 and q<0.15, respectively. Compared to the 24 hour fold 
change range of 1.10 to 1.25, a greater fold change range of -1.2 to 1.95 was determined for 
the 27 proteins. rINGAP was found to both up-regulate and down-regulate proteins in 
comparison to the untreated control. Figure 4-8 is a 2D-gel showing proteins which were 






Figure 4-7: Frequency distribution of the p-values obtained from the 48 hour rINGAP 
treatment using a sub-pooled experimental design. A distribution towards 0.1 was 
obtained and therefore valid statistical inference could be drawn from this experiment. 
 
 


















Figure 4-8: 2D pH 3-10NL DIGE gel of 48 hour rINGAP treatment. Proteins outlined in 
red represent up-regulated proteins identified as significantly changed (p<0.05, q<0.15). 
Proteins outlined in blue represent down-regulated proteins identified as significantly 
changed (p<0.05, q<0.15). 
 
Comparison of 24 hour vs. 48 hour rINGAP treatments with pooling 
To determine the treatment time dependent proteomic effect of rINGAP on hIPCs, a 
comparative analysis of the p-value distributions, fold change range and analysis of any 
proteins which were detected as significantly changed in both treatment times was 
completed. It was determined that in the 24 hour analysis, 6% of the total proteins were 
detected above the background noise as changing with a p-value < 0.05.  In comparison, it 
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was determined that in the 48 hour analysis, 13% of the total proteins were detected above 
the background noise as changing with a p-value <0.05. However, through applying a q-
value cutoff of q <0.15, a large number of the spots detected with a p-value of < 0.05 were 
removed from the analysis. This included spots with q >0.15, spots not found in all gels, as 
well as gel imperfections which were detected as spots. After removing these spots, it was 
concluded that in the 24 hour treatment experiment, 2% of the total proteins detected above 
the background noise were statistically significant and valid for further analysis. In 
comparison, in the 48 hour analysis 5% of the total proteins were detected above the 
background noise as signifcant and valid with a p-value <0.05 and q <0.15. Table 4-1  
highlights the overall dectected differences between the 24 and 48 hour rINGAP treatment 
analyses. Only four of the spots were found to be significantly changed at both treatment 
times. Interesting, all four proteins were up-regulated in the 24 hour treatment analysis, and 
down-regulated in the 48 hour treatment analysis. Table 4-2 is a list of the 4 proteins 
significant at both treatment times and the corresponding calculated fold changes, p-values, 
and q-values.  
 
No proteins were immediately chosen for identification, due to the resources associated with 
identifying proteins excised from gels. Based on the non-pooled DIGE analysis at 24 hours 
and the two sub-pooling analyses of hIPCs at 24 and 48 hours of rINGAP treatment, it was 
concluded that the sub-pooling design of experiments on one biological donor’s cells was 
most ideal for detecting small proteomic differences between cultured flasks. rINGAP had a 
proteomic effect at both 24 and 48 hours of treatment, however INGAP had an increased 
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proteomic effect at the longer treatment time of 48 hours. Prior to choosing spots for MS 
identification, it was of interest to evaluate the proteomic response after 96 hours of rINGAP 
treatment.  
 
Table 4-1: Comparison of 24 hour vs. 48 hour rINGAP treatments 
INGAP Treatment Time: 24 hours 48 hours 
# of proteins detected as 
significantly changed 
(p<0.05, q < 0.15) 
14 27 
Fold Change Range 1.10-1.25 1.2-1.95 
% of proteins with significant 
change (p<0.05) 
6% 13% 
% of proteins with significant 
change and are real spots 
(p<0.05, q < 0.15) 
2% 5% 
 
   
 
Table 4-2: Comparison of the four proteins which were found to be significantly 
changed at both treatment times. All four spots were up-regulated with the 24 hour 
treatment, and down-regulated with the 48 hour treatment. 
Master No. q-value p-value Fold Change 
24 hours 48 hours 24 hours 48 hours 24 hours 48 hours 24 hours 48 hours 
157 55 0.048 0.11 0.0023 0.0038 1.2 -1.81 
158 56 0.053 0.065 0.0035 0.0018 1.2 -1.6 
406 249 0.083 0.022 0.01 0.0003 1.16 -1.37 




Proteomic analysis at 96 hours of rINGAP treatment: with pooling 
Using the same sub-pooling design employed for the 24 and 48 hour treatments (figure 4-3), 
lysed proteins of hIPCs treated with rINGAP for 96 hours were compared to proteins of 
hIPCs which received no treatment. However, a uniform frequency histogram of p-values 
was obtained (figure 4-9). A frequency histogram of the distribution of obtained p-values is 
expected to be uniform when comparing two identical protein populations (Karp, 
McCormick et al. 2007). Therefore, the p-value distribution suggested that there were no 
significant differences between the untreated and the 96 hour rINGAP treated hIPC protein 
populations. A total of 701 proteins were detected and 313 proteins were matched. Although 
a uniform p-value distribution was obtained, statistically significant differences were found 
between 18 protein spots using stringent Student t-test and false discovery rate cut-offs of 
p<0.05 and q<0.15, respectively. A fold change range of -1.18 to 1.34 was determined for the 









Figure 4-9: Frequency distribution of the p-values obtained from the 96 hour rINGAP 
treatment using a sub-pooled experimental design. A uniform distribution was obtained 
which suggested there were no significant differences between the untreated and the 96 






Figure 4-10: 2D pH 3-10NL DIGE gel of 96 hour rINGAP treatment. Proteins outlined 
in red are up-regulated and down-regulated proteins identified as significantly changed 
(p<0.05, q<0.15). 
 
Comparison of 24 hour, 48 hour, and 96 hour rINGAP Treatments and Mass Spectrometry 
Identification 
The first non-pooled design of experiments in which each hIPC culture flask represented a 
replicate, no statistical inference could be made. To reduce the variability between the 
replicates of the same treatment group (non-treated flasks and rINGAP-treated flasks), the 
DIGE analysis was completed based on a sub-pooling design of experiments in which the 
lysed protein from two flasks of the same treatment group were pooled to form a replicate. 
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This experimental design resulted in a suitable p-value distribution towards p<0.05 at both 24 
and 48 hours of rINGAP treatment. However, the 96 hour p-value distribution was uniform, 
suggesting that there were no significant differences between the untreated and the rINGAP 
treated hIPC protein populations.  
 
Table 4-2 outlines the number of proteins detected as signifcantly changed (p<0.05, q < 
0.15) at each treatment point (24, 48 and 96 hours) and the respective fold change ranges. 
The greatest proteomic effect (in terms of largest fold change range and number of detected 
signifcant proteins) was at 48 hours of rINGAP treatment (figure 4-11). To achieve a general 
analysis into the types of proteins in which rINGAP up and/or down-regulated, these proteins 
were evaluated to determine which proteins would be of greatest interest for identification. 
Thirteen protein spots were manually excised from a preparative gel and were identified by 
MS. The ten spots were chosen to include proteins from various positions on the gels, as well 
as both up and down regulated proteins. Specifically, it was of interest to identify the proteins 
which had the greatest fold changes and/or were detected at several timepoints and/or were 
detected as significantly changed protein charge trains in multiple experiments. A complete 
list of the proteins identified by MS, including the treatment time in which they was detected, 
as well as the associated p and q-values are presented in table 4-3. Furthermore, a brief 
description of each protein is provided in table 4-4 and a complex protein interaction 




Table 4-2: Comparison of 24, 48 and 96 hours of rINGAP treatment 
Treatment Time: 24 Hours 48 Hours 96 Hours 
Number of Proteins 
Significantly Up or 
Down Regulated: 
14 27 18 
Log Fold Change 
Range: 






Figure 4-11: Comparison of the detected protein log fold change range at each 




















24 157 Caldesmon 1.2 0.0023 0.048 
24 158 Caldesmon 1.2 0.0035 0.053 
48 45 Caldesmon ‐1.46 0.0084 0.15 
48 47 Caldesmon ‐1.7 0.000039 0.0084 
      
24 834 Transgelin 1.25 0.0028 0.048 
48 688 Transgelin ‐1.72 0.00092 0.044 
48 689 Transgelin ‐1.36 0.0084 0.15 
      
24 406 Straitin (STRN) 1.16 0.01 0.0003 
48 249 Straitin (STRN) ‐1.37 0.083 0.022 
      
48 555 Tropomyosin ‐1.36 0.0043 0.11 
       
48 336 Plasminogen 
Activator Inhibitor 
‐1.68 0.00005 0.0084 
       
24 680 Annexin V  ‐1.16 0.019 0.11 
       
24 450 Alpha‐enolase  1.21 0.0097 0.083 
       
48 62 Heat Shock Protein 
90 (HSP 90) 
1.46 0.0062 0.13 
       
48 669 Cofilin 1  ‐1.38 0.0097 0.15 
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Table 4-4: List of the MS identified proteins and brief descriptions 
Protein Name Description 
Caldesmon A calmodulin, actin, myosin and tropomyosin-binding 
protein that plays an essential role in the regulation of 
smooth muscle and nonmuscle contraction. 
Transgelin A transformation and shape-change sensitive actin 
binding protein found in fibroblast and smooth muscle 
cells.  
STRN A calmodulin-binding protein which may function as 
scaffolding or signaling protein. 
Tropomyosin An actin-binding protein that regulates actin 
mechanics. 
Plasminogen Activator Inhibitor Inhibits proteases and controls proteolytic cascades 
Annexin V A calcium-dependent phospholipid-binding protein 
associated with many cellular functions, including: 
vesicle trafficking, cell division, apoptosis, calcium 
signaling, and growth regulation 
Alpha-enolase A glycolytic enzyme expressed in most tissues. 
Heat Shock Protein 90 (HSP 90) A member of the heat shock protein family which is 
upregulated in response to stress. 
Cofilin 1 An actin-binding protein which disassembles actin 
filaments. 
Homeobox protein HOX-C8 A transcription factor that plays an important role in 








Thirteen proteins were chosen for MS identification and ten proteins were identified. One 
digested protein spot was undetectable and several spots were isoforms of the same protein.  
Six of the ten proteins were actin binding, calmodulin binding and/or calcium-dependent 
proteins. These proteins included caldesmon, straitin, transgelin, tropomyosin, annexin and 
cofilin 1. Of the greatest significance, the actin-binding proteins caldesmon, transgelin and 
tropomyosin were both found be to significantly changed at multiple time points. Actin, the 
cytoskeleton of cell, is vital for a diverse number of critical cellular processes, including, cell 
motility, cell division and cell surface receptor movement. Actin-binding proteins regulate 
actin organization both individually and cooperatively to control these cellular processes.  
 
Caldesmon is a large 87 kDa multifunctional protein which binds specifically to calmodulin, 
tropomyosin, myosin, actin and tropomyosin (Smith, Pritchard et al. 1987; Ikebe and 
Reardon 1988). In nonmuscle cells, caldesmon differs in its structural organization as it 
serves as an important cross-linker between actin and myosin (Marston 1989). The functions 




Figure 4-12: Complex protein network of identified up or down-regulated proteins (shown in colours).
Black squares are proteins which interacted with the identified proteins with 2-5 degrees of interaction.  
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as the regulation of cell contraction and intracellular motility processes, are controlled by 
calcium-calmodulin binding or caldesmon phosphorylation (Dabrowska, Kulikova et al. 
2004). Interestingly, in this study, a caldesmon protein-charge train was detected as 
significantly changed at every time point. Although not fully understood, after 24 hours of 
rINGAP exposure the charged forms of caldesmon were found to be up-regulated, however 
at the 48 hour time point all of these caldesmon spots were detected to be down-regulated. 
This suggests that since rINGAP is affecting every form of caldesmon, the mRNA expression 
of caldesmon may also be perturbed in hIPCs following rINGAP treatment. Caldesmon has 
been linked to both type 1 and type 2 diabetes (Imperatore, Hanson et al. 1998; Fogarty, 
Moczulski et al. 1999). The chromosome in which the caldesmon gene is located (7q35), is 
associated with type two diabetes (Imperatore, Hanson et al. 1998; Fogarty, Moczulski et al. 
1999). Furthermore, caldesmon has been linked to diabetic nephropathy in type 1 diabetic 
patients and an important role of the actin cytoskeleton in the pathogenesis of diabetes was 
suggested (Conway, Maxwell et al. 2004).  
 
Transgelin is a 22kDa actin-binding, gelling and transformation sensitive protein found in 
smooth muscle and non-muscle cells (Shapland, Hsuan et al. 1993). Transgelin is localized in 
the cytoplasm where it binds actin (Shapland, Hsuan et al. 1993), however it has also been 
reported to be localized in the nuclear compartment (Bregant, Renzone et al. 2009). The 
protein plays important roles in the circulatory, genitourinary, respiration and digestive 
systems (Li, Li et al. 2008). Transgelin expression is lost in several cancers, including: 
prostate, breast and colon (Shields, Rogers-Graham et al. 2002; Prasad, Stanton et al. 2010). 
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Therefore, it has been suggested that transgelin acts as a tumour suppressor and may be used 
as a diagnostic marker of cancer development (Assinder, Stanton et al. 2009). Similar to 
caldesmon, transgelin was up-regulated at the 24 hour treatment point and down-regulated at 
48 hours of rINGAP treatment. Significantly, the protein was detected as changed in two 
spots on the gel, which indicated that both transgelin isoforms were affected from rINGAP 
exposure. The physiological diabetes significance of the down-regulation of transgelin is 
unclear, however transgelin expression has been strongly associated with cell transformation 
and differentiation (Li, Li et al. 2008; Shapland Hsuan et al. 1993). Its expression is one of 
the first markers of smooth muscle differentiation during embryogenesis (Li, Li et al. 2008). 
In a 2D DIGE study of cultured human fibroblast cells from type 1 diabetics in comparison to 
healthy subjects, transgelin was found to be significantly down-regulated (Puricelli, Iori et al. 
2006). Furthermore, several other 2D DIGE analyses have identified the protein as 
significantly down-regulated during the transition from proliferative to differentiated cellular 
states (Roche, Provansal et al. 2006; Bregant, Renzone et al. 2009; Kantawong, Burgess et al. 
2009). Therefore, it is possible that this DIGE analysis may begin to establish transgelin as 
an early marker of hIPC differentiation following rINGAP treatment or as a useful 
differentiation marker in other INGAP and/or pancreatic cellular studies. 
 
In addition to the actin-binding proteins caldesmon and transgelin, the actin binding protein 
tropomyosin was down-regulated after 48 hours of rINGAP treatment. Tropomyosin is a  
37kDa protein that plays a critical role in regulating the actin filaments in both muscle and 
nonmuscle cells (Gunning, O'Neill et al. 2008). Multiple isoforms of the protein exist in all 
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mammalian cells, including alpha-tropomyosin, beta-tropomyosin, gamma-tropomyosin and 
delta-tropomyosin, also termed tropomyosin 1, 2, 3, 4; respectively (Lin, Hegmann et al. 
1988). It is believed that these isoforms play central roles in several, if not all, actin 
cytoskeleton functions, including: intracellular vesicle movement, cell migration, cytokinesis, 
cell proliferation and apoptosis (Lin, Eppinga et al. 2008). Tropomyosin and its binding 
proteins, specifically caldesmon (discussed above), have previously been suggested to be 
required for the regulation of actin filament stability, cell shape determination, and 
cytokinesis (Lin, Warren et al. 1997).  
 
The 48 hour 2D DIGE analysis detected an area of the gels consisting of seven protein spots 
which were localized together and all down-regulated following rINGAP treatment (figure 
4-8). The preparative gel used for MS spot picking, however, did not resolve the seven 
protein spots, rather the area appeared to be three stained proteins. As a result, these three 
protein spots (which were detected by DIGE as 7 spots) were excised from the preparative 
gel and digested for MS analysis. MS identified three of the four tropomyosin isoforms 
within each of the digested protein samples, including tropomyosin-1, tropomyosin-2 and 
tropomyosin-4, as well as homeobox protein HOX-C8. HOX genes code transcription 
factors, including HOX-C8, which are considered master regulators of embryonic 
development (Axlund, Lambert et al. 2010). The overall functional roles of HOX proteins 
have been directly related to body patterning, developmental growth and cellular 
differentiation (Lewis 1978; Mann and Morata 2000; Pearson, Lemons et al. 2005). 
However, it is not known which proteins and exactly how each protein controls cellular 
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development. Little has been published on specifically the HOX-C8 protein which was 
identified as down-regulated after 48 hours of rINGAP treatment.  However, the protein has 
been directly linked to differentiation of mesenchymal cells into chondrocytes using 2D 
DIGE (Cormier, Mello et al. 2003). This is of significant interest since the expanded hIPCs 
have been suggested to represent a pancreatic mesenchymal stem cell population (Sordi, 
Melzi et al. 2010). 
 
In general, heat shock proteins are known to be molecules which are up-regulated in response 
to environmental changes, as they function to maintain cellular homeostasis (Yamada, 
Hashiguchi et al. 2000). Heat shock protein 90 (HSP 90) was the only protein identified at 
the 48 hour rINGAP treatment point which was up-regulated. This result is confirmation that 
rINGAP induced a response on hIPCs. Furthermore, HSP90 has been strongly associated 
with cellular morphogenesis and differentiation. The protein has been suggested to enable 
morphological evolution at the molecular level (Rutherford and Lindquist, 1998; Lele et al., 
1999). Hsp90 homeostasis serves as a cellular thermometer, controlling both the heat shock 
response and morphological differentiation (Wiesgigl and Clos 2001). Hsp90 has been shown 
to interact directly with ligand-dependent transcription factors and cell cycle regulators 
(Rutherford and Zuker, 1994; Scheibel and Buchner, 1998; Buchner, 1999), which then 
impacts morphological differentiation of multicellular organisms (Wiesgigl and Clos 2001).  
 
 
Overall, the temporal proteomic analysis revealed perturbation and possible reorganization of 
the hIPC cytoskeleton following rINGAP treatment. Several of the identified proteins 
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although directly linked to the actin cytoskeleton, have also been previously linked to 
diabetes, cell proliferation, as well as cell differentiation (Imperatore, Hanson et al. 1998; 
Fogarty, Moczulski et al. 1999). While other proteins, specifically plasminogen activator 
inhibitor and alpha-enolase were also identified as down-regulated, it is unclear how these 
proteins are involved in INGAPs overall mechanistic affect on hIPCs. No proteins were 
identified which were directly related to insulin secretion. Therefore, to further evaluate if 
hIPCs were being differentiated towards insulin secreting islet-like cells following rINGAP 
treatment, it was of interest to complete a temporal mRNA analysis on islet expressing genes. 
4.7.2 rINGAP Treatment Alters mRNA Expression of hIPCs 
Gene expression studies were carried out to examine whether short-term exposure to rINGAP 
alone could alter mRNA expression levels in addition to proteomic levels. Of specific interest 
was to evaluate whether rINGAP was promoting the in vitro differentiation of hIPCs towards 
an insulin-secreting β-cell lineage. The DIGE results demonstrated that rINGAP treatment 
changed the global protein expression levels of hIPCs at various treatment times. The most 
significant result was the down regulation of hIPC actin binding proteins associated with the 
cytoskeletal platform. In this real-time PCR study, we present two repeat experiments of 
hIPCs treated with rINGAP. Total RNA samples were derived from one donor’s hIPCs and 
analyzed at 24, 48 and 96 hours of rINGAP exposure (same treatment times as the DIGE 
analysis). As well, the hIPCs were analyzed after 15 minutes and 1 hour of rINGAP 




Similar results were obtained from the two experiments; however, in the second experiment 
insulin was not detected. In the first experiment, after a 15 min of rINGAP treatment, no 
significant differences were observed between the treated cells and the non-treated controls 
with respect to cytokeratin-19 (CK-19), glucagon (GLU), insulin (INS), and pancreatic 
polypeptide genes (PPY) (figure 4-13i). Hence, for the second experiment, it was decided 
not to perform the analysis at the 15 min treatment point. The 1 hour treatment point revealed 
the most inconsistent results of all time points and the error bars were large. After 1 hour of 
rINGAP exposure, PPY decreased in both experiments at this time point (figure 4-13ii). In 
the first experiment, CK-19 and GLU increased slightly (figure 4-13ii), however in the 
second experiment both gene expression levels were down at the 1 hour time point (figure 4-
13ii). At the 24 hour treatment point, the decrease in GLU and CK-19 expression was 
consistent between the two experiments. However, PPY expression showed inconsistent 
results (increasing in experiment 1 and decreasing in experiment 2), with large error bars 
(figures 4-13iii and 4-14ii). Significantly, in the second experiment all gene expression 
levels decreased following rINGAP treatment at 1 hour, 24 hours and 48 hours (figures 4-
14i, 4-14ii, 4-14iii). In the first experiment, however, PPY increased at 24 and 48 hours 
(figure 4-13iv). Finally, since DIGE analysis was performed after 96 hours of culture, in the 
second qRT-PCR experiment 96 hour expression levels were evaluated. In comparison to the 
extent of mRNA expression changes at the earlier time points, no significant expression 





Figure 4-13: First experiment of rINGAP treatment which altered mRNA expression of 
hIPCs shown by real-time RT-PCR. Treated hIPCs were exposed to 10nM of rINGAP 
with a media change on day two which included rINGAP supplementation. Shown are 
mRNA expressions of treated versus non-treated controls at (i) 15 minutes (ii) 1 hour 





Figure 4-14: Second experiment of rINGAP treatment which altered mRNA expression 
of hIPCs shown by real-time RT-PCR. Treated hIPCs were exposed to 10nM of 
rINGAP with a media change on day two which included rINGAP supplementation. 
Shown are mRNA expressions of treated versus non-treated controls at (i) 1 hour (ii) 24 




Overall, it was observed that rINGAP exposure altered the mRNA expression of hIPCs. 
These results complement the DIGE analysis. Decreases in islet associated gene expression 
was the main trend observed in the PCR analysis, and a similar trend was determined by 
DIGE with many of the protein changes having decreases in expression level. The first PCR 
analysis had large or overlapping error bars and overall no statistically conclusive results can 
be drawn. In the second experiment, all gene expression levels (glucagon, PPY and CK-19) 
decreased significantly to varying extents from 1 to 48 hours of rINGAP treatment. As the 
absolute expression levels of some proteins, including: PPY, glucagon and CK-19 are likely 
low (Davani, Ikonomou et al. 2007), the decrease in their levels may not have been readily 
detected by DIGE. The DIGE results demonstrated the greatest changes in protein expression 
at 48 hours of treatment. In the second PCR analysis, immediate and comparable decreases in 
mRNA levels were seen at 1 through 48 hours of treatment (figure 4-14i, ii, iii). This is 
consistent with development and regeneration, in which growth factors often rapidly 
influence transcriptional and post-transcriptional regulation, with subsequent altered protein 
expression (Alberts et al. 2008; Gilbert et al. 2006).  
 
In both experiments, insulin expression was either unchanged or inconsistent (experiment 1) 
or not detected (experiment 2). Inconsistency in insulin detection may have been observed 
while decreases in the levels of glucagon were detected because while both insulin and 
glucagon gene promoters have activation histone marks, the glucagon promoter has fewer 
repressive marks (Wilson, Wong et al. 2009). Hence, rINGAP may act to suppress basal 
levels of PPY and glucagon endocrine hormones in hIPCs, possibly leaving insulin 
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unchanged and hIPCs further poised differentiation. Previous in vitro work with neonatal rat 
islets has shown that INGAP pentadecapeptide 104-108 (INGAP-PP) treatment increases 
insulin and glucagon mRNA expression levels (Barbosa, Bordin et al. 2006). While species 
differences may exist, the islets in that study were a complex combination of endocrine, 
stromal, and vascular endothelial cells (Edlund 2002; Hess, Li et al. 2003; Sordi, Melzi et al. 
2010), rather than an enriched population of progenitor cells (Davani, Ikonomou et al. 2007). 
Alternatively, it has been shown that when human cells are INGAP-PP treated in vitro CK-19 
is typically seen down regulated from duct-like epithelial cells (Jamal, Lipsett et al. 2005). 




Evidence suggests that hIPCs may represent an important stem cell population that when 
expanded and cultured in vitro could offer a useful supply of cells for islet transplantation. 
Although the differentiation of hIPCs into functional insulin producing cells has not yet been 
achieved in this study or others, the investigation of various differentiation protocols using 
assorted factors, including INGAP, is warranted. It was proposed that INGAP may be a 
factor required for islet progenitor cell dedifferentiation in vitro, as it is suggested for 
physiological islet regeneration in vivo (Rosenberg, Lipsett et al. 2004; Dungan, Buse et al. 
2009). Given the correct culture conditions, INGAP supplementation in vitro could induce 
insulin secretion of islet-derived progenitor cells which then could be aggregated into islets 




The proteomics coupled with genomics investigation presented in this chapter, further 
characterizes at the mechanistic level both INGAP and hIPCs therapeutic potential in the 
treatment of diabetes. As the field of proteomics advances, proteins will be identified with 
newly discovered functions. These proteins will serve as new bio-markers and will be vital 
for deducing the mechanisms and responses of drug treatments and differentiation protocols. 
Of particular importance for drug effect and differentiation studies is the characterization of 
temporal protein expression in relation to mRNA expression. In this study, we characterized 
rINGAPs affect on hIPCs to gain insights into possible mechanisms to explain the observed 
clinical effects of INGAP. DIGE and PCR analyses on hIPCs at three rINGAP treatment 
times indicated a time-dependent rINGAP effect with the most significant changes in mRNA 
levels were from 1-24 hours and with the greatest proteomic perturbation at 48 hours of 
rINGAP exposure. 
 
We have identified for the first time a series of proteins which rINGAP altered expression. 
Cytoskeletal proteins, specifically, the actin binding proteins: caldesmon, transgelin, 
tropomyosin and cofilin-1; a heat shock protein (HSP90); and a glycolytic enzyme (alpha-
enolase), a protein possibly involved in glucose metabolism, were among those identified as 
significantly changed. These proteins and their related binding proteins form complex protein 
interaction networks which have been previously linked to diabetes, cell proliferation and 
cell differentiation (Imperatore, Hanson et al. 1998; Fogarty, Moczulski et al. 1999). Overall, 
the temporal proteomic analysis suggests perturbation and possible reorganization of the 
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hIPC cytoskeleton following rINGAP treatment. Of significant importance, cytoskeletal 
reorganization in mesenchymal stem cells and progenitor cells has previously been reported 
(Rodriguez, Gonzalez et al. 2004; Yourek, Hussain et al. 2007; Hong, Chen et al. 2010), 
which could indicate hIPCs are undergoing differentiation.  
 
The qRT-PCR data indicated that following rINGAP treatment, glucagon, pancreatic 
polypeptide and CK-19 expression is decreased from 1 hour to 48 hours after treatment 
initiation, while insulin expression is largely unchanged or undetected. The insulin gene 
promoter in hIPCs has shown histone modifications indicative of active genes (Mutskov, 
Raaka et al. 2007), however repressive modifications have been also observed (Wilson, 
Wong et al. 2009). We propose that rINGAP may act to suppress basal levels of PPY and 
glucagon endocrine hormones in hIPCs, possibly further poising hIPCs for differentiation. If 
INGAP is acting early in the differentiation pathway, similar to embryonic cells where such a 
phenomenon has been confirmed (Fleming and Rosenberg 2007), additional factors are likely 
required for the differentiation of hIPCs into functional β-like cells (Wilson, Wong et al. 
2009). In studies where streptozotocin was administered to animals and islet regeneration 
was reported (Fernandes, King et al. 1997; Rosenberg, Lipsett et al. 2004), INGAP with 
other factors aided or contributed to this regeneration - likely at the early stage (Fleming and 
Rosenberg 2007). Interestingly, at 96 hours of rINGAP exposure, most of the changes in 
expression levels were attenuated; that is the levels became similar to the control at the 
mRNA and proteomic levels. It has been observed in previous studies that INGAP is induced 
rapidly after pancreatic partial obstruction with cellophane wrapping in hamsters and is 
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detected for up to 2 days (Rafaeloff, Pittenger et al. 1997). Therefore, it has been 
hypothesized that INGAP may act early in the islet cell induction cascade (Rafaeloff, 
Pittenger et al. 1997; Fleming and Rosenberg 2007). The early changes in mRNA profiling of 
hIPCs  followed by the detected down-regulation of the actin cytoskeleton following rINGAP 
treatment is consistent with this hypothesis (Oliver-Krasinski and Stoffers 2008). However, it 
is acknowledged that the changes were not large and insulin was either unchanged or not-
detected. The genes which were analyzed are expressed or down regulated late in the 
differentiation pathway to islet cells. Therefore, analyses of earlier genes such as Pdx-1 and 
Ngn-3 which have been correlated with ductal- and islet-associated progenitor cells 
(Fernandes, King et al. 1997; Seaberg, Smukler et al. 2004; Xu, D'Hoker et al. 2008), would 
be of interest to confirm this hypothesis. Moreover, it would be of interest to monitor the 
genes of the proteins determined through DIGE analysis at the mRNA level, to fully 
understand the mechanism(s) of INGAP action.  
 
The mechanism of INGAP-mediated repression of proteins and mRNA levels remain to be 
investigated further. It may include developmental and regenerative mechanisms of 
differential transcriptional control, chromatin structure, mRNA processing, mRNA stability, 
RNA interference, and translational control (Alberts et al. 2008; Gilbert et al. 2006). 
Different cell populations may be required to orchestrate complete differentiation, where one 
cell population may induce another (Gilbert et al. 2006). Other cells may respond to INGAP 
to induce hIPC differentiation. Alternatively, INGAP may be acting on hIPCs to induce 
genes that influence the fate of other cells (Gilbert et al. 2006). Finally, some studies have 
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proposed that hIPCs may form a stromal population of cells in the islets in vivo (Sordi, Melzi 
et al. 2010), which INGAP may be targeting and inducing islet neogenesis in the treated 





Chapter 5 Live Cell Imaging Analysis of Human Islet-Derived 
Progenitor Cells Treated with rINGAP 
5.1 Preamble 
To further understand the cellular, specifically cytoskeletal effects of rINGAP on hIPCs, this 
chapter expands the previous mechanistic findings of rINGAP. Long term live-cell imaging 
was used to study cell motility and proliferation effects and immunofluorescent imaging of 
two actin binding proteins which were identified in the DIGE analysis in the previous chapter 
are utilized to understand the cytoskeletal effects of rINGAP on hIPCs.  
5.2 Publication Title and Authors 
The results presented within this chapter have been prepared for publication to the Journal of 
Cytoskeleton. 
 
Title: rINGAP Induces Morphological Changes and Cytoskeletal Reorganization in 
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Expansion of isolated human islets in culture yields a proliferative population of nestin 
positive human islet-derived progenitor cells (hIPCs) that have been previously characterized 
as pancreatic mesenchymal stem cells (pMSCs). The therapeutic potential of hIPCs for 
diabetes treatment is not understood and requires further investigation. Here, we use long 
term live-cell imaging and immunocytochemistry to characterize the phenotypic effects of a 
therapeutic protein, islet neogenesis associated protein (INGAP), on hIPCs in culture.  In 
human clinical trials INGAP peptide increased C-peptide secretion in Type 1 diabetic 
patients and improved glycemic control in Type 2 diabetic patients. The mechanism of 
INGAP action, including cellular specificity and receptor, is unknown. Live-cell imaging 
enabled the tracking of nuclear motion every 5 minutes over 76 hours. Analysis revealed a 
greater than 50% decrease in average nuclear speed and a change in morphology of cells 
exposed to recombinant INGAP (rINGAP). Furthermore, immunofluorescent labeling of 
actin binding proteins (ABPs) tropomyosin and caldesmon exhibited perinuclear and 
extranuclear translocation in rINGAP-treated cells, respectively. These results combined are 
suggestive of a decreased proliferation potential of hIPCs exposed to rINGAP. We 
demonstrate rINGAP affects cell morphology, cell motility, cytoskeletal arrangement and 








Live-cell imaging; lineage analysis; human islet-derived progenitor cells (hIPCs); islet 
neogenesis associated protein (INGAP); pancreatic mesenchymal stem cells (pMSCs); actin 
binding proteins (ABPs); caldesmon; tropomyosin 
 
5.4 Introduction  
Diabetes is a disease strongly associated with the loss of β-cell mass in the pancreas.   Type 1 
diabetes mellitus is the result of a progressive autoimmune-mediated destruction of β-cells, 
and patients with Type 2 diabetes typically have a 50% decrease in β-cells mass (Halban 
2004). This decrease in cell mass results in a decline of insulin secretion and contributes to a 
loss of glucose homeostasis. Although islet transplantation has resulted in improved glucose 
stability with a significant reduction of insulin dependence, a shortage of pancreas organ 
donors in combination with engraftment and immunosuppressant toxic effects, limits the 
therapeutic potential of this approach (Shapiro, Lakey et al. 2000; Ryan, Paty et al. 2005). 
Islet regeneration is an ideal treatment for this loss of insulin production. In vivo, islet 
neogenesis associated protein (INGAP) is being administered in animal models and clinical 
trials, and evaluated for islet cell neogenesis, C-peptide secretion, and glycemic control 
(Rosenberg, Lipsett et al. 2004; Barbosa, Bordin et al. 2006; Dungan, Buse et al. 2009). In 
vitro, a central goal of regenerative diabetes research is the generation of functional islet cells 
for transplantation (Serup, Madsen et al. 2001; Peck, Cornelius et al. 2002; Baharvand, Jafary 
et al. 2006; Tateishi, He et al. 2008). 
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Targeting cells derived from the in vitro expansion of pancreatic islets may represent an ideal 
cell source for islet differentiation, since these expanded cells retain epigenetic marks 
(Joglekar, Joglekar et al. 2009) and activity of the islet gene modules (Kutlu, Kayali et al. 
2009). The expansion of isolated islets results in a proliferative cell population of islet 
derived progenitor cells (IPCs) characterized as pancreatic mesenchymal stem cells (pMSCs) 
(Sordi, Melzi et al. 2010), that express insulin mRNA at low levels and are capable of 
differentiating into hormone-expressing cells at levels 1% of adult islets (Davani, Ikonomou 
et al. 2007). Additionally, when pMSCs are transplanted with minimal pancreatic islet mass, 
they facilitate neovascularization of the graft and restoration of normoglycemia in the mice 
(Sordi, Melzi et al. 2010). Although it is known that pMSCs do not express the insulin gene 
(Mutskov, Raaka et al. 2007) and express negligible levels of islet-specific genes (Sordi, 
Melzi et al. 2010), they do possess epigenetic markers that could position them for activation 
of insulin expression (Mutskov, Raaka et al. 2007). 
 
Activation of insulin expression of IPCs may require one or more factors to induce 
differentiation into functional insulin producing cells. Several factors have been suggested as 
inducers of beta-cell mass which may also act on IPCs, including but not limited to a 
combination of gastrin and epidermal growth factor (EGF) (Brand, Tagerud et al. 2002; 
Suarez-Pinzon, Lakey et al. 2005; Suarez-Pinzon, Yan et al. 2005), glucagon-like peptide-1 
(GLP-1) (Tourrel, Bailbe et al. 2001; Xu, Kaneto et al. 2006), exendin-4 (Xu, Stoffers et al. 
1999; Xu, Kaneto et al. 2006) and INGAP (Rafaeloff, Pittenger et al. 1997; Rosenberg, 
Lipsett et al. 2004; Barbosa, Bordin et al. 2006). INGAP is a 17 kDa protein which was 
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discovered to be a constituent of ilotropin (Pittenger, Vinik et al. 1992), an islet-specific 
growth factor, which is expressed during islet neogenesis. Through further sequencing of 
INGAP, an active region of the protein (amino acids 104-118) was determined to have 
similar islet neogenesis effects and has been termed INGAP peptide (Rafaeloff, Pittenger et 
al. 1997). In human clinical trials, INGAP peptide increased C-peptide secretion in Type 1 
diabetic patients and improved glycemic control in Type 2 diabetic patients (Dungan, Buse et 
al. 2009). Furthermore, dissection of mouse pancreata has shown that INGAP peptide 
increases β-cell mass (Rosenberg, Lipsett et al. 2004), however the precise mechanism of 
INGAP action, including cell target and receptor is unknown.  
 
To date, studies of INGAP have focused on evaluating the islet neogenesis effects of INGAP 
peptide. Although the original work of the cloning and sequencing of INGAP concluded that 
both the peptide and the protein demonstrated effects of islet neogenesis, it was noted that the 
INGAP protein appeared to have a more potent effect (Rafaeloff, Pittenger et al. 1997).  
Recently, the production and characterization of full-length recombinant INGAP (rINGAP) 
has been reported to facilitate studies of the mechanism(s) of INGAP action (Assouline-
Thomas, Pilotte et al. 2009). Importantly, rINGAP exhibits 100 times the bioactivity in 
comparison to the INGAP peptide using an in vitro assay (Assouline-Thomas, Pilotte et al. 
2009). Mechanistic studies of rINGAPs action on various pancreata cell types require further 
investigation, including rINGAPs effect on IPCs. Although it is unknown if these cells 
represent a physiological stem cell population, characterization of an islet neogenesis factor 
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such as rINGAP is necessary for the clinical development of both INGAP and islet-derived 
cells in diabetes treatment applications. 
 
Here, we use live-cell imaging to characterize the effect of rINGAP on human islet derived 
progenitor cells (hIPCs) with a previously reported novel culture system (Ramunas, Illman et 
al. 2006). The imaging chamber culture system allowed for nuclear tracking using 
differential interference contrast (DIC) microscopy, lineage tree construction, and phenotypic 
scoring, to characterize rINGAP-treated hIPCs. Our results reveal rINGAP significantly 
decreases nuclear speed, indicating that rINGAP affects nucleo-cytoplasmic coupling, a 
previously unknown cellular consequence of rINGAP. We demonstrate that hIPCs respond 
immediately to rINGAP and reach an average nuclear speed of 8 μm/hr from an initial 
average speed of 18 μm/hr within 10 hours of rINGAP addition. Furthermore, two actin 
binding proteins, tropomyosin and caldesmon, which have been previously associated with 
cell speed (Bach, Creed et al. 2009; Jiang, Huang et al. 2010), differentiation (Abd-el-Basset, 
Ahmed et al. 1991) and rINGAP exposure (manuscript in preparation), exhibited perinuclear 
and extranuclear localization following rINGAP treatment of hIPCs. These results were 
consistent with the rINGAP cellular motility and nuclear speed effects observed through the 
live-cell imaging analysis. These observations provide novel mechanistic insights into 
rINGAPs effect on hIPCs, which include: a decrease in cell speed and directional persistence, 
a change in tracked morphology, and the cytoskeletal reorganization of hIPCs exposed to 
rINGAP.  These observations suggest a potential mechanism of hIPCs in the therapeutic 
effect of INGAP, which may prove clinically relevant for the treatment of diabetes. 
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5.5 Materials and Methods 
Human Islet-Derived Progenitor Cell (hIPC) Culture 
Human islet isolation protocols were approved by the Institutional Review Board of McGill 
University, Montréal, QC. A healthy pancreas was obtained from an adult cadaveric donor 
through an organ procurement organization at Montréal General Hospital. The islets were 
isolated according to established protocols (Shapiro, Lakey et al. 2000; Jamali, Emmerson et 
al. 2005). Briefly, islets ranging from 75 to 400 μm were determined to be greater than 90% 
purity by dithizone staining (Sigma, St Louis, MO), collected, washed and re-suspended in 
CMRL-1066 medium with penicillin, streptomycin, and amphotericin B (Antibiotic-
Antimycotic (100X) liquid; Gibco, Burlington, ON) and 10% fetal bovine serum (MBI, 
Amherst, NY). Suspended islets were placed in a polypropylene container without airspace 
and shipped on ice overnight from Montréal, QC to Waterloo, ON.  
 
The hIPCs were derived from the fresh human islets as described previously (Gershengorn, 
Hardikar et al. 2004; Gallo, Gambelli et al. 2007; Sordi, Melzi et al. 2010) with 
modifications. Briefly, the islets were plated in 75 cm2 tissue culture-treated flasks at a 
density of approximately 1 islet/mm2 in modified RPMI-1640 medium (11.1 mM glucose) 
(Invitrogen, Burlington, ON), supplemented with 10% FBS (Invitrogen, Burlington, ON). 
The flasks were incubated at 37°C, 5% CO2 and 95% humidified air, and after 48 hours non-
adherent cells were removed and 12.5 mL of fresh media was replenished. The media was 
then replaced every 3 days for the remainder of the culture. At day 15 of culture the islets 
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which were spread into a monolayer were detached from the surface with 2.5 g/L trypsin 
with 0.38 g/L EDTA (Invitrogen, Burlington, ON) and reseeded as single cells at a density of 
1.2x104 cells/cm2, followed by subsequent passaging at 4x103 cells/cm2 once 85% 
confluence had been obtained, approximately every 10 days.  
 
Live-Cell Imaging 
Trypsinized hIPCs were resuspended in media at a concentration of 2x107 cells/mL.  
Commercial 10 μm size standard beads (Corpuscular Inc., Cold Spring, NY) were used to 
maintain spacing when loaded under aminopropyl trimethoxy silane (APTS)-treated glass 
imaging chambers as previously described (Ramunas, Illman et al. 2006; Moogk, Hanley et 
al. 2007). The chambers were filled with 1.5 mL of RPMI-1640 medium with 10% FBS. 
Imaging chambers were then cultured under standard conditions for 24 hours to allow for cell 
attachment before long term imaging on inverted microscopes using DIC (Axiovert 200; Carl 
Zeiss MicroImaging GmbH, Berlin, Germany). Imaging was performed in a humidified 37°C 
atmosphere with 5% CO2 for 76 hours using monochrome high resolution CCD cameras 
(XCD-SX910/X710; Sony Corporation, Tokyo, Japan) at 5 minute intervals with 20X 
objective and a 0.5X camera adapter.  Image mosaics were compiled using custom-built 
motorized stages and image software (Moogk, Hanley et al. 2007). After 23 hours of 
imaging, 1.5 mL of media was replaced with fresh media supplemented with 10nM of 
rINGAP supplied by the Rosenburg Lab, Montréal, QC, produced and purified as previously 
described (Assouline-Thomas, Pilotte et al. 2009). In the control population, 1.5 mL of fresh 
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media was replaced without rINGAP addition. At 48 hours, 10nM of rINGAP was re-
supplemented into the media of the rINGAP-treated chamber. Both the rINGAP-treated and 
control chambers were imaged for 53 hours after the first rINGAP addition. 
 
Cell Tracking 
Individual fields of view were combined to create mosaics covering 3.4 mm2. Time-lapse 
image mosaics were tracked as previously described (Moogk, Hanley et al. 2007) to capture 
cell nuclei x-y position using distinct cellular features as references, including: cell 
membrane, cell cytoplasm, nuclear envelope and nucleoli. Nuclear tracking was performed 
by manual examination of image frames captured every 5 minutes over the 76 hours of 
acquisition. The tracker was uninformed of the experimental details to prevent biased 
tracking. Cell fates, including cell divisions, deaths and loss-of-trackability were recorded 
and lineage trees were generated. Loss-of-trackability included loss of observable nuclear 
features, such as: nuclear envelope and nucleoli, and cell migration from the field of view. In 
total, 24,675 positional data points were recorded for the rINGAP-treated cells and 15,845 
positional data points were recorded for the control population. Figures 5-1 a-c demonstrates 
an individual hIPC tracked by nuclear position over 56 hours, using observable nuclear 






Figure 5-1: Nuclear position was tracked using nuclear features including nuclear 
envelope and nucleoli.  DIC images were taken every 5 minutes.  Images are shown at 0 
(a), 18 (b), and 56 (c), hours of a typical tracked hIPC. The arrowheads indicate the 






At the first recorded time-step the nuclear x-y positions were determined and a nearest 
neighbor distance was calculated for each cell to verify comparable cell loadings between the 
two chambers, with respect to both cell density and spatial distribution. The cell density ( ) 
was also calculated for the mosaic area. The average nearest neighbor distance ( ) was 
normalized to the expected value for randomly distributed nuclei, 
√
 , to yield the 
index of aggregation (Clark and Evans 1954) 2 · √ .  
 
Position data was used to calculate speeds for each cell over time in both rINGAP-treated 
and control hIPC populations. Trackable motions were determined from consecutive nuclear 
position measurements, calculating speed as displacement per time-step. Due to human 
tracking limitations, cells with nuclear motions less than 0.5 μm/hr were considered 
stationary. These measurements comprised only 0.3% of all tracked movements in 
comparison to 30% of measurements which were tracked as stationary. Speed and the 
logarithmic transformation of speed were used to identify trends and to determine statistical 
significance. Cell movement paths, normalized to an arbitrary origin, were visualized as rose 







Error bars on graphs depicting speed correspond to the standard error of the mean (SEM), 
while error bars on logarithmically transformed speed graphs correspond to 95% confidence 
intervals. Statistical analysis was performed in Statistica 8 (StatSoft™) and Microsoft Excel 
2007™. 
Immunostaining and Confocal Microscopy 
hIPCs were expanded from isolated human islets and cultured in imaging chambers for 100 
hours as described above. The expression of nestin, CD133, vimentin, cytokeratin 19 (CK-
19), tropomyosin and caldesmon, were examined with immunofluorescent confocal 
microscopy.  At the end of the image acquisition cells were rinsed twice with PBS, fixed with 
4% paraformaldehyde for 20 min, rinsed twice with PBS, permeabilized with 0.5% Triton X-
100™ for 45 min, rinsed twice with PBS and blocked with 5% BSA at room temperature 
overnight. Cells were then rinsed with PBS and incubated with primary antibodies for 4 
hours at room temperature.  All antibodies were purchased from Abcam Inc. Cambridge, MA 
or Miltenyi Biotec, Germany. The primary antibodies used were 1:1000 mouse monoclonal 
anti-nestin (ab22035), 1:11 mouse monoclonal anti-CD133 (MACS 130-090-851), 1:150 
rabbit polyclonal anti-vimentin (ab15248), 1:4 rabbit polyclonal anti-cytokeratin 19 
(ab15464), 1:50 mouse monoclonal anti-tropomyosin (ab7785) and 1:250 rabbit monoclonal 
anti-caldesmon (ab32330).  Following primary antibody staining, cells were rinsed with PBS 
and blocked with 1% BSA overnight.  Secondary antibodies were then incubated overnight at 
4°C and comprised 1:2000 goat polyclonal to mouse IgG FITC (ab6785) and 1:800 goat 
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polyclonal to rabbit IgG Cy5 (ab6564). The cells were rinsed twice with PBS, nuclear stained 
using DAPI with antifade (Vector Laboratories Inc., Burlington, ON) for 20 min and imaged 
sequentially on a laser scanning confocal microscope (FV1000; Olympus Canada Inc., 
Markham, ON). 
5.6 Results 
Human Islet-Derived Cells Express Mesenchymal Markers (Nestin+ and Vimentin+) 
Phenotype was evaluated using immunocytochemistry of mesenchymal (nestin, vimentin) 
and epithelial (CK19, CD133) markers to verify that the outgrowth cells from expanded 
human islets were characteristic of a mesenchymal cell population. These results showed the 
entire population to be nestin+, vimentin+, CK19-, and CD133- at passages four, six, and eight 
(figures 5a-c).  This was in agreement with previous characterization of IPCs as pMSCs in 
which nestin+ pMSCs were found to completely replace the non-proliferative highly 
apoptotic epithelial (CD133+) cells from expanded islets (Sordi, Melzi et al. 2010).    
 
Cell Tracking, Scoring and Lineage Analysis Demonstrates a Change in Morphology 
Following rINGAP Treatment 
Wide field live-cell DIC microscopy was employed to image 3.4 mm2 areas at high spatial 
and temporal resolution for 76 hours using mosaics of 20X magnification collected every 5 
minutes.  To confirm comparable hIPC loadings of the imaging chambers, cells were counted 
in each mosaic element 24 hours after cell seeding. The distribution of loadings was 
evaluated using the Clark-Evans nearest-neighbor statistic (Clark and Evans 1954). Cells 
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were counted in the control mosaic (N=387) and in the chamber to be treated with rINGAP 
(N=400). Clark-Evans R-statistic values for the control and rINGAP chamber, were 
calculated and determined to be comparable (R=1.02 and 1.07, respectively). A value of R=1 
represents complete spatial randomness (Clark and Evans 1954), indicating hIPC loadings 
were randomly distributed in both chambers at the beginning of the imaging run. Of the 400 
cells in the mosaic of the rINGAP chamber, 32 hIPCs were randomly selected to be tracked, 
with 7 of these cells remaining trackable for the entire 76 hours of imaging. In comparison, 
25 cells were randomly selected to be tracked in the control chamber with 9 remaining 
trackable to the end of the experiment. 
 
Cell lineages were produced by manual nuclear tracking of x-y positions, cell divisions and 
deaths (figures 5-2 a,b). In the lineage trees, an ‘X’ indicates cell death in which cells 
typically spontaneously rounded up and burst. A ‘∆’ indicates that the cell left the imaging 
field of view and therefore became untrackable. An ‘O’ indicates that the cell lost DIC 
imaged nuclear features, such as distinct nuclear envelope and nucleoli, and therefore became 
untrackable. 6 of the 32 tracked cells divided in the rINGAP chamber, which included 4 cells 
that divided before and 2 cells that divided after the rINGAP addition. In comparison, none 
of the 25 randomly-selected tracked cells divided in the control. A one-sided Fishers exact 
test showed poor evidence of a difference in proliferation frequency between the two 
chambers prior to rINGAP addition (p=0.1054). Additionally, examination of randomly-
selected fields of view from each chamber (n=8), failed to demonstrate a significant 
difference in the number of division events during the first 10 hours of imaging (p=0.2359). 
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These results reveal that both chambers were proliferating at comparable rates prior to the 
addition of rINGAP.  Based on the reported doubling time of pMSCs (84±16 hours (Sordi, 
Melzi et al. 2010)), doubling time was evaluated and no cells divided more than once in the 
76 hours of imaging in either the rINGAP or control chambers.  
 
We determined through the live-cell tracking and scoring a change in cellular morphology 
following rINGAP addition. The rINGAP-treated hIPCs exhibited a transition from an 
adherent state in which the nuclear membrane and nucleoli were visible to partial losses of 
attached phenotype and observable nuclear features, which rendered a significant proportion 
of hIPCs untrackable at the 5 min time-steps following rINGAP addition. Live-cell imaging 
analysis of the control versus the rINGAP-treated chamber revealed only one cell of 25 
tracked hIPCs in the control population was found to become permanently untrackable 
(figure 5-2a). In comparison, 12 of 32 tracked cells in the rINGAP-treated chamber were 
scored as having a permanent loss of trackable nuclear features with the described 
morphological changes (figure 5-2b), consistent with the cytoplasmic retraction of the 
plasma membrane. These untrackable cells were confirmed to exhibit features of live cells, 
such as cytoplasmic activity and vesicular movement, and to retain their untrackable 
morphology until the end of the imaging run (figures 5-2c,d). It is concluded that the loss of 
trackable nuclear features especially the loss of distinct nucleoli, combined with 
morphological changes, was a morphogenetic response of hIPCs induced by rINGAP.  Of 




Figure 5-2: Lineage trees of randomly selected hIPCs tracked every 5 minutes over 76 hours, with a 
representative cell shown. (a) Control lineage with 25 randomly selected tracked cells. (b) rINGAP-
treated lineage with 32 randomly selected tracked cells. rINGAP was added at 23 hours indicated by the 
dotted horizontal line.  X, ∆, and O indicate cell death, cell migration from the imaging field of view and a 
loss of trackable nuclear features, respectively. A typical cell in which the nucleus was visible for tracking 
for the first 30 hours of imaging (c) followed by a loss of trackable nuclear features and change in cell 
morphology after rINGAP addition (d) this cell was scored with an O. 
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membrane ruffling, and cytoplasmic retraction have been associated with cell motility 
(Okamoto, Kajiya et al. 2004; Fackler and Grosse 2008), as well as the differentiation of 
MSCs and other stem cells (Worster, Nixon et al. 2000; Wenisch, Trinkaus et al. 2006; 
Rowlands, George et al. 2008). 
 
rINGAP Reduces Cellular Movement and Nuclear Speed 
To determine if rINGAP had an effect on hIPC motility, the 76 hours of x-y nuclear position 
data was used to generate rose plots to visualize the migration paths of the tracked hIPCs in 
culture (figure 5-3). Two rose plots were generated for each of the control and rINGAP 
chambers; at 0-20 hours of imaging (before rINGAP addition) and at 50-70 hours (27 hours 
after rINGAP addition) (figures 5-3 a,b,d,e). For the first 20 hours of imaging, the rose plots 
of 20 randomly selected cells in the control chamber and in the chamber to be treated with 
rINGAP, revealed the cells migrated approximately the same distance over time (80 μm over 
20 hours) and with similar migratory trajectories before rINGAP was supplemented in the 
media (figures 5-3 a,d). Following the addition of rINGAP, comparison of the rose plots 
revealed an overall decrease in directional persistance at 50-70 hours in both the control and 
the rINGAP-treated hIPC populations (figure 5-3). It was concluded that although the cells 
were incubated for 24 hours to allow for cell attachement prior to imaging, during the first 20 
hours of imaging the cells were not fully attached therefore resulting in increased cell motion 
at the beginning of the run in both chambers. Most importantly, closer evaluation of the rose 
plots following rINGAP addition (figures 5-3c,f) revealed a reduced density of nuclear paths 
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in the rINGAP-treated chamber relative to the control. In summary, the rose plots 
demonstrated qualitatively that the hIPCs in both chambers were migrating over comparable 
distances with similar trajectories prior to the addition of rINGAP, however the rINGAP-
treated hIPCs significantly decreased migration in response to rINGAP. Since cell migration 
is dependent on both cell direction and speed, it was unclear from the qualitative 
observations of the rose plots if rINGAP affected both, or just one parameter. To accurately 
evaluate the distance the cells travelled over the 76 hours of imaging, nuclear paths were 
analyzed in terms of cumulative distance.  Average cumulative distance plots for both the 
control and the rINGAP-treated hIPCs revealed that prior to rINGAP induction (0-23 hours) 
both chambers hIPCs had comparable cumulative distance trajectories, consistent with the 
rose plots, however at 23 hours of rINGAP addition rINGAP-treated hIPCs show a reduction 
in distance travelled over time (figure 5-4a).  
 
We next determined the average speed of the hIPCs over 70 hours (figure 5-4b). Following 
rINGAP addition, rINGAP-treated hIPCs exhibited a significant decrease in average nuclear 





Figure 5-3: Rose plots of control and rINGAP-treated hIPCs. Each line represents the 
migration path of a tracked nucleus, normalized to the origin. Control (a) and rINGAP-
treated cells (d) are shown at 0-20 hours (n=20 cells), and at 50-70 hours (n=14 cells) 
(b,e respectively). (c,f) Enlarged rose plots of b,e (respectively). Scale divisions 
correspond to 20μm (a,b,d,e) and 10μm (c,f). Prior to rINGAP addition both cell 
populations are migrating over the same distances with comparable cellular movements 
(a,d). Comparison of 0-20 hours versus 50-70 hours reveal both cell populations exhibit 
a decrease in overall migration attributed to increased cell attachment (a-b,d-e).  
Comparison of control versus rINGAP-treated cells at 50-70 hours shows decreased 





the experiment. In comparison, there was no overall reduction in cellular speed in the control 
cell population. Nuclear movement has been shown to be saltatory, with average speed as the 
product of movement frequency and magnitude (Danowski, Khodjakov et al. 2001; 
Umeshima, Hirano et al. 2007; Nichols, Carney et al. 2008). Therefore, the reduction in 
speed following rINGAP-treatment may have then been caused by either smaller saltatory 
motions and/or less frequent motions. In other words, when the rINGAP-treated hIPCs 
moved, they travelled shorter distances and/or they remained non-motile more often, 
resulting in the reduction in cellular speed.  In order to more precisely evaluate the rINGAP 
effect on hIPCs in terms of migratory behavior, the time course imaging data was used to 
plot saltatory motion distances and frequencies over time (figures 5-4c-f). Saltatory behavior 
of hIPCs was confirmed with both large movements and non-motile periods. Prior to 
rINGAP addition both the control and rINGAP chambers demonstrated similar movement 
frequencies and magnitudes (figures 5-4c,e). However, following rINGAP addition the 
frequency and magnitude of saltatory motions decreased in comparison to the control 
(figures 5-4d,f). The percentage of non-motile observations increased from 30 to 45% 
following rINGAP-treatment, indicating fewer cellular motions as a result of rINGAP 
exposure (figure 5-4i). In comparison, control cells did not show a change in movement 
frequency over the 70 hours of the experiment (figure 5-4i).  
 
Although it was concluded that rINGAP induced an increase in the frequency of stopped 
motions, it remained qualitative that rINGAP also reduced the magnitude of nuclear 
movements. To evaluate the magnitude of nuclear movements, the distribution of non-zero 
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measurements (motions > 0.5 μm) were logarithmically transformed before and after 
rINGAP-addition (figures 5-4g,h). In the rINGAP-treated chamber, the distribution of 
transformed speeds shifted left, indicating an increase in small motions and a reduction of 
larger motions (figure 5-4h), confirming rINGAP decreased the magnitude of the saltatory 
motions in addition to the frequency of non-motile periods.  This shift had a significant (p < 
0.001) overall decrease in mean log speed compared to no significant change in the control 
cell population (figure 5-4j). Since cell motility is driven by the actin cytoskeleton 
(Lambrechts, Van Troys et al. 2004), it is suggested that rINGAP disrupts the actin 
cytoskeleton, amongst a cascade of other cellular mechanisms which remain to be 































Figure 5-4: (a) Average cumulative distance plot of control versus rINGAP-treated cells.  The dotted line represents the trend prior 
to rINGAP addition. Deviation from this line illustrates the immediacy of the rINGAP effect. (b) Average speeds over 10 hour 
intervals show a persistent loss of speed following rINGAP addition; standard error shown. (c,d,e,f) Velocity profiles of typical cells 
over 12hr periods show saltatory motion of nuclei. (d,f) Comparison of nuclei motions after rINGAP addition indicates rINGAP 
stops movement. (i) The proportion of measurements without movement was found to increase from 30 to 45% for rINGAP-treated 
cells. (g,h) The logarithmic transformation of the nuclear speed yielded a nuclear speed distribution diagram showing a reduction in 
the magnitude of nuclear motions that occurred after rINGAP addition. (j) The reduction in the mean log speed was statistically 
significant (p < 0.001) for rINGAP-treated cells.  Vertical lines at 23hr indicate rINGAP addition (a,b,i).  
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Actin Binding Proteins are Reorganized in rINGAP-Treated hIPCs 
Changes in nucleokinetic speed and cellular morphology were indicative of cytoskeletal 
effects on the hIPCs following rINGAP exposure. We performed a proteomic analysis using 
2D Differential in Gel Electrophoresis (2D-DIGE) and identified several proteins responsive 
to rINGAP-treatment, including tropomyosin and caldesmon (manuscript in preparation). 
The effects on morphology and cell motility observed through the live-cell imaging led us to 
further investigate these two actin binding proteins (ABPs). Tropomyosin and caldesmon are 
involved in the organization and remodeling of the actin cytoskeleton in muscle and 
nonmuscle cells (Wang 2008). Specifically, they are both classified as actin “side-binders” 
because they stabilize F-actin (Wang 2008). The actin cytoskeleton maintains cell shape and 
its stability, is implicated in cell division, migration, endocytosis, apoptosis, vesicle 
trafficking, gene expression and differentiation (Mack, Somlyo et al. 2001; Pollard and 
Borisy 2003; Winder 2003; Albinsson, Nordstrom et al. 2004).  ABPs are related to many, if 
not all of these cellular processes by controlling filament nucleation, elongation, severing, 
capping and depolymerization (Lee and Dominguez 2010). To evaluate the effect rINGAP 
had on the cytoskeleton, the localization of tropomyosin and caldesmon in hIPCs was 
investigated by immunofluorescence using antibodies specific for alpha and beta isoforms of 
tropomyosin and endogenous caldesmon (figure 5-5).   
 
The control cells exhibited a more distinct fibrous-like localization of both tropomyosin and 
caldesmon throughout the cytoplasm compared to rINGAP-treated cells, indicative of both 
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proteins binding to the actin cytoskeleton in controls (figure 5-5d,e). The overlay image of 
the proteins in the controls demonstrates the co-localization of tropomyosin and caldesmon 
throughout the cytoplasm, consistent with a stable actin cytoskeleton and stress fibres, 
required for cell motility, changes in cell shape and the presence of focal adhesions (Abd-el-
Basset, Ahmed et al. 1991; Tanaka, Watanabe et al. 1993). In addition, a strong co-localized 
signal was observed along the cell edges (figure 5-5d). Caldesmon was detected both in the 
cytoplasm and nucleus of control hIPCs. In comparison, rINGAP-treated hIPCs exhibited 
weak localization of caldesmon along the cell perimeters with a weaker distribution 
throughout the cytoplasm and a near-total loss of nuclear signal (figure 5-5e). The specific 
role(s) of caldesmon in the regulation of nuclear functions remain(s) unknown, however, the 
nuclear translocation of the protein coincides with the activation of the intranuclear protein 
kinase p34cdc2, a regulator of G2/M transition, and the phosphorylation of caldesmon (Nurse 
1990; Zheng, Weiden et al. 2007). Moreover, tropomyosin staining in rINGAP-treated hIPCs 
exhibited a loss of the distinct fibrous-like staining following rINGAP-treatment, consistent 
with tropomyosin dissociation from the actin filaments (figure 5-5e). Lastly, tropomyosin 
was redistributed into the perinuclear region of rINGAP-treated hIPCs. Although in vitro 
studies of caldesmon have commonly reported the protein as exclusively cytoplasmic, the 
novelty and validity of the caldesmon nuclear staining in control hIPCs can be supported 
since a recent study has provided evidence of the nuclear localization of caldesmon, 
implicating the protein in nuclear signaling and the regulation of cell proliferation (Zheng, 
Weiden et al. 2007). Of importance, to our knowledge no primary patient donor-derived cells 






























Figure 5-5: Immunocytochemistry of hIPCs at passage eight. (a) nestin+, vimentin+ ; (b) nestin+, CK19- ; (c) nestin+, CD133-  
Expression and localization of (d) control and (e) rINGAP-treated tropomyosin and caldesmon proteins in hIPCs. (d) 
Control cells stained for tropomyosin and visualized with FITC (green) demonstrate a uniform distribution of tropomyosin 
throughout the cytoplasm and no nuclear localization. Control cells stained for caldesmon and visualized with Cy5 (red) 
also demonstrate a relatively uniform distribution of caldesmon throughout the cytoplasm as well as in the nuclei. DAPI 
staining (blue) shows the cellular nuclei. The merged image shows organized co-localization of tropomyosin and caldesmon 
throughout the cytoplasm (yellow) and localization of caldesmon in the nuclei (purple). (e) rINGAP-treated cells stained for 
tropomyosin and visualized with FITC (green) demonstrate a non-uniform perinuclear distribution of tropomyosin in the 
cytoplasm concentrated around the nuclei. rINGAP-treated cells stained for caldesmon antibody and visualized with Cy5 
(red) demonstrate a relatively uniform distribution of caldesmon throughout the cytoplasm however no nuclear localization. 
DAPI staining (blue) shows the cellular nuclei. The merged image shows disorganized perinuclear staining of tropomyosin, 
moderate colocalization of tropomyosin and caldesmon throughout the cytoplasm and a loss of caldesmon in the nuclei (blue 




We investigated the response of hIPCs as a potential target of INGAP in this work. It was of 
interest to use long-term live-cell imaging to determine the duration and temporal correlation 
of any observed effects in relation to a previous proteomic analysis of hIPCs by our group 
which identified a potential perturbation of the actin cytoskeleton in response to rINGAP 
(manuscript in preparation). It was determined that expanded human islet-derived cells 
undergo cytoskeletal and nuclear motility changes upon rINGAP exposure. Investigation into 
the two parameters of migration, cell direction and speed, revealed hIPCs responded 
immediately to rINGAP with a decrease in cumulative distance travelled and average speed 
by more than 50% following rINGAP addition. rINGAP both decreased the magnitude of 
saltatory motions and increased the percentage of stationary instances, rendering 45% of the 
cells non-motile and decreasing the motility of the cells which remained motile.   
 
We observed a loss in clearly defined nuclear features of hIPCs in response to rINGAP, 
rendering high resolution cell tracking very difficult or impossible under the given imaging 
conditions. This morphological change was often accompanied by cell rounding and 
retraction of the cytoplasm towards the nucleus and reduced cellular motility.  Importantly, 
changes in cell morphology are commonly associated with mammalian cell differentiation, 
including MSCs (Rodriguez, Gonzalez et al. 2004). Immunocytochemistry of ABPs 
tropomyosin and caldesmon, exhibited pronounced perinuclear and extranuclear localization 
in rINGAP-treated cells, respectively, which confirms cytoskeletal reorganization. These 
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combined results suggest cell fate may be altered following rINGAP exposure, corresponding 
to the observed loss of adherence, the cytoplasmic retraction and the reduction in clearly 
defined nuclear features. To our knowledge, the subcellular localization of tropomyosin and 
caldesmon has not been previously studied in islet-derived cells, nor have the specific 
cellular functions of these proteins been fully identified and elucidated.  Of importance, these 
proteins are known to play key roles in cell speed and motility through modulation of the 
actin cytoskeleton (Bach, Creed et al. 2009; Jiang, Huang et al. 2010), consistent with our 
live-cell imaging analysis.   
 
Changes in tropomyosin expression have been correlated with tissue and organ 
differentiation during embryogenesis (Muthuchamy, Pajak et al. 1993; Clayton and Johnson 
1998; Gunning, O'Neill et al. 2008). Furthermore, it has been proposed that tropomyosin 
regulates the transition of focal adhesions essential for directed cell movement (Bach, Creed 
et al. 2009). Therefore, the dissociation of tropomyosin from actin and its perinuclear 
localization in rINGAP-treated hIPCs supports the disruption of focal adhesions, consistent 
with decreased migration and speed. Additionally, intracellular sorting of tropomyosin has 
been associated with the retrograde translocation of organelles into the perinuclear area 
(Pelham, Lin et al. 1996), cell maturation in neuronal and epithelial cells (Gunning, 
Schevzov et al. 2005) and cell cycle regulation in fibroblast and epithelial cells (Percival, 
Thomas et al. 2000). Indeed, the observed changes in tropomyosin localization, further 
substantiates the potential effect of rINGAP on cell proliferation and fate. In addition, 
rINGAP-treated hIPCs revealed a weaker distribution of caldesmon throughout the 
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cytoplasm with the extranuclear translocation of the protein. The nuclear translocation of 
caldesmon corresponds with the activation of the intranuclear protein kinase p34cdc2, and the 
phosphorylation of caldesmon (Nurse 1990; Zheng, Weiden et al. 2007). The 
phosphorylation of caldesmon by p34cdc2 reduces its affinity for the actin cytoskeleton and 
allows for cytoskeletal rearrangements at the time of mitosis (Yamashiro, Yamakita et al. 
1991). Caldesmon was reported to undergo intranuclear localization in proliferating cells 
(Zheng, Weiden et al. 2007), which supports the hypotheses that (1) non-rINGAP-treated 
hIPCs were proliferative; (2) extranuclear translocation of caldesmon in rINGAP-treated 
hIPCs is consistent with a loss of mitotic ability and proliferative potential.   
 
Collectively, our studies indicate tropomyosin dissociates from the actin cytoskeleton and re-
localizes in the perinuclear region, while caldesmon undergoes extranuclear translocation 
following rINGAP treatment. Furthermore, both findings are believed to contribute to the 
morphological and cell migration responses of rINGAP-treated hIPCs determined through 
live-cell imaging speed and tracking analyses. Based on the limited literature of tropomyosin 
perinuclear and caldesmon nuclear localization, it is hypothesized rINGAP involves the 
retrograde translocation of organelles into the perinuclear area (Pelham, Lin et al. 1996) of 
hIPCs, which may be related to cell maturation (Gunning, Schevzov et al. 2005) and cell 
cycle regulation (Percival, Thomas et al. 2000). Furthermore, rINGAP may activate the 
intranuclear protein kinase p34cdc2, which phosphorylates caldesmon (Nurse 1990; Zheng, 
Weiden et al. 2007), triggering the extranuclear translation of caldesmon and the transition of 
hIPCs from a proliferative to differentiated state. These are previously unreported potential 
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mechanistic effects of rINGAP related to the cytoskeletal reorganization of hIPCs. These 
novel findings encourage further investigations into the role of ABPs and other proteins on 
the rINGAP mode of action on hIPCs. 
 
MSCs and other cell types exhibit cytoskeletal changes during differentiation (Rodriguez, 
Gonzalez et al. 2004; Oh, Karlmark Raja et al. 2006; Yourek, Hussain et al. 2007), which is 
of noted significance to our reported cytoskeletal effects of rINGAP on hIPCs which have 
been previously characterized as pMSCs. In general, cytoskeletal reorganization and 
morphological changes are strongly associated with mammalian cell differentiation 
(Rodriguez, Gonzalez et al. 2004). Differentiating cells are also known to undergo states of 
motility and non-motility accompanied by the reorganization of F-actin (Abd-el-Basset, 
Ahmed et al. 1991). Furthermore, the reorganization and changes in expression levels of 
ABPs tropomyosin and caldesmon in differentiating astroglia cells has been observed (Abd-
el-Basset, Ahmed et al. 1991). In human MSCs, imaging provides early clues for adipogenic 
or osteogenic outcomes during differentiation (Treiser, Yang et al. 2010). These fates can 
also be directly generated by the disruption of specific cytoskeletal elements. Specifically, 
disruption of actin filaments generates a strong preference for adipogenic differentiation in 
MSCs, while disruption of microtubules favours osteogenic differentiation (Kilian, Bugarija 




rINGAP induced cytoskeleton disruption in islet-derived cells may also be significant from 
an insulin-secretion perspective.  It is well reported that the disruption of actin filaments can 
enhance glucose-induced insulin release from β-cells (Lacy, Klein et al. 1973; van 
Obberghen, Somers et al. 1973; Wang and Thurmond 2009). This may represent an 
accessory function of INGAP in supporting insulin homeostasis, although rINGAP-treated 
hIPCs did not stain for C-peptide (results not shown).  hIPCs continued to express the stem 
cell marker vimentin after the 53 hours of rINGAP treatment, however with an observed 
reduction in intensity compared to control cells.  As the statistical reliability of quantitative 
immunocytochemistry can be questioned, these results were not presented. However, the 
apparent reduction in vimentin expression, combined with morphological, nuclear motility 
and cytoskeletal reorganization of tropomyosin and caldesmon effects may indicate that 
hIPCs are poised for differentiation following exposure to rINGAP. 
 
Expanded hIPCs may represent a useful mesenchymal stem cell population offering a large 
supply of cells for clinical diabetes applications.  Although many exogenous growth factors 
have been explored for the proliferation and differentiation of hIPCs (Kutlu, Kayali et al. 
2009; Sordi, Melzi et al. 2010), this work is the first to use live-cell imaging to investigate 
the cellular responses of rINGAP on hIPCs. We show that rINGAP decreases cell motility 
through reducing cell speed and directional persistence, induces a change in cellular 
morphology and rearranges the cytoskeleton in terms in ABPs tropomyosin and caldesmon.  
Due to the direct responses of expanded islet cells to rINGAP, we hypothesize that hIPCs 
play a role in the therapeutic mechanism of INGAP.  It is acknowledged that the generation 
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of functional insulin secreting cells through in vitro culture and manipulation of hIPCs has 
not yet been achieved, however this work supports the incorporation of INGAP in future in 
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Chapter 6   Human Islet-Derived Progenitor Cells Treated with 
INGAP-PP 
6.1 Preamble 
This chapter extends the study of INGAP by evaluating the binding and the effects of the 
INGAP peptide, INGAP-PP, on hIPCs. The two previous chapters evaluated the effects of 
the recombinant form of INGAP (rINGAP) using proteomics, long-term live cell imaging 
and immunofluorescent staining. This chapter presents the study of INGAP-PP using 
fluorescent microscopy and flow cytometry analysis. 
6.1.1 Objective 
The main objective of this chapter was to evaluate the specificity of binding of INGAP-PP to 
hIPCs. hIPCs were exposed to either fluorescently labeled INGAP-PP or a scrambled 
fluorescent construct and imaged to determine if INGAP-PP bound specifically to islet-
derived cells, relative to other non-pancreatic cell lines. Additionally, the phenotype of hIPCs 
exposed to INGAP-PP was analyzed and flow cytometry was utilized to evaluate INGAP-
PPs effect on cell cycle.  
6.1.2 Justification 
The two previous chapters focused on the study of rINGAP, at the proteomic, behavioral and 
immunocytochemical levels. Although conclusive results were obtained which identified 
proteins perturbed from rINGAP exposure as well as phenotypic and migratory responses, 
the cellular specificity of INGAP was not confirmed. The specific mechanism of INGAP 
action, including cellular specificity and receptor, remain widely unknown. Using the 
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available fluorescent INGAP peptide and the scrambled peptide as a control, INGAPs 
binding to hIPCs was established. This confirmed the previous findings presented in chapters 
4 and 5 which suggested that INGAP binds to hIPCs based on the observed cellular 
responses. All of these results combined, establishes previous unknown INGAP effects on 
hIPCs in vitro, which may prove to be clinically relevant in understanding the therapeutic 
potential of INGAP and hIPCs in the treatment of diabetes. 
6.2 Publication Title and Authors 
This research has not yet been submitted for publication. Additional live-cell imaging and 
flow cytometry analyses are being performed on hIPCs exposed to INGAP-PP which may 
provide sufficient clarification of the described nuclear phenomenon and verification of the 
data which indicated increased cellular granulation. With this supplementary data, firmer 
conclusions will be able to be drawn and the INGAP-PP analysis presented in this chapter 
will be complete for publication.  
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Islet neogenesis associated protein pentadecapeptide (INGAP-PP) expands beta-cell mass 
while reversing diabetes in rodents and increases endogenous insulin secretion in humans 
with diabetes.  The mechanisms of INGAP-PP action, including a potential cellular receptor, 
remain to be identified. We studied the specificity of INGAP-PP binding and its 
morphological effects on human islet-derived progenitor cells (hIPCs) using a fluorescently-
tagged form of the peptide and a scrambled construct. We show INGAP-PP binds 
specifically to hIPCs, and no binding was observed on two non-pancreatic derived cell lines.  
Furthermore, we report the observation of larger nuclei within 4.5 hours of hIPCs exposed to 
INGAP-PP compared to controls, which was dependent on the peptide sequence. Several 
mechanisms can be responsible for this nuclear phenomenon, such as the replication of the 
nuclear genome in the absence of cell division, termed endoreduplication. Additional copies 
of genetic material are characteristic of increased metabolic functions in terminally 
differentiated cells. To further explore this nuclear phenomenon, flow cytometry analysis on 
hIPCs treated with INGAP-PP was performed. One of the two analyses determined a larger 
proportion of cells with increased granularity, indicative of decreased proliferative potential 
which was previously suggested by our group in the study of rINGAP and hIPCs. These 
findings further support the hypothesis that hIPCs may be poised to differentiate following 
INGAP-PP exposure. 
 
Key Words. Human islet-derived progenitor cell · Pancreatic mesenchymal stem cells · Islet 




Islet neogenesis associated protein (INGAP) is a 17 kDa protein that is involved in pancreatic 
islet neogenesis. A region of the protein consisting of 15 amino acids, termed INGAP 
pentadecapeptide (INGAP-PP), was identified to induce similar islet neogenesis effects as the 
full length protein (Rafaeloff, Pittenger et al. 1997). INGAP-PP has been shown to reverse 
diabetes in rodents (Rosenberg, Lipsett et al. 2004), expand beta-cell mass in normoglycemic 
rodents and dogs (Pittenger, Taylor-Fishwick et al. 2007), and most significantly to increase 
endogenous insulin secretion and improve glycemic control in humans with type 1 and type 2 
diabetes (Dungan, Buse et al. 2009). Although there is substantial evidence indicating 
INGAP-PP holds therapeutic potential in the treatment of diabetes, an INGAP cellular 
receptor and its mechanisms of action remain unknown.  Various groups have reported the 
outgrowth of mesenchymal cells following the in vitro expansion of islet cells (Gallo, 
Gambelli et al. 2007; Kutlu, Kayali et al. 2009; Russ, Ravassard et al. 2009). In particular, 
gene expression analysis of human pancreatic islets after in vitro expansion confirmed the 
expanded cells are highly comparable to other established mesenchymal stem cells (Kutlu, 
Kayali et al. 2009). Recently, it was determined that the expanding cells from pancreatic islet 
cultures are pancreatic mesenchymal stem cells (pMSCs), with the capacity to improve 
transplanted islet function (Sordi, Melzi et al. 2010). In the Sordi study, the expanded islet 
cells were confirmed to be pMSCs as they were able to differentiate along all three 
mesenchymal lineages, including: adipocytes, osteocytes and chondrocytes. It still remains to 
be established if all similar protocols which expand human islets in culture results in a 
population of pMSCs. Nevertheless, the exposure of extrinsic factors, such as INGAP, on 
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expanded islet-derived progenitor cells may induce insulin expression through 
differentiation. 
 
In this study, we evaluated INGAP-PP binding and its morphological effects on human islet-
derived progenitor cells (hIPCs). These cells stained positive for nestin+ and vimentin+ 
(mesenchymal markers) and negative for CK-19- and CD133- (epithelial markers) (figure 5-5 
a-c). This suggested MSC phenotype; however the cells were not differentiated into all three 
mesenchymal lineages. Therefore, although the expanded islet cells may represent a pMSC 
population, MSC phenotype was not confirmed. We evaluated INGAP binding based on 
detected FAM (green fluorescent) punctate signal using labeled INGAP-PP, labeled 
scrambled INGAP-PP and three human cell lines, including hIPCs. Furthermore, we 
performed a fluorescence-activated cell sorting analysis (FACS) on hIPCs treated with 
INGAP-PP to analyze the effects of INGAP-PP on cell cycle. We show that INGAP-PP 
binds specifically to hIPCs, however we obtained inconclusive FACS results which could not 
confirm INGAP-PPs effect on granularity or cell cycle. Importantly, we report a significant 
and rapid increase in nuclear size following INGAP-PP exposure, suggestive of a change in 
the ploidy state of hIPCs exposed to INGAP.     
6.5 Materials and Methods 
hIPCs were derived from fresh human islets obtained from a non-diabetic adult cadaveric 
donor, approved by the Institutional Review Board of McGill University, Montréal, QC, as 
previously described (Jamal, Lipsett et al. 2005). Islets were plated in tissue culture-treated 
flasks at a density of 1 islet/mm2, cultured in modified RPMI-1640 medium (Invitrogen, 
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Burlington, ON) with 10% FBS and incubated at 37ºC, 5% CO2 and 95% humidified air for 
15 days with complete media changes every 3 days. At day 15, the islets which had spread 
into monolayers were detached with 2.5 g/L trypsin (Invitrogen, Burlington, ON) and seeded 
as single cells at 1.2x104 cells/cm2, followed by subsequent passing at 4x103 cells/cm2 once 
90% confluence was obtained. Human fetal neural stem cells (hfNSCs) were cultured 
according to a standard adherent culture protocol (Pollard, Yoshikawa et al. 2009) and 
human umbilical vein endothelial cells (HUVECs) were obtained from Lonza MD, USA and 
cultured according to the company’s protocol. FAM-INGAP-PP and scrambled-FAM-
INGAP-PP were synthesized and purified by Sheldon Biotech Centre, Montréal, QC and 5-
FAM (Cedarlane Laboratories, Burlington, ON) was utilized as a fluorescent control.   
 
Immunofluorescent Imaging and Analysis 
The three constructs (5-FAM, FAM-INGAP-PP or scrambled-FAM-INGAP-PP) were 
supplemented into the media at 58 µM. All three cell types (hIPCs, HUVECs or hfNSCs) 
were seeded onto aminopropyl trimethoxy silane (APTS) glass treated imaging chambers at 
90% confluency for 24 hours prior to being exposed to the various constructs for 4.5 hours 
the next day. Following exposure, the chambers were rinsed twice in PBS, fixed with 4% 
parafomaldehyde for 15 minutes, rinsed and nuclear stained using DAPI with antifade 
(Vector Laboratories Inc., Burlington, ON). The chambers were then replenished with PBS 







Propidium iodide staining and analysis was carried out as previously described (Crissman, 
Mullaney et al. 1975; Nunez 2001), with minor modifications. Untreated, INGAP-PP treated 
or scrambled-INGAP-PP treated hIPCs were trypsinized, washed, and transferred to PBS. 
Three volumes of absolute ethanol were added drop wise while vortexing. Cells were fixed 
on ice for 45 minutes and stored at -20°C for no more than one week. After storage, cells 
were stained and RNA was digested in a solution containing 40μg/mL PI and 500 ng/mL 
RNase (DNase-free) for 30 min at 37°C. Flow cytometry analysis with doublet 
discrimination was then performed (Nunez 2001).  
6.6 Results and Discussion 
Immunofluorescent Imaging and Analysis 
The physiological effects of INGAP-PP have been studied on rat and hamster islet cells, 
hamster ductal cells and mouse embryonic stem cells (Rafaeloff, Pittenger et al. 1997; 
Barbosa, Bordin et al. 2006; Francini, Del Zotto et al. 2009; Madrid, Del Zotto et al. 2009).  
Furthermore, INGAP-PP binding specificity has been investigated in hamsters (Borelli, Del 
Zotto et al. 2007) but the existence of a specific receptor remains elusive. To test whether 
INGAP-PP binds specifically to hIPCs, we subjected hIPCs, hfNSCs and HUVECs to media 
supplemented with FAM-INGAP-PP, scrambled-FAM-INGAP-PP or FAM, for 4.5 hours at 
370C. When we evaluated the FAM signal using confocal microscopy, the FAM signal was 
only observed on hIPCs treated with FAM-INGAP-PP. Moreover, every hIPC observed 
(n>104) exhibited the punctate FAM-INGAP-PP signal (figure 6-1a), suggestive of bound 
receptor aggregation as reported for several other receptor-mediated signaling pathways 
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(Blumbach, Pancer et al. 1998; Sako, Minoghchi et al. 2000; Burke, Schooler et al. 2001). 
The punctate FAM-INGAP-PP cellular signal was completely absent on hfNSCs and 
HUVECs (figures 6-1b and c), indicating that INGAP-PP binding is somewhat cell-type 
specific with potential receptor expression restricted to hIPCs or other islet-derived cell 
type(s). Additionally, FAM signal was not detected on hIPCs exposed to the scrambled-
FAM-INGAP-PP nor FAM (figure 6-2). This demonstrated that binding of INGAP-PP is 
dependent on the peptide sequence and independent of the attached FAM fluorescent label.  
 
To further understand the binding of INGAP-PP, hIPCs were also imaged after 4.5 hours of 
FAM-INGAP-PP exposure at 4oC (figure 6-3a). In comparison to hIPCs exposed to the 
peptide at 37oC (figures 6-1a, 6-3b, 6-4 and 6-5), the punctate FAM signal was near 
undetectable using identical sensitivity settings. This decrease in punctate signal is consistent 
with decreased binding, transport and cellular uptake at potential membrane binding sites, as 
previously observed at low temperatures (Goodrich and Morita 1977). All together, these 
results provide novel evidence that hIPCs exhibit specific INGAP surface binding and uptake 
mechanism(s), such as a cell surface receptor, whose expression may be restricted to islet 






Figure 6-1: FAM-INGAP-PP treatment at 37ºC (a) hIPCs (b) hfNSCs (c) HUVECs were 
each incubated with 58 nM of FAM-INGAP-PP for 4.5 hours at 37ºC. Cells were rinsed 
twice in PBS, fixed with 4% parafomaldehyde for 15 minutes, rinsed and nuclear 
stained using DAPI. Shown are the confocal images of FITC excitation at 40X 







Figure 6-2: FAM and Scrambled-FAM-INGAP-PP hIPC treatment at 37ºC. hIPCs were 
incubated with 58 nM of (a) FAM or (b) Scrambled-FAM-INGAP-PP for 4.5 hours at 37ºC. 
Cells were rinsed twice in PBS, fixed with 4% parafomaldehyde for 15 minutes, rinsed and 
nuclear stained using DAPI. Shown are the confocal images of FITC excitation at 40X 
magnification. 
 
Figure 6-3: Comparison of FAM-INGAP-PP treatment at 4ºC versus 37 ºC. (a) hIPCs were 
incubated with 58 nM of FAM-INGAP-PP for 4.5 hours at 4ºC. (b) hIPCs were incubated with 
58 nM of FAM-INGAP-PP for 4.5 hours at 37ºC. Cells were rinsed twice in PBS, fixed with 4% 
parafomaldehyde for 15 minutes, rinsed and nuclear stained using DAPI. Shown are the 








Following the demonstration of INGAP-PP binding specificity, cellular morphologies were 
examined 4.5 hours after FAM-INGAP-PP exposure at 37ºC. Overall, hIPCs treated with 
INGAP-PP presented large masses of cells with the loss of observed distinctive membranes. 
The most significant observation was that FAM-INGAP-PP exposed hIPCs had a significant 
increase in nuclear size. In particular, two distinct morphologies were identified, including 
hIPCs with oversized circular nuclear masses (figure 6-4), as well as hIPCs with oversized 
linear nuclear masses (figure 6-5). In the first case, the DNA staining revealed large nuclei 
with up to a seven times the nuclear perimeter found amongst other normally sized hIPC 
nuclei in the same field of view (figure 6-4 a-d). These large nuclei were either circular in 
shape (figure 6-4 c,d), appearing to be one extra-large nucleus, or several cells presented 
DNA staining which revealed among the extra-large nuclei the appearance of multiple 
smaller nucleus (figure 6-4 a,b). In the second case, hIPCs with oversized linear nuclear 
masses, there was the appearance of individual nuclei amongst the larger linear nuclear 
masses (figure 6-5 a-d). For example, in figure 6-5c there is the appearance of five nuclei 
within one large linear nuclear mass.  
 
Neither of the observed nuclear morphologies have been previously reported in hIPCs. The 
increase in genetic material contained within an oversized nucleus has been hypothesized as 
a potentiator of metabolic function as cells differentiate (Ullah, Lee et al. 2009). In mammals, 
cell types known to be polyploid such as megakaryocytes (Ravid, Lu et al. 2002) and 
trophoblasts (Cross 2000) undergo a process called endoreduplication in which the genetic 
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material is duplicated but nuclear separation and cytokinesis do not follow (Edgar and Orr-
Weaver 2001). This developmentally controlled event is a terminal differentiation point in 
the lineage hierarchy and these cells generally never re-enter mitosis (Lee, Davidson et al. 
2009). Although hIPCs have never been reported to undergo endoreduplication, it is possible 
that the described extra-large nuclei appear from continuous DNA replication without 
nuclear separation and cytokinesis. This raises the interesting hypothesis that INGAP-PP may 
trigger endoreduplication and terminal differentiation of hIPCs in vitro, which to date has 
never been observed or reported. 
 
As an alternative hypothesis to endoreduplication, the appearance of the extra-large nuclei 
may be explained from the mechanism of fusion, cellular and/or nuclear. The formation of 
multinucleated giant cells in vitro is known to occur from the cellular fusion of monocytes or 
macrophages during inflammatory response, however very little is known about the 
mechanism of fusion process or its role in vivo (Parwaresch, Kreipe et al. 1986; Chiozzi, 
Sanz et al. 1997; Most, Spotl et al. 1997; Gasser and Most 1999).  Importantly, it is known 
that the formation of the multinucleated giant cells in culture is enhanced by various 
developmentally related cytokines (Enelow, Sullivan et al. 1992). In addition to cellular 
fusion, nuclear fusion may explain the observed extra-large hIPC nuclei following INGAP-
PP exposure. Nuclear fusion following cell fusion has been described as rare, however it is 
known to occur between embryonic stem cells and bone marrow cell populations which 
contain hematopoietic stem cells, as well as with neural stem cells (Wurmser and Gage 
2002). Of importance, thus far cell fusion has only been observed to occur in vitro and 
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between stem cell phenotypes. Therefore, if nuclear fusion is indeed the mechanism of the 
observed extra-large nuclei, the hIPCs likely represent a MSC population. However, it would 
remain unclear how relevant the observed INGAP-PP nuclear effect would be in vivo. 
 
Finally, it has been reported that chemical disruption of cytoskeletal filaments alters nuclear 
morphology (Mazumder and Shivashankar 2010). The balance between microtubule pushing 
forces and actin-based pulling forces regulates nuclear shape (Mazumder and Shivashankar 
2010), which raises a third mechanism; that INGAP-PP triggers cytoskeletal rearrangements 
in hIPCs leading to changes in nuclear morphology in vitro. Interestingly, the results 
presented in the previous chapter, Chapter 5, outlined the observed effects of rINGAP on 
hIPCs, which included the perturbation of the actin cytoskeleton and a near loss of nuclear 
features. However, these INGAP-PP results report enhanced nuclear features including the 
increase in size of the nuclei. Although we present evidence that both rINGAP and INGAP-
PP alters the cytoskeleton of hIPCs following treatment, the observed nuclear effects are 
conflicting and opposing. The mechanisms of endoreduplication and fusion, would each 
involve cytoskeleton rearrangements. Therefore, cytoskeletal rearrangement may not be the 
primary mechanism responsible for the extra-large nuclei, however the cytoskeleton of hIPCs 
may be rearranged as a result of another principal nuclear mechanism, including 






Figure 6-4: hIPCs treated with FAM-INGAP-PP at 37ºC with oversized circular 
nuclear masses (a-e). hIPCs were incubated with 58 nM of FAM-INGAP-PP for 4.5 
hours at 37ºC. Cells were rinsed twice in PBS, fixed with 4% parafomaldehyde for 15 
minutes, rinsed and nuclear stained using DAPI. Shown are the confocal images of 









Figure 6-5: hIPCs treated with FAM-INGAP-PP at 37ºC with oversized linear nuclear 
masses (a-d). hIPCs were incubated with 58 nM of FAM-INGAP-PP for 4.5 hours at 
37ºC. Cells were rinsed twice in PBS, fixed with 4% parafomaldehyde for 15 minutes, 
rinsed and nuclear stained using DAPI. Shown are the confocal images of FITC 









To further explore the observed nuclear phenomenon, flow cytometry analysis on hIPCs 
treated with INGAP-PP was performed. First, a FACS method for looking at cell cycle 
distributions was optimized using an assay on THP-1 monocytic cells provided by Dr. Maud 
Gorbet, Systems Design Engineering Department, University of Waterloo. In this assay, 
permeabilized cells were stained with a red-fluorescing DNA-binding dye, propidium iodide 
(PI; Nunez 2001). During optimization, several parameters were evaluated, including:  cell 
concentration during fixation and PI staining, the duration of fixation, the fixation mode 
(adding cells dropwise to 70% (v/v) ethanol versus adding 100% ethanol drop wise to the 
cells, to a final ethanol concentration of 70%), storage conditions, gating, and voltage 
settings on the flow cytometer. Figure 6-6 outlines the FACS optimization. Doublet 
discrimination gating was performed as per (Nunez 2001), and a valid cell cycle analysis was 
obtained (figure 6-6a). As well, it was confirmed that nocodazole treatment of THP-1 cells 
increased the proportion of cells with twice the DNA content (figure 6-6b). Finally, it was 
determined that a slow increase in ethanol concentration gave less variability in the forward 
scatter of THP-1 (figure 6-6c). Overall, it was found that the procedure outlined in section 
1.5 Materials and Methods gave the best results for FACS analysis on THP-1 monocytic cells 
using the flow cytometer located in Dr. Maud Gorbet’s laboratory. Therefore, these settings 





Figure 6-6: Optimization of propidium iodide (PI) cell cycle determination analysis by 
flow cytometry using THP-1 monocytes. (a) To select the population for analysis, events 
were gated based on forward and side scatter. Subsequently, a doublet discrimination 
gate was applied (Pi-signal area vs. width) and number of events versus PI-signal-area 
was plotted (Nunez 2001). (b) THP-1 cells were subjected to 100 ng/mL nocodazole for 
18 hours and the percent of events with 2C DNA content increased. (c) Ethanol 
concentration was increased slowly during fixation. The variability in event forward 




















Following FACS optimization, to determine whether INGAP-PP treatment resulted in 
changes to the nuclear organization and/or cell cycle of hIPCs, a FACS analysis was 
performed with INGAP-PP treated (14μM) and untreated hIPCs (figure 6-7). hIPCs exposed 
to INGAP-PP for approximately 2 days (44 hours) were found to have no significant 
difference between treated and untreated samples in terms of proportions of C1 (66% vs. 
69%, respectively) and C2 (twice the DNA content of diploid cells; 28% vs. 25%) DNA 
content (figure 6-7a top). This suggested that since there were no significant differences in 
accumulation of DNA content between the C2 peaks, that endoreduplication may not be the 
mechanism responsible for the appearance of large hIPC nuclei (Edgar and Orr-Weaver, 
2001). However, when PI-signal (FL2A) was plotted against side scatter (SSC-H), it 
appeared that the proportion of SSC-HHIGH in INGAP-PP treated cells increased in C1 and 
C2 populations (figure 6-7a bottom). This suggested that following INGAP-PP treatment, 
there were a larger proportion of more granulated cells at both C1 and C2. Interestingly, 
following the INGAP-PP treatment at day 2 of the experiment, the INGAP-PP treated 
population had half the number of cells compared to the untreated hIPC population. It is 
possible that the decrease in PILOW SSC-HLOW treated population (potentially small, recently 
divided cells), could indicate of decreased proliferative potential of hIPCs treated with 
INGAP-PP. This finding is consistent with effects of rINGAP on the cytoskeletal 
organization of hIPCs discussed in the previous chapter.  
 
To confirm the initial FACS analysis which indicated a larger proportion of hIPCs with 
increased nuclear granularity, the INGAP treatment and FACS analysis was repeated 
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utilizing scrambled-INGAP-PP as an additional control. However, a similar effect on 
increased nuclear complexity was not observed (figure 6-7b). Treatment with an equivalent 
concentration and length of INGAP-PP did not produce the same effect found in the first 
analysis. Several possibilities could account for this inconsistency; however the only known 
difference between both experiments was the passage number of the hIPCs. The passage 
number of the hIPCs analyzed in the second trial (figure 6-7b) was 6. However, the first trial 
had a much higher passage number of 13. It is possible that these later passaged cells may 





Figure 6-7. Cell cycle analysis of hIPCs following INGAP-PP treatment. Both histograms and 
dot plots are shown. hIPCs at 70-80% confluency were incubated with 14 µm of INGAP-PP in 
complete media. (a) First analysis with 44 hours of INGAP-PP treatment at passage 13. 
Demonstrated was a reduction in PILOW SSCLOW population, consistent with the large nuclei 
presented above. (b) Second analysis with 46 hours of INGAP-PP treatment at passage 6. 
Scrambled-INGAP-PP was included as an additional control. There was no difference in cell 















6.7 Conclusions  
We evaluated INGAP-PP binding using fluorescently labeled INGAP-PP and a scrambled 
construct as a control. We show that INGAP-PP appeared to bind specifically to hIPCs and it 
did not bind to at least two other non-pancreatic-derived human cell lines. The most 
significant observation was the rapid appearance of hIPCs with oversized nuclei following 
FAM-INGAP-PP exposure. The nucleus is the most prominent cellular organelle. Its size and 
shape are indicative regulators of genome function. The increase in genetic material 
contained within an oversized nucleus has been suggested as a potentiator of metabolic 
function as cells differentiate (Ullah, Lee et al. 2009). The formation of multinucleated giant 
cells in vitro has also been reported in monocytes and macrophages (Most, Spotl et al. 1997; 
Gasser and Most 1999), however hIPCs with oversized or multinucleated cells has not been 
previously reported. Three mechanisms were presented and discussed as potential 
mechanisms of the observed large nuclei, including: endoreduplication, fusion and 
cytoskeletal rearrangement. However, the precise mechanism to elucidate this nuclear 
phenomenon remains to be determined. 
 
Flow cytometry analysis on hIPCs treated with INGAP-PP was performed to further explore 
the observed nuclear change. One of the two analyses determined a larger proportion of cells 
with increased granularity, indicative of decreased proliferative potential which was 
previously suggested in the study of rINGAP and hIPCs (Chapter 5). Endoreduplication or 
the evasion of some parts of the S, G2, or M phases in the cell cycle was suggested to 
account for this phenomenon (Edgar and Orr-Weaver, 2001). Alternatively, nuclear fusion 
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may explain this observation, especially since this phenomena was only observed at higher 
cell densities, consistent with other nuclear fusion reports (Glick et al, 2010). Moreover, 
work presented in the previous chapter has shown that rINGAP treatment causes 
morphological alterations of hIPCs, including: cytoskeletal reorganization, decreased nuclear 
borders, and decreased cellular and nuclear motility. The unpacking of DNA and 
cytoskeleton rearrangement may also be occurring, perhaps representing an activated state of 
hIPCs, similar to lymphocytes upon antigen recognition (Mazumder and Shivashankar 2010). 
 
In conclusion, the INGAP-PP analysis and results presented within this chapter indicate that 
INGAP-PP may specifically bind to hIPCs in a receptor-mediated fashion. It is proposed that 
INGAP-PP binding results in the rapid emergence of previously unreported extra-large hIPC 
nuclei. This phenomenon suggests increased metabolic activity and terminal differentiation 
of hIPCs following INGAP-PP exposure. However, the exact mechanism (endoreduplication, 
nuclear fusion, cytoskeletal rearrangement or otherwise) requires further investigation. Long 
term live-cell imaging and additional FACS analyses are currently being performed to further 
explain the rapid increase in nuclear size observed from hIPCs exposed to INGAP-PP. In 
particular, as both mechanisms should be observable in real-time, live-cell imaging is being 
utilized to confirm or rule out endoreduplication as well as fusion. Additionally, FACS 
analysis’s are being repeated on later passage hIPCs to determine if the results of the first 
analysis which revealed a higher proportion of INGAP-PP treated hIPCs with increased 
complexity can be repeated. Although studies are still being performed, the results presented 
within this chapter further support the hypothesis presented from chapters four and five; that 
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hIPCs respond to INGAP exposure, undergoing cytoskeletal rearrangements and may be 




Chapter 7 Human Islet-Derived Progenitor Cell Aggregates Treated 
with INGAP 
7.1 Preamble 
This chapter investigates a means to create islet like spherical structures from INGAP treated 
hIPCs. The three previous chapters evaluated the effects of the recombinant and peptide 
forms of INGAP, rINGAP and INGAP-PP, respectively. This chapter focuses on a potential 
method of engineering islets for transplantation using hIPCs and an INGAP treatment.  
7.1.1 Objective 
Engineering islets for in vivo transplantation would be the ultimate goal of this research. The 
main objective of this chapter is to extend the results of the previous three chapters, by 
presenting and evaluating a method to aggregate INGAP treated hIPCs. Specifically, hIPCs 
were treated with rINGAP or FAM-INGAP-PP and aggregated using an established method 
to create embryoid bodies. The aggregates were stained for insulin secretion and epithelial 
mesenchymal markers, as well the INGAP distribution within the spheroids was evaluated. 
7.1.2 Justification 
Pancreatic islet transplantation has proven to be successful in patients with type 1 diabetes, 
however there remains a large shortage of islet cells for transplantation. INGAP-PP enhances 
the secretion of insulin in animals and humans with diabetes, therefore tissue engineering 
islets in vitro from hIPCs exposed to INGAP may provide a large supply of islets for diabetic 




The pancreas acts as both an endocrine gland, secreting vital hormones directly into the 
blood and as an exocrine gland by secreting and transporting digestive enzymes to the small 
intestine. The endocrine cells are disbursed throughout the organ in clusters, termed islets of 
Langerhans or islets. Islets are composed of four cells types, which together regulate blood 
glucose levels. They include, alpha, beta, delta and pancreatic polypeptide secreting cells, 
which produce the hormones glucagon, insulin, somatostatin and pancreatic polypeptide, 
respectively. Beta cells are the most prevalent cell type, comprising 65-85% of a pancreas. 
These cells are solely responsible for the secretion of insulin, the major hormone which 
maintains glucose homeostasis. Type I and type II diabetes are both characterized by the 
impairment of islet secretary function of the beta cells; therefore patients often require 
synthetic insulin injections. Unfortunately, long-term insulin therapy can ultimately lead to 
unstable blood glucose control, resulting in the risk of hypo- or hyperglycemic episodes. In 
attempts to achieve independence from insulin therapy, clinical trials have demonstrated 
promise of islet transplantation (Ryan, Lakey et al. 2001; Shapiro, Ryan et al. 2001). 
However, up to three islet transplants are needed to achieve insulin independence, as well as 
there is a frequent immune response to the transplanted islets (de Kort, de Koning et al. 
2011). Besides the poor long-term results of islet transplantation, the availability of 
functional islet cells remains the primary obstacle to its widespread clinical application 
(Kodama, Kojima et al. 2009). 
 
The results of the previous three chapters presented and analyzed the effects of INGAP on 
hIPCs. Specifically, hIPCs treated with rINGAP had 50% decrease in average nuclear speed, 
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a change in nuclear morphology and the differential translocation of two actin-binding 
proteins. Furthermore, the rapid emergence of larger nuclei in hIPCs exposed to INGAP-PP 
was reported. Based on these results which indicate that hIPCs in vitro respond to INGAP, 
combined with the fact that INGAP has been shown to promote islet neogenesis in animal 
diabetic models and to increase C-peptide secretion in humans with type 1 diabetes (Dungan, 
Buse et al. 2009; Madrid, Del Zotto et al. 2009), aggregating hIPCs treated with INGAP may 
provide a novel method for engineering transplantable islets.  
 
Here, hIPCs were expanded, treated with rINGAP or FAM-INGAP-PP and aggregated to 
form islet like structures using an established method to create embryoid bodies. rINGAP 
treated aggregates appeared to have an increase in the nestin+ cells localized at the centre of 
the aggregates. This suggested that rINGAP in combination with aggregation promoted the 
multicelluar organization of the hIPCs and/or an epithelial-mesenchymal transition (EMT). 
Furthermore, when hIPCs were aggregated and treated with labeled FAM-INGAP-PP, the 
peptide signal was localized to the center of the aggregates. These results demonstrate that it 
is possible to create uniformly-sized and shaped hIPC ‘islet-like’ aggregates which appear to 
have a unique cellular organization and structure.  
7.3 Methods 
hIPCs were derived and cultured as previously described in section 5.5 Materials and 
Methods. After 3 or 8 passages, aggregates were created using the AggrewellTM technology 
((Stem Cell Technologies, Canada; (Ungrin, Joshi et al. 2008)) (figure 7-1). In short, hIPCs 
were treated with 10 nM of rINGAP in complete media for 48 hours or not treated (controls 
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and INGAP-PP experiment). The cells were then trypsinized, washed, counted, and placed in 
1.5 mLs of complete media to Aggrewell-400 plates which were previously prepared to 
remove bubbles by centrifugation at 2000g for 5 minutes. Once the cells were placed into the 
pre-spun plates, they were centrifuged at 100g for 3 minutes and incubated at 37°C, 100% 
humidity, and 5% CO2 for 24 hours in the presence of 58 uM of FAM-INGAP-PP with 
media or just in complete media (controls and previously rINGAP treated). Following the 24 
hours of incubation, the aggregates were extracted from the plates by pipette and placed in 
APTS-treated glass chambers to adhere overnight. The following day the aggregates were 
fixed in formaldehyde, stained with CK-19 and Nestin (rINGAP experiment), or C-peptide 
and phalloidin (FAM-INGAP-PP experiment) and DAPI. The chambers were imaged on an 
inverted microscope using DIC (Axiovert 200; Carl Zeiss MicroImaging GmbH, Berlin, 
Germany) or on a laser scanning confocal microscope (Olympus FV1000). 
 
Figure 7-1: Generation of hIPC aggregates by the AggrewellTM (Stem Cell 
Technologies) method. (a) hIPCs are cultured from expanded human islets as described 
above (b) hIPCs are placed into AggrewellsTM  with 1.5 mLs of media supplemented 
with 58 µM FAM-INGAP-PP or just standard media. (c) The AggrewellTM plate is 
centrifuged at 100g for 3 minutes to form hIPC aggregates. (d) The hIPC aggregates 






7.4 Results and Discussion 
The AggrewellTM plate consists of small pyramidal wells and was designed to create 
embryoid bodies using cultured embryonic stem cells and centrifugation (Ungrin, Joshi et al. 
2008). Since its commercialization, several groups have reported this method as superior to 
the previously established culture procedures due to the achieved uniform shape and size-
control of the bodies achieved from the design (Bauwens, Peerani et al. 2008; Niebruegge, 
Bauwens et al. 2009; Gauvin and Khademhosseini 2011). In this study, the AggrewellTM 
technology was applied to hIPCs treated with INGAP in attempts to create insulin secreting 
islet like structures for transplantation. To our knowledge the AggrewellTM has not 
previously been employed to make islets using hIPCs.  
 
Two different approaches of creating INGAP treated hIPC aggregates were evaluated. In the 
first experiment, the patient derived hIPCs were at passage 3 and half the cells were treated 
with rINGAP for 48 hours prior to aggregation. 48 hours of rINGAP treatment was 
performed based on the results presented in chapter 4, which revealed the largest proteomic 
response after 48 hours of rINGAP exposure. Figures 7-2 a,c show the aggregates following 
centrifugation and figures 7-2 b,d show the aggregates after 24 hours in the wells. Overall, 
there were no observable differences between the bright field images of the non-treated and 
rINGAP treated hIPCs neither in the AggrewellsTM immediately after centrifugation nor after 
24 hours (figure 7-2). Following the removal and adherence of the aggregates, they were 
nuclear stained with DAPI, as well as for mesenchymal and epithelial markers, nestin and 
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CK-19, respectively. Figure 7-3 shows four fluorescent images of the hIPC aggregates 
formed using the AggrewellTM plates. The aggregates were relatively comparable in size with 
diameters ranging from 200-250 µm and were of a uniform spherical shape.  
 
In comparison to the non-treated controls, the fluorescently stained rINGAP treated 
aggregates appeared to have an increase in nestin+ cells localized at the centre of the 
aggregates (figure 7-3). It is unknown if there was an increase in the number of nestin+ cells 
or if the rINGAP aggregates achieved greater organization of the two cells types which gave 
the appearance of an increase in the number of nestin+ cells. Several reasons could explain 
this observation, including: rINGAP in combination with aggregation promoted muticellular 
organization, rINGAP in combination with aggregation induced EMT of the epithelial cells 
to mesenchymal phenotype at the core of the aggregates, or, a fluorescent imaging artifact 
was observed. The aggregation in combination with rINGAP exposure could have promoted 
multicellular organization in which the CK-19+ cells were signaled to localize towards the 
outside of the aggregates and the nestin+ cells on the inside. This may have been achieved 
based on differential properties of these cells, such as deformability and cytoskeletal 
characteristics, or expression of differential complementary cell adhesion molecules, 
signaling factors and pathways (Ungrin, Joshi et al. 2008).  
 
Alternatively, although widely disputed in the literature, an epithelial-to-mesenchymal 
transition could have occurred, in which a population of the epithelial (CK-19+ cells) were 
dedifferentiated into mesenchymal (nestin+) cells. EMT has been shown to be critical in 
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embryogenesis, in which epithelial cells lose their mature characteristics (i.e. gap junctions) 
and acquire characteristics of mesenchymal cells (i.e. nestin and vimentin expression) 
(Vicovac and Aplin 1996). Studies have suggested that pancreatic beta-cells when cultured in 
vitro undergo EMT and dedifferentiate into hIPCs (Ozcan 2009; Russ, Ravassard et al. 2009; 
Joglekar and Hardikar 2010). Additionally, it has been shown that nestin+ pMSCs are found 
to completely replace the non-proliferative highly apoptotic epithelial cells from expanded 
islets (Sordi, Melzi et al. 2010). Therefore, it is possible that rINGAP in combination with 
the aggregate formation, induced EMT or promoted apoptosis of the CK-19+ cells. Lastly, it 
must be considered that since the fluorescent imaging was not performed using a confocal 
microscope, z-stacks of the aggregates were not evaluated. To conclusively examine the 
centers of the islet like structures confocal imaging must be performed. Therefore, it is 
possible that the observed difference in the nestin+ rINGAP aggregate centres may actually 





Figure 7-2: Bright field images at 5X magnification of hIPCs in the AggrewellsTM . (a) 
Non-treated hIPCs after 3 minutes of centrifugation at 100g. (b) Non-treated hIPCs 
shown in a) after 24 hours. (c) rINGAP treated hIPCs after 3 minutes of centrifugation 






Figure 7-3: rINGAP aggregates at 10X magnification. (a,b) Non-treated hIPCs after 
immunostaining for DNA, Nestin and CK-19. (c,d) rINGAP-treated hIPCs after 
immunostaining for DNA, Nestin and CK-19. 
 
To further understand the effect of INGAP and aggregation on the islet derived cells, in the 
second experiment labeled INGAP-PP was evaluated. hIPCs at passage 8, in comparison to 
the first experiment in which the hIPCs were at passage 3, were exposed to INGAP-PP upon 
aggregation. Immediately prior to aggregation, the media in the hIPC wells was 
supplemented with 58 µM of FAM-INGAP-PP. This concentration and strategy was 
performed based on the results presented in chapter 5, which revealed an increase in nuclear 
size following FAM-INGAP-PP exposure. In this experiment, the aggregates were not 




vimentin+, CK-19– and CD133-, demonstrated in figure 5-5 a,b,c. This was consistent with 
the report that nestin+ pMSCs are found to completely replace the non-proliferative highly 
apoptotic epithelial cells from expanded islets (Sordi, Melzi et al. 2010).  
 
It was of interest to determine if any differences in the cytoskeletal structure of the 
aggregates could be observed and if INGAP was localizing centrally. Therefore, following 
FAM-INGAP-PP exposure and adherence, the hIPCs were stained for actin and DNA, using 
phalloidin and DAPI, respectively. Figure 7-4 shows the FAM-INGAP-PP fluorescent 
images for three different z-positions (bottom, middle, top) and the corresponding bright field 
image of an adhered hIPC aggregate. The phalloidin staining did not penetrate through the 
cellular structures and was observed primarily on the edges of the hIPCs. Therefore, the 
cytoskeletal organization of the hIPCs within the aggregates was not observed. Overall, the 
most significant observation was the FAM signal was observed at the centre of the 
aggregates. The controls revealed no FAM signal (figure 7-5); therefore it is conclusive that 
the observed central signal was not an imaging artifact. However, it could be argued that the 
detected signal was free FAM or free FAM-INGAP-PP and not definitively FAM-INGAP-PP 
bound to the hIPCs. Although it is unclear why FAM-INGAP-PP would centrally localize, it 
is hypothesized that if a sub-population of the hIPCs bound/reacted to INGAP-PP they would 
potentially orientate according to their phenotype, similar to islets with beta cells located at 





Figure 7-4: FAM-INGAP-PP treated hIPC aggregates at 20X magnification using 
confocal imaging. (a) Bright field image at z-bottom. (b) Fluorescent image of phalloidin 
and DAPI staining of aggregate shown in a) at z-bottom. (c) Fluorescent image of 
phalloidin and DAPI staining of aggregate shown in a) at z-middle (d) Fluorescent 





Figure 7-5: Untreated hIPC aggregates at 20X magnification using confocal imaging. 
(a) Bright field image at bottom. (b) Fluorescent image of phalloidin and DAPI  staining 
of aggregates shown in a). 
 
7.5 Conclusions 
We evaluated a method originally designed to create embryoid bodies for feasibility of 
engineering organized islet-like structures from patient-derived expanded islet progenitor 
cells. The organized structure of an islet is perhaps key to its physiological functionality, 
consisting of β-cells throughout its core with the other endocrine cell types at and near its 
perimeter (Fernandes, King et al. 1997). It was of interest to evaluate if rINGAP or INGAP-
PP induced phenotypic responses in the context of aggregated hIPCs. In summary, rINGAP 
treated aggregates appeared to have an increase in the nestin+ cells localized at the centre of 




multicelluar organization of the hIPCs. Furthermore, when hIPCs were aggregated and 
treated with FAM-INGAP-PP, the signal was localized at the center of the aggregates. These 
results demonstrate that it is possible to create uniformly-sized and shaped hIPC islet-like 
aggregates which appear to have increased cellular organization in the presence of INGAP.  
 
In conclusion, the results presented in this chapter provide evidence that using the 
AggrewellsTM and INGAP treated hIPCs, allows for the creation of organized islet-derived 
hIPC structures. It must be acknowledged that under the two presented experimental 
conditions, neither rINGAP nor FAM-INGAP-PP aggregates stained positive for C-peptide 
(negative result not shown). Therefore, it remains unclear if the hIPC INGAP aggregates can 
be coaxed to secrete insulin. Furthermore, the nature of the cells present at the centre versus 
the periphery of the aggregates remains to be determined. Nevertheless, the application of the 
AggrewellTM technology to generate islets should be investigated further to determine the 
validity of aggregating hIPCs treated with INGAP. Several factors should be considered in 
future trials, including, the length of time the hIPCs are in the AggrewellsTM and exposed to 
INGAP, the ideal passage number (early or late) and analyzing the effects of introducing 
additional factors or supporting cell types, such as endothelial cells (Hess, Li et al. 2003), 
must be performed. It will be of interest to examine these trials by immunocytochemistry for 
the expression of several proteins, including the proteins identified in the rINGAP DIGE 
analysis (chapter 4) and early insulin secretion transcription factors, such as PDX-1 and Ngn-
3. Furthermore, the use of the scrambled peptide in combination with the FAM fluorophore 
as presented in chapter 6, would provide complete controls for a more detailed analysis. 
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Chapter 8 Conclusions and Future Work 
This thesis presents findings from studying two cellular systems using a proteomics coupled 
with a long term live-cell imaging approach. The two cellular systems were: 
1)  Calmodulin (CaM) in the differentiation of a human glioblastoma cell line 
2) Human islet-derived progenitor cells (hIPCs) treated with islet neogenesis associated 
protein (INGAP) 
Review of the overall hypothesis: 
Live-cell imaging and proteomics can be collectively employed to systematically 
image and identify regulatory cellular changes, such as phenotypic variations and 
protein expression differences, which guide undifferentiated cells to different 
lineages; providing important information about the progression of cellular 
signaling at various stages of its development, having an impact in the fields of 
drug discovery and regenerative medicine. 
 
Two cellular systems were proposed based on practical considerations. Each system had 
potential challenges, including the unknown uptake efficiency of a cell penetrating peptide 
and the availability of human islet cells. To complete these investigations, affinity 
chromatography, DIGE, and long term live-cell imaging techniques were utilized. It was 
anticipated that the work of the first proposed CaM-mutant based cellular system would 
identify a new population of CaM binding proteins and that characterization of the CaM 
binding mediated cell signaling would be achieved through the use of a cell penetrating 
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peptide. As CaM is involved in various cellular processes, using the two non-conventionally 
combined methods was an attractive approach to advance the current understanding of the 
function of CaM protein interactions in cell division and differentiation. It was hypothesized 
that: 
Mutations to the calcium binding sites of CaM would identify a new sub-population 
of CaMBPs which bind to the CaM-mutant at high affinities and upon cellular 
delivery, the CaM-mutant would perturb critical signaling pathways involved in 
cellular function. 
 
Overall, the hypothesis of the first proposed cellular system was not confirmed. We initially 
performed affinity chromatography using columns coupled with a CaM-mutant and another 
with calcium-CaM. The columns were loaded with porcine brain extract and eluted to isolate 
calcium dependent and independent binding proteins. A limitation to this approach was the 
isolation of sufficient amounts of the CaM binding proteins to perform a subsequent 
proteomic analysis on the two protein populations. Using various packing and loading 
concentrations, the conditions required to elute protein quantities for DIGE were determined. 
Once the optimal coupling density and loading quantities were determined, the columns were 
re-loaded to obtain replicates for the DIGE analysis. DIGE achieves statistical inference 
through replication. Although DIGE is a very powerful proteomics technique, using three 
repeat column runs to represent replicates was a poor experimental design. Analysis of the 
elution profiles determined that the non-specific binding to the CaM column increased as the 
columns were re-used, introducing high variability between the runs and therefore between 
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the replicates. It was concluded that replication with N > 6 independent affinity 
chromatography packing and elution’s in which the resin is coupled in batch would be 
required to reduce the variability between runs. 
 
The second objective of the proposed experimental plan, the cellular uptake of CaM, overall, 
obtained inconclusive results. This work was premised on the cellular up-take of CaM using 
the HIV-derived TAT-binding domain, which had not previously been reported. The TAT-
FITC construct which was to be used as a control to evaluate TAT cellular uptake, yielded a 
punctate cell staining pattern. This suggested that the TAT-FTIC construct was endocytosed 
into the cell cytoplasm, however it was inconclusive if TAT was indeed internalized or if 
TAT was simply bound to the cellular membrane. It was confirmed that there was no non-
specific interactions between FITC and the human glioblastoma cells and therefore it was 
concluded that FITC is a suitable fluorophore to be utilized to label TAT for fluorescent 
cellular analysis. On the other hand, the TRITC fluorophore used to label CaM was 
unsuitable for cellular analysis due to the detected non-specific binding in the TRITC only 
control. Therefore, it was suggested that a different fluorophore be utilized to label CaM and 
recommended that the chosen fluorophore be evaluated for non-specific cellular interactions 
prior to the CaM constructs being labeled.  
 
In conclusion, although inconclusive results were obtained from the study of the first 
proposed cellular system, it is possible with a large experimental design in which the column 
replicates are not obtained by re-using the columns, potentially new CaMBPs could be 
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identified and studied at the cellular level using the TAT cell penetrating peptide. No doubt 
there is great promise in elucidating a wide spectrum of CaM binding protein interactions 
using the proposed methods and purified CaM proteins. Unfortunately, time did not allow for 
such large scale experimental modifications and further analysis. However, there was 
valuable DIGE technique and experimental design knowledge obtained from studying the 
first cellular system.  
 
It was anticipated that the work on the second proposed hIPC cellular system would 
determine the proteomic and phenotypic effects of INGAP on hIPCs. Specifically, it was 
hypothesized that by combing 2D DIGE and long term live-cell imaging:  
1) a subset of INGAPs mechanistic effects will be determined  
2) INGAPs phenotypic effects will be observed 
3) a clinically relevant understanding of INGAPs overall effects will be achieved 
 
hIPCs were cultured and long term live-cell imaging was performed while the cells were 
exposed to INGAP. After a proteomic DIGE analysis to determine if INGAP induced an 
effect, aggregates and single cells were characterized by immunofluorescence staining for 
markers of insulin, beta-cell maturation and proteins identified as significantly up-regulated 
or down-regulated in the DIGE analysis. This combined approach enabled isolation, 
separation and population comparisons of the hIPC proteins. A limitation to this approach 
was the inherent flask to flask variability within the same treatment group. Consequently, it 
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was determined that a flask sub-pooling design of experiments was required to perform a 
DIGE analysis with statistically valid protein detection. We identified for the first time a 
series of proteins which rINGAP altered expression. Specifically, the following proteins were 
identified: actin binding proteins caldesmon, transgelin, tropomyosin, and cofilin-1, heat 
shock protein 90 (HSP90), straitin, plasminogen activator inhibitor, annexin V, and alpha-
enolase (glycolytic enzyme). These proteins and their related binding proteins form complex 
protein interaction networks which have been previously linked to diabetes, cell proliferation 
and cell differentiation (Imperatore, Hanson et al. 1998; Fogarty, Moczulski et al. 1999). Of 
the 13 proteins chosen for mass spectrometry analysis, 5 were cytoskeletal proteins 
(caldesmon, transgelin, tropomyosin, STRN and cofilin-1), involved in process formation, 
migration and differentiation. The identification of these proteins revealed major regulation 
of the hIPC cytoskeleton at 48 hours of rINGAP exposure. Overall, the temporal proteomic 
analysis suggests rINGAP perturbs and possibly reorganizes the hIPC cytoskeleton. 
 
To evaluate if hIPCs were being differentiated towards insulin secreting islet-like cells 
following rINGAP treatment, a temporal mRNA analysis on islet genes was completed. The 
DIGE results demonstrated that rINGAP treatment changed the global protein expression 
levels of hIPCs at various treatment times, therefore the PCR analysis was performed at those 
same treatment times (24, 48 and 96 hours of rINGAP exposure). As well, the hIPCs were 
analyzed after 15 minutes and 1 hour of rINGAP treatment to evaluate immediate hIPC 
mRNA expression. Overall, it was determined that rINGAP exposure decreased the mRNA 
expression of the islet associated genes, glucagon, PPY and CK-19, while insulin expression 
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was unchanged or undetected. These results complement the DIGE analysis, as a similar 
trend was determined by DIGE with many of the protein changes having decreases in 
expression levels. Furthermore, at 96 hours of rINGAP exposure, most of the changes in 
expression levels were attenuated; that is the rINGAP hIPC expression levels were in the 
range of control mRNA and protein levels. It has been previously hypothesized that INGAP 
may act early in the islet cell induction cascade (Rafaeloff, Pittenger et al. 1997; Fleming and 
Rosenberg 2007). The early changes in mRNA profiling of hIPCs followed by the detected 
down-regulation of the actin-binding proteins following rINGAP treatment is consistent with 
this hypothesis. We have shown that rINGAP affects the hIPC cytoskeleton based on the 
down-regulation of five identified actin-binding proteins, as well as down-regulates three 
islet associated genes. These proteomic and mRNA results confirmed hypothesis 1- a subset 
of INGAPs mechanistic effects will be determined. Of relevance, cytoskeletal changes 
during mesenchymal differentiation have previously been reported (Rodriguez, Gonzalez et 
al. 2004; Yourek, Hussain et al. 2007; Hong, Chen et al. 2010). Therefore, rINGAP may act 
to suppress basal levels of PPY and glucagon endocrine hormones while reorganizing the 
hIPC cytoskeleton, possibly further poising hIPCs for differentiation. 
 
To understand if INGAP induced any phonotypical effects through specific binding to hIPCs, 
live-cell imaging, FACS and immunofluorescent staining was performed. Live-cell imaging 
analysis revealed a greater than 50% decrease in average nuclear speed and a change in 
morphology of hIPCs exposed to rINGAP. Immunofluorescent labeling of two proteins 
which were identified through DIGE exhibited differential translocation in rINGAP-treated 
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cells. Furthermore, it was reported through imaging fluorescent INGAP-PP, that INGAP 
binds specifically to hIPCs and the rapid emergence of larger nuclei was observed. The large 
nuclei were suggestive of either increased ploidy following impaired nuclear separation after 
DNA duplication, the unpacking of DNA and/or changes in cytoskeletal organization or 
cellular/nuclear fusion. A FACS analysis was performed to evaluate cell cycle distributions 
and nuclear size. It was determined in one of the FACS experiments, a larger proportion of 
cells had increased granularity, indicative of decreased proliferative potential. All of these 
phenotypic findings, although not all understood at the mechanistic level, demonstrate that 
INGAP effects hIPCs in vitro, which confirmed hypothesis 2 - INGAPs phenotypic effects 
will be observed. 
 
The data presented in this thesis establishes newly identified mechanistic and phenotypic 
effects of INGAP. It is acknowledged that the specific in vivo molecular mechanism(s) 
responsible for INGAP’s islet regenerating effects in animals and humans remain unknown. 
Thus, hypothesis 3 - A clinically relevant understanding of INGAPs overall effects will 
be determined, was not fully established. However, taken together, this INGAP research 
will aid in further INGAP clinical developments and future investigations into the potential 
of hIPCs in relation to diabetes. Further work is necessary to determine possible 
mechanism(s) of hIPC differentiation into insulin-expressing β-like cells, in order to engineer 
islets for regenerative medicine applications. Future work should include parallel 
investigations into both rINGAP and INGAP-PPs effects on hIPCs, as well as on other 
pancreatic cell types, including pancreatic ductual cells. The DIGE analyses determined ten 
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proteins either up-regulated or down-regulated in response to rINGAP exposure, however 
only two of these proteins (caldesmon and tropomyosin) were evaluated using 
immunofluorescent staining. To further determine INGAPs effect on the perturbation of the 
actin cytoskeleton, the cellular distribution and localization of each protein identified in the 
DIGE analyses, specifically the actin binding proteins, is warranted for study. Supplemental 
to immunofluorescent staining, western blots on the 10 identified proteins would be valuable 
to support the results of the DIGE analyses.  Furthermore, additional PCR analyses on the 
genes of the proteins identified would determine if INGAP has affects at the mRNA level as 
well as at the proteomic level. Moreover, earlier genes implicated in islet differentiation and 
the effects of complementary factors and cell types (e.g. endothelial cells) on hIPCs exposed 




Abd-el-Basset, E. M., I. Ahmed, et al. (1991). "Actin and actin-binding proteins in differentiating 
astroglia in tissue culture." J Neurosci Res 30(1): 1-17. 
Albinsson, S., I. Nordstrom, et al. (2004). "Stretch of the vascular wall induces smooth muscle 
differentiation by promoting actin polymerization." J Biol Chem 279(33): 34849-34855. 
Asoh, S., I. Ohsawa, et al. (2002). "Protection against ischemic brain injury by protein therapeutics." 
Proc Natl Acad Sci U S A 99(26): 17107-17112. 
Assinder, S. J., J. A. Stanton, et al. (2009). "Transgelin: an actin-binding protein and tumour 
suppressor." Int J Biochem Cell Biol 41(3): 482-486. 
Assouline-Thomas, B., A. Pilotte, et al. (2009). "Production and characterization of the recombinant 
Islet Neogenesis Associated Protein (rINGAP)." Protein Expr Purif 69(1): 1-8. 
Atouf, F., C. H. Park, et al. (2007). "No evidence for mouse pancreatic beta-cell epithelial-
mesenchymal transition in vitro." Diabetes 56(3): 699-702. 
Aubry, S., F. Burlina, et al. (2009). "Cell-surface thiols affect cell entry of disulfide-conjugated 
peptides." FASEB J 23(9): 2956-2967. 
Axlund, S. D., J. R. Lambert, et al. (2010). "HOXC8 inhibits androgen receptor signaling in human 
prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes." Mol 
Cancer Res 8(12): 1643-1655. 
Bach, C. T., S. Creed, et al. (2009). "Tropomyosin isoform expression regulates the transition of 
adhesions to determine cell speed and direction." Mol Cell Biol 29(6): 1506-1514. 
Baharvand, H., H. Jafary, et al. (2006). "Generation of insulin-secreting cells from human embryonic 
stem cells." Dev Growth Differ 48(5): 323-332. 
Bar, Y., H. A. Russ, et al. (2008). "HES-1 is involved in adaptation of adult human beta-cells to 
proliferation in vitro." Diabetes 57(9): 2413-2420. 
Barbosa, H., S. Bordin, et al. (2006). "Islet Neogenesis Associated Protein (INGAP) modulates gene 
expression in cultured neonatal rat islets." Regul Pept 136(1-3): 78-84. 
Bartolome, F., N. de Las Cuevas, et al. (2007). "Impaired apoptosis in lymphoblasts from Alzheimer's 
disease patients: cross-talk of Ca2+/calmodulin and ERK1/2 signaling pathways." Cell Mol 
Life Sci 64(11): 1437-1448. 
Bauwens, C. L., R. Peerani, et al. (2008). "Control of human embryonic stem cell colony and 
aggregate size heterogeneity influences differentiation trajectories." Stem Cells 26(9): 2300-
2310. 
Bennett, R. D., A. S. Mauer, et al. (2007). "Calmodulin-like protein increases filopodia-dependent 
cell motility via up-regulation of myosin-10." J Biol Chem 282(5): 3205-3212. 
Blumbach, B., Z. Pancer, et al. (1998). "The putative sponge aggregation receptor. Isolation and 
characterization of a molecule composed of scavenger receptor cysteine-rich domains and 
short consensus repeats." J Cell Sci 111 ( Pt 17): 2635-2644. 
Borelli, M. I., H. Del Zotto, et al. (2007). "Transcription, expression and tissue binding in vivo of 
INGAP and INGAP-related peptide in normal hamsters." Regul Pept 140(3): 192-197. 
Bouwens, L. and D. G. Pipeleers (1998). "Extra-insular beta cells associated with ductules are 
frequent in adult human pancreas." Diabetologia 41(6): 629-633. 
Brand, S. J., S. Tagerud, et al. (2002). "Pharmacological treatment of chronic diabetes by stimulating 
pancreatic beta-cell regeneration with systemic co-administration of EGF and gastrin." 
Pharmacol Toxicol 91(6): 414-420. 
Braun, A. P. and H. Schulman (1995). "The multifunctional calcium/calmodulin-dependent protein 
kinase: from form to function." Annu Rev Physiol 57: 417-445. 
 
 211 
Bregant, E., G. Renzone, et al. (2009). "Down-regulation of SM22/transgelin gene expression during 
H9c2 cells differentiation." Mol Cell Biochem 327(1-2): 145-152. 
Brennand, K., D. Huangfu, et al. (2007). "All beta cells contribute equally to islet growth and 
maintenance." PLoS Biol 5(7): e163. 
Bugatti, A., C. Urbinati, et al. (2007). "Heparin-mimicking sulfonic acid polymers as multitarget 
inhibitors of human immunodeficiency virus type 1 Tat and gp120 proteins." Antimicrob 
Agents Chemother 51(7): 2337-2345. 
Burke, P., K. Schooler, et al. (2001). "Regulation of epidermal growth factor receptor signaling by 
endocytosis and intracellular trafficking." Mol Biol Cell 12(6): 1897-1910. 
Butler, A. E., J. Janson, et al. (2003). "Beta-cell deficit and increased beta-cell apoptosis in humans 
with type 2 diabetes." Diabetes 52(1): 102-110. 
Cai, S. R., G. Xu, et al. (2006). "The kinetics and tissue distribution of protein transduction in mice." 
Eur J Pharm Sci 27(4): 311-319. 
Cao, G., W. Pei, et al. (2002). "In Vivo Delivery of a Bcl-xL Fusion Protein Containing the TAT 
Protein Transduction Domain Protects against Ischemic Brain Injury and Neuronal 
Apoptosis." J Neurosci 22(13): 5423-5431. 
Carlotti, F., A. Zaldumbide, et al. (2010). "Isolated human islets contain a distinct population of 
mesenchymal stem cells." Islets 2(3): 164-173. 
Caron, N. J., Y. Torrente, et al. (2001). "Intracellular delivery of a Tat-eGFP fusion protein into 
muscle cells." Mol Ther 3(3): 310-318. 
Chase, L. G., F. Ulloa-Montoya, et al. (2007). "Islet-derived fibroblast-like cells are not derived via 
epithelial-mesenchymal transition from Pdx-1 or insulin-positive cells." Diabetes 56(1): 3-7. 
Chiozzi, P., J. M. Sanz, et al. (1997). "Spontaneous cell fusion in macrophage cultures expressing 
high levels of the P2Z/P2X7 receptor." J Cell Biol 138(3): 697-706. 
Cho, W. C. (2007). "Proteomics technologies and challenges." Genomics Proteomics Bioinformatics 
5(2): 77-85. 
Clapham, D. E. (1995). "Calcium signaling." Cell 80(2): 259-268. 
Clark, P. J. and F. C. Evans (1954). "Distance to Nearest Neighbor as a Measure of Spatial 
Relationships in Populations." Ecology 35(4): 445-453. 
Clayton, L. and M. H. Johnson (1998). "Tropomyosin in preimplantation mouse development: 
identification, expression, and organization during cell division and polarization." Exp Cell 
Res 238(2): 450-464. 
Colomer, J. and A. R. Means (2007). "Physiological roles of the Ca2+/CaM-dependent protein kinase 
cascade in health and disease." Subcell Biochem 45: 169-214. 
Conway, B. R., A. P. Maxwell, et al. (2004). "Association between variation in the actin-binding gene 
caldesmon and diabetic nephropathy in type 1 diabetes." Diabetes 53(4): 1162-1165. 
Cormier, S. A., M. A. Mello, et al. (2003). "Normal proliferation and differentiation of Hoxc-8 
transgenic chondrocytes in vitro." BMC Dev Biol 3: 4. 
Crissman, H. A., P. F. Mullaney, et al. (1975). "Methods and applications of flow systems for 
analysis and sorting of mammalian cells." Methods Cell Biol 9(0): 179-246. 
Crivici, A. and M. Ikura (1995). "Molecular and structural basis of target recognition by calmodulin." 
Annu Rev Biophys Biomol Struct 24: 85-116. 
Cross, J. C. (2000). "Genetic insights into trophoblast differentiation and placental morphogenesis." 
Semin Cell Dev Biol 11(2): 105-113. 
Dabrowska, R., N. Kulikova, et al. (2004). "Nonmuscle caldesmon: its distribution and involvement 
in various cellular processes. Review article." Protoplasma 224(1-2): 1-13. 
Danowski, B. A., A. Khodjakov, et al. (2001). "Centrosome behavior in motile HGF-treated PtK2 
cells expressing GFP-gamma tubulin." Cell Motil Cytoskeleton 50(2): 59-68. 
 
 212 
Davani, B., L. Ikonomou, et al. (2007). "Human islet-derived precursor cells are mesenchymal 
stromal cells that differentiate and mature to hormone-expressing cells in vivo." Stem Cells 
25(12): 3215-3222. 
de Kort, H., E. J. de Koning, et al. (2011). "Islet transplantation in type 1 diabetes." BMJ 342: d217. 
Demou, Z. N. and L. V. McIntire (2002). "Fully automated three-dimensional tracking of cancer cells 
in collagen gels: determination of motility phenotypes at the cellular level." Cancer Res 
62(18): 5301-5307. 
Dolphin, A. C. (2009). "Calcium channel diversity: multiple roles of calcium channel subunits." Curr 
Opin Neurobiol. 
Dor, Y., J. Brown, et al. (2004). "Adult pancreatic beta-cells are formed by self-duplication rather 
than stem-cell differentiation." Nature 429(6987): 41-46. 
Duchardt, F., M. Fotin-Mleczek, et al. (2007). "A comprehensive model for the cellular uptake of 
cationic cell-penetrating peptides." Traffic 8(7): 848-866. 
Dungan, K. M., J. B. Buse, et al. (2009). "Effects of therapy in type 1 and type 2 diabetes mellitus 
with a peptide derived from islet neogenesis associated protein (INGAP)." Diabetes Metab 
Res Rev 25(6): 558-565. 
Earle, W. R. (1962). "Some morphologic variations of certain cells under controlled experimental 
conditions." Natl Cancer Inst Monogr 7: 213-236. 
Edgar, B. A. and T. L. Orr-Weaver (2001). "Endoreplication cell cycles: more for less." Cell 105(3): 
297-306. 
Edlund, H. (2002). "Pancreatic organogenesis--developmental mechanisms and implications for 
therapy." Nat Rev Genet 3(7): 524-532. 
Enelow, R. I., G. W. Sullivan, et al. (1992). "Induction of multinucleated giant cell formation from in 
vitro culture of human monocytes with interleukin-3 and interferon-gamma: comparison with 
other stimulating factors." Am J Respir Cell Mol Biol 6(1): 57-62. 
Fackler, O. T. and R. Grosse (2008). "Cell motility through plasma membrane blebbing." J Cell Biol 
181(6): 879-884. 
Fernandes, A., L. C. King, et al. (1997). "Differentiation of new insulin-producing cells is induced by 
injury in adult pancreatic islets." Endocrinology 138(4): 1750-1762. 
Fleming, A. and L. Rosenberg (2007). "Prospects and challenges for islet regeneration as a treatment 
for diabetes: a review of islet neogenesis associated protein." J Diabetes Sci Technol 1(2): 
231-244. 
Fogarty, D. G., D. K. Moczulski, et al. (1999). "Evidence for a susceptibility locus for diabetic 
nephropathy (DN) on chromosome 7q in Caucasian families with type 2 diabetes." Diabetes 
48: A47-A47. 
Fonseca, S. B., M. P. Pereira, et al. (2009). "Recent advances in the use of cell-penetrating peptides 
for medical and biological applications." Adv Drug Deliv Rev 61(11): 953-964. 
Francini, F., H. Del Zotto, et al. (2009). "Selective effect of INGAP-PP upon mouse embryonic stem 
cell differentiation toward islet cells." Regul Pept 153(1-3): 43-48. 
Frankel, A. D., D. S. Bredt, et al. (1988). "Tat protein from human immunodeficiency virus forms a 
metal-linked dimer." Science 240(4848): 70-73. 
Frankel, A. D. and C. O. Pabo (1988). "Cellular uptake of the tat protein from human 
immunodeficiency virus." Cell 55(6): 1189-1193. 
Froese, G. (1964). "The Distribution and Interdependence of Generation Times of Hela Cells." Exp 
Cell Res 35: 415-419. 
Gallo, R., F. Gambelli, et al. (2007). "Generation and expansion of multipotent mesenchymal 
progenitor cells from cultured human pancreatic islets." Cell Death Differ 14(11): 1860-1871. 
 
 213 
Gasser, A. and J. Most (1999). "Generation of multinucleated giant cells in vitro by culture of human 
monocytes with Mycobacterium bovis BCG in combination with cytokine-containing 
supernatants." Infect Immun 67(1): 395-402. 
Gauvin, R. and A. Khademhosseini (2011). "Microscale Technologies and Modular Approaches for 
Tissue Engineering: Moving toward the Fabrication of Complex Functional Structures." ACS 
Nano. 
Gershengorn, M. C., A. A. Hardikar, et al. (2004). "Epithelial-to-mesenchymal transition generates 
proliferative human islet precursor cells." Science 306(5705): 2261-2264. 
Goodrich, T. D. and R. Y. Morita (1977). "Low temperature inhibition on binding, trasport, and 
incorporation of leucine, arginine, methionine, and histidine in Escherichia coli)." Z Allg 
Mikrobiol 17(2): 91-97. 
Gopalakrishna, R. and W. B. Anderson (1982). "Ca2+-induced hydrophobic site on calmodulin: 
application for purification of calmodulin by phenyl-Sepharose affinity chromatography." 
Biochem Biophys Res Commun 104(2): 830-836. 
Gump, J. M. and S. F. Dowdy (2007). "TAT transduction: the molecular mechanism and therapeutic 
prospects." Trends Mol Med 13(10): 443-448. 
Gunning, P., G. O'Neill, et al. (2008). "Tropomyosin-based regulation of the actin cytoskeleton in 
time and space." Physiol Rev 88(1): 1-35. 
Gunning, P. W., G. Schevzov, et al. (2005). "Tropomyosin isoforms: divining rods for actin 
cytoskeleton function." Trends Cell Biol 15(6): 333-341. 
Guz, Y., I. Nasir, et al. (2001). "Regeneration of pancreatic beta cells from intra-islet precursor cells 
in an experimental model of diabetes." Endocrinology 142(11): 4956-4968. 
Halban, P. A. (2004). "Cellular sources of new pancreatic beta cells and therapeutic implications for 
regenerative medicine." Nat Cell Biol 6(11): 1021-1025. 
Hayden-Martinez, K., L. P. Kane, et al. (2000). "Effects of a constitutively active form of calcineurin 
on T cell activation and thymic selection." J Immunol 165(7): 3713-3721. 
Hess, D., L. Li, et al. (2003). "Bone marrow-derived stem cells initiate pancreatic regeneration." Nat 
Biotechnol 21(7): 763-770. 
Hochberg, Y. and Y. Benjamini (1990). "More powerful procedures for multiple significance testing." 
Stat Med 9(7): 811-818. 
Honczarenko, M., Y. Le, et al. (2006). "Human bone marrow stromal cells express a distinct set of 
biologically functional chemokine receptors." Stem Cells 24(4): 1030-1041. 
Hong, D., H. X. Chen, et al. (2010). "Morphological and proteomic analysis of early stage of 
osteoblast differentiation in osteoblastic progenitor cells." Exp Cell Res 316(14): 2291-2300. 
Horgan, G. W. (2007). "Sample size and replication in 2D gel electrophoresis studies." J Proteome 
Res 6(7): 2884-2887. 
Houdusse, A., J. F. Gaucher, et al. (2006). "Crystal structure of apo-calmodulin bound to the first two 
IQ motifs of myosin V reveals essential recognition features." Proc Natl Acad Sci U S A 
103(51): 19326-19331. 
Hsu, T. C. and D. S. Kellogg, Jr. (1960). "Mammalian chromosomes in vitro. XII. Experimental 
evolution of cell populations." J Natl Cancer Inst 24: 1067-1093. 
Ikebe, M. and S. Reardon (1988). "Binding of caldesmon to smooth muscle myosin." J Biol Chem 
263(7): 3055-3058. 
Ikura, M. and J. B. Ames (2006). "Genetic polymorphism and protein conformational plasticity in the 




Imperatore, G., R. L. Hanson, et al. (1998). "Sib-pair linkage analysis for susceptibility genes for 
microvascular complications among Pima Indians with type 2 diabetes. Pima Diabetes Genes 
Group." Diabetes 47(5): 821-830. 
Issaq, H. and T. Veenstra (2008). "Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE): 
advances and perspectives." Biotechniques 44(5): 697-698, 700. 
Jamal, A. M., M. Lipsett, et al. (2003). "Signals for death and differentiation: a two-step mechanism 
for in vitro transformation of adult islets of Langerhans to duct epithelial structures." Cell 
Death Differ 10(9): 987-996. 
Jamal, A. M., M. Lipsett, et al. (2005). "Morphogenetic plasticity of adult human pancreatic islets of 
Langerhans." Cell Death Differ 12(7): 702-712. 
Jamali, A. A., B. C. Emmerson, et al. (2005). "Fresh osteochondral allografts: results in the 
patellofemoral joint." Clin Orthop Relat Res(437): 176-185. 
Jang, D. J., M. Guo, et al. (2007). "Proteomic and biochemical studies of calcium- and 
phosphorylation-dependent calmodulin complexes in Mammalian cells." J Proteome Res 
6(9): 3718-3728. 
Jiang, Q., R. Huang, et al. (2010). "Caldesmon regulates the motility of vascular smooth muscle cells 
by modulating the actin cytoskeleton stability." J Biomed Sci 17: 6. 
Joglekar, M. V. and A. A. Hardikar (2010). "Epithelial-to-mesenchymal transition in pancreatic islet 
beta cells." Cell Cycle 9(20): 4077-4079. 
Joglekar, M. V., V. M. Joglekar, et al. (2009). "Human fetal pancreatic insulin-producing cells 
proliferate in vitro." J Endocrinol 201(1): 27-36. 
Jurado, L. A., P. S. Chockalingam, et al. (1999). "Apocalmodulin." Physiol Rev 79(3): 661-682. 
Kantawong, F., K. E. V. Burgess, et al. (2009). "Whole proteome analysis of osteoprogenitor 
differentiation induced by disordered nanotopography and mediated by ERK signalling." 
Biomaterials 30(27): 4723-4731. 
Karp, N. A., D. P. Kreil, et al. (2004). "Determining a significant change in protein expression with 
DeCyder during a pair-wise comparison using two-dimensional difference gel 
electrophoresis." Proteomics 4(5): 1421-1432. 
Karp, N. A. and K. S. Lilley (2009). "Investigating sample pooling strategies for DIGE experiments 
to address biological variability." Proteomics 9(2): 388-397. 
Karp, N. A., P. S. McCormick, et al. (2007). "Experimental and statistical considerations to avoid 
false conclusions in proteomics studies using differential in-gel electrophoresis." Mol Cell 
Proteomics 6(8): 1354-1364. 
Karp, N. A., M. Spencer, et al. (2005). "Impact of replicate types on proteomic expression analysis." J 
Proteome Res 4(5): 1867-1871. 
Kilian, K. A., B. Bugarija, et al. (2010). "Geometric cues for directing the differentiation of 
mesenchymal stem cells." Proc Natl Acad Sci U S A 107(11): 4872-4877. 
Kodama, S., K. Kojima, et al. (2009). "Engineering functional islets from cultured cells." Tissue Eng 
Part A 15(11): 3321-3329. 
Kramer, S. D. and H. Wunderli-Allenspach (2003). "No entry for TAT(44-57) into liposomes and 
intact MDCK cells: novel approach to study membrane permeation of cell-penetrating 
peptides." Biochim Biophys Acta 1609(2): 161-169. 
Kumarasuriyar, A., C. Dombrowski, et al. (2007). "A novel use of TAT-EGFP to validate techniques 
to alter osteosarcoma cell surface glycosaminoglycan expression." J Mol Histol 38(5): 435-
447. 
Kutlu, B., A. G. Kayali, et al. (2009). "Meta-analysis of gene expression in human pancreatic islets 
after in vitro expansion." Physiol Genomics 39(1): 72-81. 
 
 215 
Lacy, P. E., N. J. Klein, et al. (1973). "Effect of cytochalasin B on the biphasic release of insulin in 
perifused rat islets." Endocrinology 92(5): 1458-1468. 
Lambrechts, A., M. Van Troys, et al. (2004). "The actin cytoskeleton in normal and pathological cell 
motility." Int J Biochem Cell Biol 36(10): 1890-1909. 
Lee, H. O., J. M. Davidson, et al. (2009). "Endoreplication: polyploidy with purpose." Genes Dev 
23(21): 2461-2477. 
Lee, S. H. and R. Dominguez (2010). "Regulation of actin cytoskeleton dynamics in cells." Mol Cells 
29(4): 311-325. 
Lewis, E. B. (1978). "A gene complex controlling segmentation in Drosophila." Nature 276(5688): 
565-570. 
Li, C. J., R. Heim, et al. (1999). "Dynamic redistribution of calmodulin in HeLa cells during cell 
division as revealed by a GFP-calmodulin fusion protein technique." J Cell Sci 112 ( Pt 10): 
1567-1577. 
Li, M., S. Li, et al. (2008). "Crystal structure of human transgelin." J Struct Biol 162(2): 229-236. 
Limback-Stokin, K., E. Korzus, et al. (2004). "Nuclear calcium/calmodulin regulates memory 
consolidation." J Neurosci 24(48): 10858-10867. 
Lin, J. J., R. D. Eppinga, et al. (2008). "Human tropomyosin isoforms in the regulation of 
cytoskeleton functions." Adv Exp Med Biol 644: 201-222. 
Lin, J. J., T. E. Hegmann, et al. (1988). "Differential localization of tropomyosin isoforms in cultured 
nonmuscle cells." J Cell Biol 107(2): 563-572. 
Lin, J. J., K. S. Warren, et al. (1997). "Tropomyosin isoforms in nonmuscle cells." Int Rev Cytol 170: 
1-38. 
Lu, J., Y. P. Gu, et al. (2005). "Adult islets cultured in collagen gel transdifferentiate into duct-like 
cells." World J Gastroenterol 11(22): 3426-3430. 
Mack, C. P., A. V. Somlyo, et al. (2001). "Smooth muscle differentiation marker gene expression is 
regulated by RhoA-mediated actin polymerization." J Biol Chem 276(1): 341-347. 
Madrid, V., H. Del Zotto, et al. (2009). "Islet neogenesis-associated protein pentadecapeptide 
(INGAP-PP): mechanisms involved in its effect upon beta-cell mass and function." Regul 
Pept 157(1-3): 25-31. 
Mann, D. A. and A. D. Frankel (1991). "Endocytosis and targeting of exogenous HIV-1 Tat protein." 
EMBO J 10(7): 1733-1739. 
Mann, R. S. and G. Morata (2000). "The developmental and molecular biology of genes that 
subdivide the body of Drosophila." Annu Rev Cell Dev Biol 16: 243-271. 
Marouga, R., S. David, et al. (2005). "The development of the DIGE system: 2D fluorescence 
difference gel analysis technology." Anal Bioanal Chem 382(3): 669-678. 
Marston, S. B. (1989). "What is latch? New ideas about tonic contraction in smooth muscle." J 
Muscle Res Cell Motil 10(2): 97-100. 
Matsushita, M., K. Tomizawa, et al. (2001). "A high-efficiency protein transduction system 
demonstrating the role of PKA in long-lasting long-term potentiation." J Neurosci 21(16): 
6000-6007. 
Mazumder, A. and G. V. Shivashankar (2010). "Emergence of a prestressed eukaryotic nucleus 
during cellular differentiation and development." J R Soc Interface 7 Suppl 3: S321-330. 
Montana, E., S. Bonner-Weir, et al. (1993). "Beta cell mass and growth after syngeneic islet cell 
transplantation in normal and streptozocin diabetic C57BL/6 mice." J Clin Invest 91(3): 780-
787. 
Moogk, D., S. Hanley, et al. (2007). "Design and analysis of a long-term live-cell imaging chamber 
for tracking cellular dynamics within cultured human islets of Langerhans." Biotechnol 
Bioeng 97(5): 1138-1147. 
 
 216 
Morton, R. A., E. Geras-Raaka, et al. (2007). "Endocrine precursor cells from mouse islets are not 
generated by epithelial-to-mesenchymal transition of mature beta cells." Mol Cell Endocrinol 
270(1-2): 87-93. 
Most, J., L. Spotl, et al. (1997). "Formation of multinucleated giant cells in vitro is dependent on the 
stage of monocyte to macrophage maturation." Blood 89(2): 662-671. 
Murray, K. D., C. M. Gall, et al. (1994). "Differential regulation of brain-derived neurotrophic factor 
and type II calcium/calmodulin-dependent protein kinase messenger RNA expression in 
Alzheimer's disease." Neuroscience 60(1): 37-48. 
Muthuchamy, M., L. Pajak, et al. (1993). "Developmental analysis of tropomyosin gene expression in 
embryonic stem cells and mouse embryos." Mol Cell Biol 13(6): 3311-3323. 
Mutskov, V., B. M. Raaka, et al. (2007). "The human insulin gene displays transcriptionally active 
epigenetic marks in islet-derived mesenchymal precursor cells in the absence of insulin 
expression." Stem Cells 25(12): 3223-3233. 
Nagahara, H., A. M. Vocero-Akbani, et al. (1998). "Transduction of full-length TAT fusion proteins 
into mammalian cells: TAT-p27Kip1 induces cell migration." Nat Med 4(12): 1449-1452. 
Nakase, I., A. Tadokoro, et al. (2007). "Interaction of arginine-rich peptides with membrane-
associated proteoglycans is crucial for induction of actin organization and macropinocytosis." 
Biochemistry 46(2): 492-501. 
Nichols, A. J., L. H. Carney, et al. (2008). "Comparison of slow and fast neocortical neuron migration 
using a new in vitro model." BMC Neurosci 9: 50. 
Niebruegge, S., C. L. Bauwens, et al. (2009). "Generation of human embryonic stem cell-derived 
mesoderm and cardiac cells using size-specified aggregates in an oxygen-controlled 
bioreactor." Biotechnol Bioeng 102(2): 493-507. 
Nir, T., D. A. Melton, et al. (2007). "Recovery from diabetes in mice by beta cell regeneration." J 
Clin Invest 117(9): 2553-2561. 
Noguchi, H. (2009). "Pancreatic islet transplantation." World J Gastrointest Surg 1(1): 16-20. 
Nunez, R. (2001). "DNA measurement and cell cycle analysis by flow cytometry." Curr Issues Mol 
Biol 3(3): 67-70. 
Nurse, P. (1990). "Universal control mechanism regulating onset of M-phase." Nature 344(6266): 
503-508. 
Oh-hora, M. and A. Rao (2008). "Calcium signaling in lymphocytes." Curr Opin Immunol 20(3): 
250-258. 
Oh, J. E., K. Karlmark Raja, et al. (2006). "Cytoskeleton changes following differentiation of N1E-
115 neuroblastoma cell line." Amino Acids 31(3): 289-298. 
Okamoto, F., H. Kajiya, et al. (2004). "Prostaglandin E2 activates outwardly rectifying Cl(-) channels 
via a cAMP-dependent pathway and reduces cell motility in rat osteoclasts." Am J Physiol 
Cell Physiol 287(1): C114-124. 
Oliver-Krasinski, J. M. and D. A. Stoffers (2008). "On the origin of the beta cell." Genes Dev 22(15): 
1998-2021. 
Ozcan, S. (2009). "MiR-30 family and EMT in human fetal pancreatic islets." Islets 1(3): 283-285. 
Pai, S. Y., D. A. Fruman, et al. (1994). "Inhibition of calcineurin phosphatase activity in adult bone 
marrow transplant patients treated with cyclosporine A." Blood 84(11): 3974-3979. 
Parwaresch, M. R., H. Kreipe, et al. (1986). "Human macrophage hybrid forming spontaneous giant 
cells." Virchows Arch B Cell Pathol Incl Mol Pathol 51(2): 89-96. 
Pearson, J. C., D. Lemons, et al. (2005). "Modulating Hox gene functions during animal body 
patterning." Nat Rev Genet 6(12): 893-904. 
Peck, A. B., J. G. Cornelius, et al. (2002). "Generation of islets of Langerhans from adult pancreatic 
stem cells." J Hepatobiliary Pancreat Surg 9(6): 704-709. 
 
 217 
Pelham, R. J., Jr., J. J. Lin, et al. (1996). "A high molecular mass non-muscle tropomyosin isoform 
stimulates retrograde organelle transport." J Cell Sci 109 ( Pt 5): 981-989. 
Percival, J. M., G. Thomas, et al. (2000). "Sorting of tropomyosin isoforms in synchronised NIH 3T3 
fibroblasts: evidence for distinct microfilament populations." Cell Motil Cytoskeleton 47(3): 
189-208. 
Pittenger, G. L., D. A. Taylor-Fishwick, et al. (2007). "Intramuscular injection of islet neogenesis-
associated protein peptide stimulates pancreatic islet neogenesis in healthy dogs." Pancreas 
34(1): 103-111. 
Pittenger, G. L., A. I. Vinik, et al. (1992). "The partial isolation and characterization of ilotropin, a 
novel islet-specific growth factor." Adv Exp Med Biol 321: 123-130; discussion 131-122. 
Pollard, S. M., K. Yoshikawa, et al. (2009). "Glioma stem cell lines expanded in adherent culture 
have tumor-specific phenotypes and are suitable for chemical and genetic screens." Cell Stem 
Cell 4(6): 568-580. 
Pollard, T. D. and G. G. Borisy (2003). "Cellular motility driven by assembly and disassembly of 
actin filaments." Cell 112(4): 453-465. 
Poon, B., M. A. Chang, et al. (2007). "Vpr is required for efficient Nef expression from unintegrated 
human immunodeficiency virus type 1 DNA." J Virol 81(19): 10515-10523. 
Prasad, P. D., J. A. Stanton, et al. (2010). "Expression of the actin-associated protein transgelin 
(SM22) is decreased in prostate cancer." Cell Tissue Res 339(2): 337-347. 
Puricelli, L., E. Iori, et al. (2006). "Proteome analysis of cultured fibroblasts from type 1 diabetic 
patients and normal subjects." J Clin Endocrinol Metab 91(9): 3507-3514. 
Rabut, G. and J. Ellenberg (2004). "Automatic real-time three-dimensional cell tracking by 
fluorescence microscopy." J Microsc 216(Pt 2): 131-137. 
Rafaeloff, R., G. L. Pittenger, et al. (1997). "Cloning and sequencing of the pancreatic islet 
neogenesis associated protein (INGAP) gene and its expression in islet neogenesis in 
hamsters." J Clin Invest 99(9): 2100-2109. 
Ramunas, J., M. Illman, et al. (2006). "True monolayer cell culture in a confined 3D 
microenvironment enables lineage informatics." Cytometry A 69(12): 1202-1211. 
Ramunas, J., H. J. Montgomery, et al. (2007). "Real-time fluorescence tracking of dynamic transgene 
variegation in stem cells." Mol Ther 15(4): 810-817. 
Ravid, K., J. Lu, et al. (2002). "Roads to polyploidy: the megakaryocyte example." J Cell Physiol 
190(1): 7-20. 
Richard, J. P., K. Melikov, et al. (2005). "Cellular uptake of unconjugated TAT peptide involves 
clathrin-dependent endocytosis and heparan sulfate receptors." J Biol Chem 280(15): 15300-
15306. 
Richard, J. P., K. Melikov, et al. (2003). "Cell-penetrating peptides. A reevaluation of the mechanism 
of cellular uptake." J Biol Chem 278(1): 585-590. 
Roche, S., M. Provansal, et al. (2006). "Proteomics of primary mesenchymal stem cells." Regen Med 
1(4): 511-517. 
Rodriguez, J. P., M. Gonzalez, et al. (2004). "Cytoskeletal organization of human mesenchymal stem 
cells (MSC) changes during their osteogenic differentiation." J Cell Biochem 93(4): 721-731. 
Rosenberg, L., M. Lipsett, et al. (2004). "A pentadecapeptide fragment of islet neogenesis-associated 
protein increases beta-cell mass and reverses diabetes in C57BL/6J mice." Ann Surg 240(5): 
875-884. 
Rosenberg, L., A. I. Vinik, et al. (1996). "Islet-cell regeneration in the diabetic hamster pancreas with 




Rowlands, A. S., P. A. George, et al. (2008). "Directing osteogenic and myogenic differentiation of 
MSCs: interplay of stiffness and adhesive ligand presentation." Am J Physiol Cell Physiol 
295(4): C1037-1044. 
Russ, H. A., P. Ravassard, et al. (2009). "Epithelial-mesenchymal transition in cells expanded in vitro 
from lineage-traced adult human pancreatic beta cells." PLoS One 4(7): e6417. 
Russ, R. D. and B. W. Tobin (1998). "Pancreatic islet transplantation, but not intensive insulin 
therapy, corrects the pulmonary vascular complications of streptozotocin diabetes." Can J 
Physiol Pharmacol 76(4): 407-417. 
Ryan, E. A., J. R. Lakey, et al. (2001). "Clinical outcomes and insulin secretion after islet 
transplantation with the Edmonton protocol." Diabetes 50(4): 710-719. 
Ryan, E. A., B. W. Paty, et al. (2005). "Five-year follow-up after clinical islet transplantation." 
Diabetes 54(7): 2060-2069. 
Sako, Y., S. Minoghchi, et al. (2000). "Single-molecule imaging of EGFR signalling on the surface of 
living cells." Nat Cell Biol 2(3): 168-172. 
Schmied, B. M., A. Ulrich, et al. (2001). "Transdifferentiation of human islet cells in a long-term 
culture." Pancreas 23(2): 157-171. 
Schmied, B. M., A. B. Ulrich, et al. (2000). "Alteration of the Langerhans islets in pancreatic cancer 
patients." Int J Pancreatol 28(3): 187-197. 
Schwarze, S. R., A. Ho, et al. (1999). "In vivo protein transduction: delivery of a biologically active 
protein into the mouse." Science 285(5433): 1569-1572. 
Seaberg, R. M., S. R. Smukler, et al. (2004). "Clonal identification of multipotent precursors from 
adult mouse pancreas that generate neural and pancreatic lineages." Nat Biotechnol 22(9): 
1115-1124. 
Serup, P., O. D. Madsen, et al. (2001). "Islet and stem cell transplantation for treating diabetes." BMJ 
322(7277): 29-32. 
Shamoon, H., H. Duffy, et al. (1993). "The Effect of Intensive Treatment of Diabetes on the 
Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes-
Mellitus." New England Journal of Medicine 329(14): 977-986. 
Shapiro, A. M., J. R. Lakey, et al. (2000). "Islet transplantation in seven patients with type 1 diabetes 
mellitus using a glucocorticoid-free immunosuppressive regimen." N Engl J Med 343(4): 
230-238. 
Shapiro, A. M., E. A. Ryan, et al. (2001). "Clinical islet transplant--state of the art." Transplant Proc 
33(7-8): 3502-3503. 
Shapland, C., J. J. Hsuan, et al. (1993). "Purification and properties of transgelin: a transformation 
and shape change sensitive actin-gelling protein." J Cell Biol 121(5): 1065-1073. 
Shields, J. M., K. Rogers-Graham, et al. (2002). "Loss of transgelin in breast and colon tumors and in 
RIE-1 cells by Ras deregulation of gene expression through Raf-independent pathways." J 
Biol Chem 277(12): 9790-9799. 
Shigeri, Y., A. Ishida, et al. (2008). "[Ca2+/calmodulin-dependent protein kinase signaling: 
regulatory mechanisms for switching on/off and their involvement in the pathogenesis of 
various diseases]." Tanpakushitsu Kakusan Koso 53(11): 1360-1367. 
Sienaert, I., N. Nadif Kasri, et al. (2002). "Localization and function of a calmodulin-apocalmodulin-
binding domain in the N-terminal part of the type 1 inositol 1,4,5-trisphosphate receptor." 
Biochem J 365(Pt 1): 269-277. 
Silva, K. E., H. C. Barbosa, et al. (2008). "INGAP-PP up-regulates the expression of genes and 
proteins related to K+ ATP channels and ameliorates Ca2+ handling in cultured adult rat 
islets." Regul Pept 148(1-3): 39-45. 
Slack, J. M. (1995). "Developmental biology of the pancreas." Development 121(6): 1569-1580. 
 
 219 
Smith, C. W., K. Pritchard, et al. (1987). "The mechanism of Ca2+ regulation of vascular smooth 
muscle thin filaments by caldesmon and calmodulin." J Biol Chem 262(1): 116-122. 
Smith, L. (2006). "Proteomics: challenges and emerging technologies, EuroSciCon." Expert Rev 
Proteomics 3(6): 573-577. 
Sommerer, N., D. Centeno, et al. (2007). "Peptide mass fingerprinting: identification of proteins by 
MALDI-TOF." Methods Mol Biol 355: 219-234. 
Sordi, V., R. Melzi, et al. (2010). "Mesenchymal cells appearing in pancreatic tissue culture are bone 
marrow-derived stem cells with the capacity to improve transplanted islet function." Stem 
Cells 28(1): 140-151. 
Steffes, M. W., B. M. Chavers, et al. (2003). "Sustained effect of intensive treatment of type 1 
diabetes mellitus on development and progression of diabetic nephropathy - The 
Epidemiology of Diabetes Interventions and Complications (EDIC) study." Jama-Journal of 
the American Medical Association 290(16): 2159-2167. 
Storey, J. D. and R. Tibshirani (2003). "Statistical significance for genomewide studies." Proc Natl 
Acad Sci U S A 100(16): 9440-9445. 
Suarez-Pinzon, W. L., J. R. Lakey, et al. (2005). "Combination therapy with epidermal growth factor 
and gastrin induces neogenesis of human islet {beta}-cells from pancreatic duct cells and an 
increase in functional {beta}-cell mass." J Clin Endocrinol Metab 90(6): 3401-3409. 
Suarez-Pinzon, W. L., Y. Yan, et al. (2005). "Combination therapy with epidermal growth factor and 
gastrin increases beta-cell mass and reverses hyperglycemia in diabetic NOD mice." Diabetes 
54(9): 2596-2601. 
Suzuki, T., S. Futaki, et al. (2002). "Possible existence of common internalization mechanisms among 
arginine-rich peptides." J Biol Chem 277(4): 2437-2443. 
Takahashi, K., K. Tanabe, et al. (2007). "Induction of pluripotent stem cells from adult human 
fibroblasts by defined factors." Cell 131(5): 861-872. 
Tanaka, J., T. Watanabe, et al. (1993). "Morphological and biochemical analyses of contractile 
proteins (actin, myosin, caldesmon and tropomyosin) in normal and transformed cells." J Cell 
Sci 104 ( Pt 2): 595-606. 
Tateishi, K., J. He, et al. (2008). "Generation of insulin-secreting islet-like clusters from human skin 
fibroblasts." J Biol Chem 283(46): 31601-31607. 
Tourrel, C., D. Bailbe, et al. (2001). "Glucagon-like peptide-1 and exendin-4 stimulate beta-cell 
neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose 
homeostasis at adult age." Diabetes 50(7): 1562-1570. 
Treiser, M. D., E. H. Yang, et al. (2010). "Cytoskeleton-based forecasting of stem cell lineage fates." 
Proc Natl Acad Sci U S A 107(2): 610-615. 
Tyagi, M., M. Rusnati, et al. (2001). "Internalization of HIV-1 tat requires cell surface heparan sulfate 
proteoglycans." J Biol Chem 276(5): 3254-3261. 
Ullah, Z., C. Y. Lee, et al. (2009). "Developmentally programmed endoreduplication in animals." 
Cell Cycle 8(10): 1501-1509. 
Umeshima, H., T. Hirano, et al. (2007). "Microtubule-based nuclear movement occurs independently 
of centrosome positioning in migrating neurons." Proc Natl Acad Sci U S A 104(41): 16182-
16187. 
Ungrin, M. D., C. Joshi, et al. (2008). "Reproducible, ultra high-throughput formation of multicellular 
organization from single cell suspension-derived human embryonic stem cell aggregates." 
PLoS One 3(2): e1565. 
van Obberghen, E., G. Somers, et al. (1973). "Dynamics of insulin release and microtubular-
microfilamentous system. I. Effect of cytochalasin B." J Clin Invest 52(5): 1041-1051. 
 
 220 
Vicovac, L. and J. D. Aplin (1996). "Epithelial-mesenchymal transition during trophoblast 
differentiation." Acta Anat (Basel) 156(3): 202-216. 
Violini, S., V. Sharma, et al. (2002). "Evidence for a plasma membrane-mediated permeability barrier 
to Tat basic domain in well-differentiated epithelial cells: lack of correlation with heparan 
sulfate." Biochemistry 41(42): 12652-12661. 
Vives, E. (2003). "Cellular uptake [correction of utake] of the Tat peptide: an endocytosis mechanism 
following ionic interactions." J Mol Recognit 16(5): 265-271. 
Vives, E., J. P. Richard, et al. (2003). "TAT peptide internalization: seeking the mechanism of entry." 
Curr Protein Pept Sci 4(2): 125-132. 
Vogel, H. J., R. D. Brokx, et al. (2002). "Calcium-binding proteins." Methods Mol Biol 172: 3-20. 
Wadia, J. S. and S. F. Dowdy (2005). "Transmembrane delivery of protein and peptide drugs by 
TAT-mediated transduction in the treatment of cancer." Adv Drug Deliv Rev 57(4): 579-596. 
Wadia, J. S., R. V. Stan, et al. (2004). "Transducible TAT-HA fusogenic peptide enhances escape of 
TAT-fusion proteins after lipid raft macropinocytosis." Nat Med 10(3): 310-315. 
Wang, C. L. (2008). "Caldesmon and the regulation of cytoskeletal functions." Adv Exp Med Biol 
644: 250-272. 
Wang, Z. and D. C. Thurmond (2009). "Mechanisms of biphasic insulin-granule exocytosis - roles of 
the cytoskeleton, small GTPases and SNARE proteins." J Cell Sci 122(Pt 7): 893-903. 
Webb-Robertson, B. J. and W. R. Cannon (2007). "Current trends in computational inference from 
mass spectrometry-based proteomics." Brief Bioinform 8(5): 304-317. 
Weissmann, C. and R. Brandt (2008). "Mechanisms of neurodegenerative diseases: insights from live 
cell imaging." J Neurosci Res 86(3): 504-511. 
Weljie, A. M., A. P. Yamniuk, et al. (2003). "Protein conformational changes studied by diffusion 
NMR spectroscopy: application to helix-loop-helix calcium binding proteins." Protein Sci 
12(2): 228-236. 
Wenisch, S., K. Trinkaus, et al. (2006). "Immunochemical, ultrastructural and electrophysiological 
investigations of bone-derived stem cells in the course of neuronal differentiation." Bone 
38(6): 911-921. 
Wiesgigl, M. and J. Clos (2001). "Heat shock protein 90 homeostasis controls stage differentiation in 
Leishmania donovani." Mol Biol Cell 12(11): 3307-3316. 
Wilson, L. M., S. H. Wong, et al. (2009). "Insulin but not glucagon gene is silenced in human 
pancreas-derived mesenchymal stem cells." Stem Cells 27(11): 2703-2711. 
Winder, S. J. (2003). "Structural insights into actin-binding, branching and bundling proteins." 
Current Opinion in Cell Biology 15(1): 14-22. 
Worster, A. A., A. J. Nixon, et al. (2000). "Effect of transforming growth factor beta1 on 
chondrogenic differentiation of cultured equine mesenchymal stem cells." Am J Vet Res 
61(9): 1003-1010. 
Wurmser, A. E. and F. H. Gage (2002). "Stem cells: cell fusion causes confusion." Nature 416(6880): 
485-487. 
Xie, F., E. Goldys, et al. (2007). "Amplified protein sensing using deep purple fluorophores on 
homogeneous Au substrates." Biofactors 30(4): 249-253. 
Xu, G., H. Kaneto, et al. (2006). "GLP-1/exendin-4 facilitates beta-cell neogenesis in rat and human 
pancreatic ducts." Diabetes Res Clin Pract 73(1): 107-110. 
Xu, G., D. A. Stoffers, et al. (1999). "Exendin-4 stimulates both beta-cell replication and neogenesis, 
resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats." 
Diabetes 48(12): 2270-2276. 
Xu, X., J. D'Hoker, et al. (2008). "Beta cells can be generated from endogenous progenitors in injured 
adult mouse pancreas." Cell 132(2): 197-207. 
 
 221 
Yamada, T., A. Hashiguchi, et al. (2000). "Function of 90-kDa heat shock protein in cellular 
differentiation of human embryonal carcinoma cells." In Vitro Cell Dev Biol Anim 36(2): 
139-146. 
Yamashiro, S., Y. Yamakita, et al. (1991). "Phosphorylation of non-muscle caldesmon by p34cdc2 
kinase during mitosis." Nature 349(6305): 169-172. 
Yamniuk, A. P. and H. J. Vogel (2004). "Calmodulin's flexibility allows for promiscuity in its 
interactions with target proteins and peptides." Mol Biotechnol 27(1): 33-57. 
Yezid, H., K. Konate, et al. (2009). "Mechanism for HIV-1 TAT insertion into the endosome 
membrane." J Biol Chem. 
Yokouchi, K., Y. Numaguchi, et al. (2006). "l-Caldesmon regulates proliferation and migration of 
vascular smooth muscle cells and inhibits neointimal formation after angioplasty." 
Arterioscler Thromb Vasc Biol 26(10): 2231-2237. 
Yourek, G., M. A. Hussain, et al. (2007). "Cytoskeletal changes of mesenchymal stem cells during 
differentiation." ASAIO J 53(2): 219-228. 
Yuan, S., L. Rosenberg, et al. (1996). "Transdifferentiation of human islets to pancreatic ductal cells 
in collagen matrix culture." Differentiation 61(1): 67-75. 
Zheng, P. P., M. Weiden, et al. (2007). "Hela /-CaD undergoes a DNA replication-associated switch 
in localization from the cytoplasm to the nuclei of endothelial cells/endothelial progenitor 
cells in human tumor vasculature." Cancer Biol Ther 6(6): 886-890. 
Zhou, Q., J. Brown, et al. (2008). "In vivo reprogramming of adult pancreatic exocrine cells to beta-
cells." Nature 455(7213): 627-632. 
Zulewski, H., E. J. Abraham, et al. (2001). "Multipotential nestin-positive stem cells isolated from 
adult pancreatic islets differentiate ex vivo into pancreatic endocrine, exocrine, and hepatic 
phenotypes." Diabetes 50(3): 521-533. 
 
 
